{
    "meta": {
        "name": "aml_v2.0",
        "timestamp": "20250124",
        "sheet_id": "1_KyfeZNsepIxSU0Nzw5Mi8mk1PiKCWlSBjatw0AECQ0"
    },
    "info": {
        "title": "Acute Myeloid Leukemia (AML) Data Dictionary",
        "name": "aml_v2.0",
        "release_notes": "https://github.com/chicagopcdc/d4cg-modeling/blob/main/pcdc/aml/aml_v2.0/README.md",
        "parent_data_model": "pcdc_v2.0",
        "license": "Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/)",
        "wiki": "https://docs.pedscommons.org/",
        "consortium_info": "https://commons.cri.uchicago.edu/pcdc/",
        "description": "The AML data dictionary is a consensus data schema built by an international group of pediatric acute myeloid leukemia experts and maintained by Data for the Common Good (D4CG) at the University of Chicago in collaboration with the International Acute Myeloid Leukemia Consortium (INTERACT). It is based on the collective requirements of its contributors.",
        "total": 187
    },
    "domains": {
        "protocol": {
            "subject_characteristics": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "Subject identifier assigned by the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "CONSORTIUM": {
                    "type": "Enum",
                    "tier": "",
                    "description": "The consortium under which this data is being contributed to the Pediatric Cancer Data Commons.",
                    "codes": [
                        "ncit:C61538"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "INTERACT": {
                            "description": "International Pediatric Acute Myeloid Leukemia Consortium (INTERACT). A consortium launched in 2021 as a collaboration between acute myeloid leukemia researchers from Children's Oncology Group, European Pediatric Acute Leukemia, Japan Children's Cancer Group, and St. Jude Children's Research Hospital. To date, INTERACT has identified 18 studies from 10 clinical trials research groups that can be contributed to the data commons, and its statisticians are actively working to harmonize clinical data from more than 6,000 individuals who have had pediatric cancer.",
                            "codes": [
                                "ncit:C192762"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "DISEASE_GROUP": {
                    "type": "Enum",
                    "tier": "",
                    "description": "",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "AML": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "DATA_CONTRIBUTOR_ID": {
                    "type": "Enum",
                    "tier": "",
                    "description": "An identifier assigned to a data contributor.",
                    "codes": [
                        "ncit:C168950"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "AIEOP": {
                            "description": "A group from Bologna, Italy, comprised mainly of pediatricians, hematologists, oncologists, surgeons, biologists, nurses and psychologists who are devoted to addressing the problems of hematology, oncology and immunology in the child and adolescent.",
                            "codes": [
                                "ncit:C168887"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "BFM-SG": {
                            "description": "A study group formed in 1975 by three individuals, Hansjorg Riehm in Berlin (B), Bernhard Kornhuber in Frankfurt (F) and Gunther Schellong in Munster (M), who initiated the first multicenter BFM trial. The BFM treatment concept was based on an intensive chemotherapeutic approach employing eight different drugs which led to a revolutionary increase in the survival of children and adolescents with acute lymphoblastic leukemia.",
                            "codes": [
                                "ncit:C168888"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "COG": {
                            "description": "An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.",
                            "codes": [
                                "ncit:C39353"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "DCOG": {
                            "description": "A collaborating partner in Innovative Therapies for Children with Cancer Consortium (ITCC), a European based consortium to promote the clinical evaluation of new anti-cancer compounds in children with cancer.",
                            "codes": [
                                "ncit:C168889"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "MRC": {
                            "description": "A publicly funded organization that is part of United Kingdom Research and Innovation, and is dedicated to improving human health through world-class medical research.",
                            "codes": [
                                "ncit:C168892"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "NOPHO": {
                            "description": "A collaborative group formed in 1984 with members from Denmark, Finland, Iceland, Lithuania, Norway and Sweden and whose goal was to secure that all Nordic children suffering from leukemia would receive optimal therapy wherever they lived.",
                            "codes": [
                                "ncit:C168893"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "PPLLSG": {
                            "description": "A collaborative group established in 1974 that had the original goal of implementing unified protocols with standardized diagnostic criteria and therapy regimens for Hodgkin's disease and acute lymphoblastic leukemia. The prospects were widened to include non-Hodgkin's lymphomas and acute myelogenous leukemia in 1983.",
                            "codes": [
                                "ncit:C168894"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "JACLS": {
                            "description": "A study group in Japan investigating childhood leukemia.",
                            "codes": [
                                "ncit:C168890"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "JPLSG": {
                            "description": "A study group in Japan investigating pediatric leukemia and lymphoma.",
                            "codes": [
                                "ncit:C168891"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "SJCRH": {
                            "description": "The Saint Jude Children's Research Hospital received its NCI designation in 1977 and was awarded status as a comprehensive cancer center by NCI in 2008. Research is focused specifically on childhood cancers, acquired and inherited immunodeficiencies and genetic disorders.",
                            "codes": [
                                "ncit:C39510"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "AGE_AT_ENROLLMENT": {
                    "type": "Integer",
                    "tier": "",
                    "description": "Age in Days at Enrollment",
                    "codes": [
                        "ncit:C168843"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "ENROLLED_STATUS": {
                    "type": "Enum",
                    "tier": "",
                    "description": "Enrollment Status",
                    "codes": [
                        "ncit:C168928"
                    ],
                    "implementation_notes": [
                        "This variable indicates if the subject was enrolled in the study, or if the subject was not enrolled in the study but received treatment per the study's protocol."
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Enrolled": {
                            "description": "The study subject is enrolled.",
                            "codes": [
                                "ncit:C142715"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Enrolled": {
                            "description": "The study subject is not enrolled.",
                            "codes": [
                                "ncit:C168929"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "STUDY_ID": {
                    "type": "Enum",
                    "tier": "",
                    "description": "Study Identifier",
                    "codes": [
                        "ncit:C83082"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "AML-BFM83/87": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AML-BFM87/93": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AML-BFM93": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AML-BFM98": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "ML-DS-2006": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AML-BFM2004 Interim": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AML-BFM2019": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AML-BFM2020": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AML-BFM98 Interim 2003": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "APL": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "NOPHOAML1993": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AAML03P1": {
                            "description": "The identifier AAML03P1, assigned to a study in a clinical trial.",
                            "codes": [
                                "ncit:C168936"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AAML0531": {
                            "description": "The identifier AAML0531, assigned to a study in a clinical trial.",
                            "codes": [
                                "ncit:C168937"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AAML1031": {
                            "description": "The identifier AAML1031, assigned to a study in a clinical trial.",
                            "codes": [
                                "ncit:C168938"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AML-BFM2004": {
                            "description": "The identifier AML-BFM 2004, assigned to a study in a clinical trial.",
                            "codes": [
                                "ncit:C168939"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AML-BFM2012": {
                            "description": "The identifier AMLBFM2012, assigned to a study in an AML clinical trial.",
                            "codes": [
                                "ncit:C173250"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AML-BFM Registry2012": {
                            "description": "The identifier AMLBFMRegistry2012, assigned to a study in an AML clinical trial.",
                            "codes": [
                                "ncit:C173251"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AML-BFM1998": {
                            "description": "The identifier AMLBFM1998, assigned to a study in an AML clinical trial.",
                            "codes": [
                                "ncit:C182032"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AML-BFM Registry2017": {
                            "description": "The identifier AMLBFMRegistry2017, assigned to a study in an AML clinical trial.",
                            "codes": [
                                "ncit:C182031"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "SJCRHAML02": {
                            "description": "The identifier SJCRHAML02, assigned to a study in a clinical trial.",
                            "codes": [
                                "ncit:C168940"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "JPLSGAML05": {
                            "description": "The identifier JPLSGAML05, assigned to a study in a clinical trial.",
                            "codes": [
                                "ncit:C168941"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AEIOPAML2002": {
                            "description": "The identifier AEIOPAML2002, assigned to a study in a clinical trial.",
                            "codes": [
                                "ncit:C168942"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "JACLSAML99": {
                            "description": "The identifier JACLSAML99, assigned to a study in a clinical trial.",
                            "codes": [
                                "ncit:C168943"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "DBAML01": {
                            "description": "The identifier DBAML01, assigned to a study in a clinical trial.",
                            "codes": [
                                "ncit:C168944"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "MRCAML12": {
                            "description": "The identifier MRCAML12, assigned to a study in a clinical trial.",
                            "codes": [
                                "ncit:C168945"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "MRCAML15": {
                            "description": "The identifier MRCAML15, assigned to a study in an AML clinical trial.",
                            "codes": [
                                "ncit:C173252"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "NOPHOAML2004": {
                            "description": "The identifier NOPHOAML2004, assigned to a study in a clinical trial.",
                            "codes": [
                                "ncit:C168946"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "NOPHOAML2012": {
                            "description": "The identifier NOPHOAML2012, assigned to a study in an AML clinical trial.",
                            "codes": [
                                "ncit:C173253"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "AIEOPLAM92": {
                            "description": "The identifier AIEOPLAM92, assigned to a study in an AML clinical trial.",
                            "codes": [
                                "ncit:C173254"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "SCFEELAM02": {
                            "description": "The identifier SCFEELAM02, assigned to a study in an AML clinical trial.",
                            "codes": [
                                "ncit:C173255"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "PPLLSGAML98": {
                            "description": "The identifier PPLLSGAML98, assigned to a study in a clinical trial.",
                            "codes": [
                                "ncit:C168947"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "TREATMENT_ARM": {
                    "type": "Enum",
                    "tier": "",
                    "description": "Assigned Treatment Arm by Intention-To-Treat",
                    "codes": [
                        "ncit:C15538"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "AAML1031:Arm A HR": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) group: 1) Induction I: Patients receive cytarabine intrathecally (IT) on day 1 and ADE chemotherapy comprising cytarabine intravenously (IV) over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5; and etoposide IV over 1-2 hours on days 1-5, 2) Induction II: Patients with low risk (LR) receive cytarabine IT and ADE chemotherapy as in Induction I. Patients with high risk (HR) receive cytarabine IT on day 1 and MA chemotherapy comprising high-dose cytarabine IV over 1-3 hours on days 1-4, and mitoxantrone IV over 15-30 minutes on days 3-6. Patients who achieve complete remission (CR) proceed to Intensification I (beginning on day 37). Patients with refractory disease are off protocol therapy, 3) Intensification I: Patients receive cytarabine IT on day 1 and AE chemotherapy comprising high-dose cytarabine IV over 1-3 hours, and etoposide IV over 1-2 hours on days 1-5. Patients who achieve CR proceed to Intensification II or stem cell transplantation (SCT) beginning on day 34. Patients with refractory disease are off protocol therapy, 4) Intensification II: Patients with LR receive cytarabine IT on day 1 and MA chemotherapy as in Induction II. Patients with HR and no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, and 9 and asparaginase intramuscularly (IM) on days 2 and 9, 5) Stem Cell Transplantation (SCT): high risk patients with matched family [MFD] or unrelated donor; Conditioning Regimen: Patients receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2; Transplantation: Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan; GVHD Prophylaxis: Patients receive tacrolimus IV continuously or PO beginning on day -2 and continuing until day 98 (matched sibling donor) or day 180 (with taper) (other related/unrelated donors or cord blood) and methotrexate IV on days 1, 3, and 6 (matched sibling/cord blood donors) or days 1, 3, 6, and 11 (other related/unrelated donors). Patients with unrelated donors also receive antithymocyte globulin IV over 6-8 hours on days -3 to -1.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AAML1031:Arm A LR": {
                            "description": "Patients randomized with the following course sequence for low risk (LR) group: 1) Induction I: Patients receive cytarabine intrathecally (IT) on day 1 and ADE chemotherapy comprising cytarabine intravenously (IV) over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5; and etoposide IV over 1-2 hours on days 1-5, 2) Induction II: Patients with low risk (LR) receive cytarabine IT and ADE chemotherapy as in Induction I. Patients with high risk (HR) receive cytarabine IT on day 1 and MA chemotherapy comprising high-dose cytarabine IV over 1-3 hours on days 1-4, and mitoxantrone IV over 15-30 minutes on days 3-6. Patients who achieve complete remission (CR) proceed to Intensification I (beginning on day 37). Patients with refractory disease are off protocol therapy, 3) Intensification I: Patients receive cytarabine IT on day 1 and AE chemotherapy comprising high-dose cytarabine IV over 1-3 hours, and etoposide IV over 1-2 hours on days 1-5. Patients who achieve CR proceed to Intensification II or stem cell transplantation (SCT) beginning on day 34. Patients with refractory disease are off protocol therapy, 4) Intensification II: Patients with LR receive cytarabine IT on day 1 and MA chemotherapy as in Induction II. Patients with HR and no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, and 9 and asparaginase intramuscularly (IM) on days 2 and 9.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AAML1031:Arm B HR": {
                            "description": "Patients randomized with the following course sequence gor high risk (HR) group: 1) Induction I: Patients receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, and 8, 2) Induction II: Patients with LR receive cytarabine IT, ADE chemotherapy, and bortezomib as in Induction I. Patients with HR receive cytarabine IT and MA chemotherapy as in Induction II, Arm A (HR patients) and bortezomib IV on days 1, 4, and 8, 3) Intensification I: Patients receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and bortezomib IV on days 1, 4, and 8. Patients who achieve CR proceed to Intensification II or stem cell transplantation (SCT) beginning on day 34. Patients with refractory disease are off protocol therapy, 4) Intensification II: Patients with LR receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), and bortezomib IV on days 1, 4, and 8. Patients with HR and no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, and 9 and asparaginase intramuscularly (IM) on days 2 and 9, 5) Stem Cell Transplantation (SCT): high risk (HR) patients with matched family [MFD] or unrelated donor); Conditioning Regimen: Patients receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2; Transplatation: Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan; GVHD Prophylaxis: Patients receive tacrolimus IV continuously or PO beginning on day -2 and continuing until day 98 (matched sibling donor) or day 180 (with taper) (other related/unrelated donors or cord blood) and methotrexate IV on days 1, 3, and 6 (matched sibling/cord blood donors) or days 1, 3, 6, and 11 (other related/unrelated donors). Patients with unrelated donors also receive antithymocyte globulin IV over 6-8 hours on days -3 to -1.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AAML1031:Arm B LR": {
                            "description": "Patients randomized with the following course sequence for low risk (LR) group: 1) Induction I: Patients receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, and 8, 2) Induction II: Patients with LR receive cytarabine IT, ADE chemotherapy, and bortezomib as in Induction I. Patients with HR receive cytarabine IT and MA chemotherapy as in Induction II, Arm A (HR patients) and bortezomib IV on days 1, 4, and 8, 3) Intensification I: Patients receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and bortezomib IV on days 1, 4, and 8. Patients who achieve CR proceed to Intensification II or stem cell transplantation (SCT) beginning on day 34. Patients with refractory disease are off protocol therapy, 4) Intensification II: Patients with LR receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), and bortezomib IV on days 1, 4, and 8. Patients with HR and no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, and 9 and asparaginase intramuscularly (IM) on days 2 and 9.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AAML1031:Arm C": {
                            "description": "Patients randomized with the following course sequence: 1) In Cohort 1 HR: Induction I: Patients receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, and sorafenib tosylate PO on days 9-36; In Cohort 2 HR: Induction I: Patients receive cytarabine IT and ADE chemotherapy as in Arm A, Induction I and sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including in Induction I and concurrently with chemotherapy); In Cohort 3 HR: Induction I: Patients receive cytarabine IT and ADE chemotherapy as in Arm A, Induction I and sorafenib tosylate PO on days 11-28, 2) Intensification I: Patients receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28, 3) Intensification II: Patients receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (high risk patients), and sorafenib tosylate PO on days 7-34, 4) Stem Cell Transplantation (SCT): high risk (HR) patients with matched family [MFD] or unrelated donor); Conditioning Regimen: Patients receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2; Transplantation: Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan; GVHD Prophylaxis: Patients receive tacrolimus IV continuously or PO beginning on day -2 and continuing until day 98 (matched sibling donor) or day 180 (with taper) (other related/unrelated donors or cord blood) and methotrexate IV on days 1, 3, and 6 (matched sibling/cord blood donors) or days 1, 3, 6, and 11 (other related/unrelated donors). Patients with unrelated donors also receive antithymocyte globulin IV over 6-8 hours on days -3 to -1; Maintenance: Patients receive sorafenib tosylate PO starting on day 40-100 after completion of intensification II or SCT for one year.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AEIOP LAM 2002:ICE-ICE-AVE-HAM- HD-AraC/SR": {
                            "description": "Patients received treatment in the following course sequence for standard risk (SR) group: 1) Remission Induction: Idarubicin given with etoposide and cytarabine (ICE), 2) Remission Induction: Idarubicin given with etoposide and cytarabine (ICE), 3) Etoposide given with cytarabine (AVE), 4) Consolidation 2: Cytarabine given with mitoxantrone (HAM), 5) Cytarabine (HD Ara-C, for standard risk patients only) .",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AEIOP LAM 2002:ICE-ICE-AVE-HAM-SCT/HR": {
                            "description": "Patients received treatment in the following course sequence for high risk (HR) group: 1) Remission Induction: Idarubicin given with etoposide and cytarabine (ICE), 2) Remission Induction: Idarubicin given with etoposide and cytarabine (ICE), 3) Etoposide given with cytarabine (AVE), 4) Consolidation 2: Cytarabine given with mitoxantrone (HAM), 5) Auto/Allo SCT (for high risk patients only).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AAML0531:HR": {
                            "description": "Patients are stratified according to relapse risk (high vs low). Patients are randomized to one of two treatment arms.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AAML0531:LR": {
                            "description": "Patients are stratified according to relapse risk (high vs low). Patients are randomized to one of two treatment arms.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AAML0531:Arm A HR": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) group: 1) Induction 1: Patients receive cytarabine IT at the time of diagnosis or on day 1. Patients also receive cytarabine IV on days 1-10, daunorubicin hydrochloride IV over 6 hours on days 1, 3, and 5, and etoposide IV over 4 hours on days 1-5. After 3 weeks of rest, all patients (regardless of remission status) proceed to induction 2, 2) Induction 2: Patients receive cytarabine IT on day 1, cytarabine IV on days 1-8, daunorubicin hydrochloride IV over 6 hours on days 1, 3, and 5, and etoposide IV over 4 hours on days 1-5. After 3 weeks of rest, patients in complete remission (CR) proceed to intensification 1. Patients with refractory disease are removed from protocol therapy, 3) Intensification 1: Patients receive cytarabine IT on day 1, high-dose cytarabine IV over 1 hour on days 1-5, and etoposide IV over 1 hour on days 1-5. After 3 weeks of rest, patients in remission proceed to intensification 2, followed by intensification 3. Patients in remission proceed to allogeneic SCT 2-8 weeks after blood counts recover. Patients with high-risk disease with an alternative donor proceed to intensification 2 and 3, followed by allogeneic SCT. Patients not in remission are removed from protocol therapy, 4) Intensification 2: Patients receive cytarabine IT on day 1, high-dose cytarabine IV over 2 hours on days 1-4, and mitoxantrone hydrochloride IV over 1 hour on days 3-6. After 3 weeks of rest, patients proceed to intensification 3, 5) Intensification 3: Patients receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, and 9 and asparaginase intramuscularly on days 2 and 9.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AAML0531:Arm A LR": {
                            "description": "Patients randomized with the following course sequence for low risk (LR) group: 1) Induction 1: Patients receive cytarabine IT at the time of diagnosis or on day 1. Patients also receive cytarabine IV on days 1-10, daunorubicin hydrochloride IV over 6 hours on days 1, 3, and 5, and etoposide IV over 4 hours on days 1-5. After 3 weeks of rest, all patients (regardless of remission status) proceed to induction 2, 2) Induction 2: Patients receive cytarabine IT on day 1, cytarabine IV on days 1-8, daunorubicin hydrochloride IV over 6 hours on days 1, 3, and 5, and etoposide IV over 4 hours on days 1-5. After 3 weeks of rest, patients in complete remission (CR) proceed to intensification 1. Patients with refractory disease are removed from protocol therapy, 3) Intensification 1: Patients receive cytarabine IT on day 1, high-dose cytarabine IV over 1 hour on days 1-5, and etoposide IV over 1 hour on days 1-5. After 3 weeks of rest, patients in remission proceed to intensification 2, followed by intensification 3. Patients in remission proceed to allogeneic SCT 2-8 weeks after blood counts recover. Patients with high-risk disease with an alternative donor proceed to intensification 2 and 3, followed by allogeneic SCT. Patients not in remission are removed from protocol therapy.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AAML0531:Arm B HR": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) group: 1) Induction 1: Patients receive treatment as in induction 1 of arm I. Patients also receive gemtuzumab ozogamicin (GMTZ) IV over 2 hours on day 6, 2) Induction 2: Patients receive treatment as in induction 2 of arm I, 3) Intensification 1: Patients receive treatment as in intensification 1 of arm I, 4) Intensification 2: Patients receive treatment as in intensification 2 of arm I. Patients also receive GMTZ IV over 2 hours on day 7, 5) Intensification 3: Patients receive treatment as in intensification 3 of arm I, 6) Allogeneic SCT (for patients with intermediate- or high-risk disease); MFD: Patients receive a conditioning regimen comprising busulfan IV over 2 hours every 6 hours on days -9 to -6 and cyclophosphamide IV over 1 hour on days -5 to -2. Patients undergo allogeneic SCT on day 0. Patients receive cyclosporine IV or orally twice daily on days -1 to 180 and methotrexate IV on days 1, 3, 6, and 11. Patients receive graft-vs-host disease (GVHD) prophylaxis comprising cyclosporine IV over 1-4 hours or orally twice daily on days -1 to 180 and methotrexate IV on days 1, 3, 6, and 11; Matched alternative donor: Patients receive a conditioning regimen comprising busulfan and cyclophosphamide as above. Patients also receive antithymocyte globulin IV over 6-8 hours on days -3 to -1. Patients then undergo allogeneic SCT and receive GVHD prophylaxis as above.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AAML0531:Arm B LR": {
                            "description": "Patients randomized with the following course sequence for low risk (LR) group: 1) Induction 1: Patients receive treatment as in induction 1 of arm I. Patients also receive gemtuzumab ozogamicin (GMTZ) IV over 2 hours on day 6, 2) Induction 2: Patients receive treatment as in induction 2 of arm I, 3) Intensification 1: Patients receive treatment as in intensification 1 of arm I, 4) Intensification 2: Patients receive treatment as in intensification 2 of arm I. Patients also receive GMTZ IV over 2 hours on day 7, 5) Intensification 3: Patients receive treatment as in intensification 3 of arm I.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML12:ADE-ADE-MACE-CLASP-MidAC": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin given in combination with cytarabine and etoposide (ADE), 2) Daunorubicin given in combination with cytarabine and etoposide (ADE), 3) Amsacrine given in combination with cytarabine and etoposide (MACE), 4) High dose (HD) cytosine with asparaginase (CLASP), 5) Mitoxantrone given in combination with cytarabine (MidAC).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML12:ADE-ADE-MACE-CLASP-SCT": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin given in combination with cytosine and etoposide (ADE), 2) Daunorubicin given in combination with cytosine and etoposide (ADE), 3) Amsacrine given in combination with cytarabine and etoposide (MACE), 4) High dose (HD) cytosine with asparaginase (CLASP), 5) Allogeneic Stem Cell Transplantation (Allo-SCT).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML12:ADE-ADE-MACE-MidAC": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin given in combination with cytosine and etoposide (ADE), 2) Daunorubicin given in combination with cytosine and etoposide (ADE), 3) Amsacrine given in combination with cytarabine and etoposide (MACE), 4) Mitoxantrone given in combination with cytarabine (MidAC).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML12:ADE-ADE-MACE-SCT": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin given in combination with cytosine and etoposide (ADE), 2) Daunorubicin given in combination with cytosine and etoposide (ADE), 3) Amsacrine given in combination with cytarabine and etoposide (MACE), 4) Allogeneic Stem Cell Transplantation (SCT).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML12:ADE-ADE-off trial": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin given in combination with cytosine and etoposide (ADE), 2) Daunorubicin given in combination with cytosine and etoposide (ADE), 3) Off trial if patient is not complete remission.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML12:MAE-MAE-MACE-CLASP-MidAC": {
                            "description": "Patients randomized with the following course sequence: 1) Mitoxantrone given in combination with cytosine and etoposide (MAE), 2) Mitoxantrone given in combination with cytosine and etoposide (MAE), 3) Amsacrine given in combination with cytarabine and etoposide (MACE), 4) High dose (HD) cytosine with asparaginase (CLASP), 5) Mitoxantrone given in combination with cytarabine (MidAC).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML12:MAE-MAE-MACE-CLASP-SCT": {
                            "description": "Patients randomized with the following course sequence: 1) Mitoxantrone given in combination with cytosine and etoposide (MAE), 2) Mitoxantrone given in combination with cytosine and etoposide (MAE), 3) Amsacrine given in combination with cytarabine and etoposide (MACE), 4) High dose (HD) cytosine with asparaginase (CLASP), 5) Allogeneic Stem Cell Transplantation (SCT).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML12:MAE-MAE-MACE-MidAC": {
                            "description": "Patients randomized with the following course sequence: 1) Mitoxantrone given in combination with cytosine and etoposide (MAE), 2) Mitoxantrone given in combination with cytosine and etoposide (MAE), 3) Amsacrine given in combination with cytarabine and etoposide (MACE), 4) Mitoxantrone given in combination with cytarabine (MidAC).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML12:MAE-MAE-MACE-SCT": {
                            "description": "Patients randomized with the following course sequence: 1) Mitoxantrone given in combination with cytosine and etoposide (MAE), 2) Mitoxantrone given in combination with cytosine and etoposide (MAE), 3) Amsacrine given in combination with cytarabine and etoposide (MACE), 4) Allogeneic Stem Cell Transplantation (SCT).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML12:MAE-MAE-Off Trial": {
                            "description": "Patients randomized with the following course sequence: 1) Mitoxantrone, cytosine, etoposide (MAE), 2) Mitoxantrone, cytosine, etoposide (MAE), 3) Amsacrine, cytarabine and etoposide (MACE), 4) Off trial if patient is not complete remission.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE-ADE-MACE-MidAC-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE), 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Amsacrine, cytarabine, etoposide (MACE), 4) Mitozantrone, cytosine arabinoside (MidAC), 5) Ara-C ",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE-ADE-MACE-MidAC-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin 50 mg/m2 d1,3,5; cytarabine 100 mg/m2 d1-10 every 12h; etoposide 100 mg/m2 d1-5 (ADE), 2) Daunorubicin 50 mg/m2 d1,3,5; cytarabine 100 mg/m2 d1-8 every 12h; etoposide 100 mg/m2 d1-5 (ADE), 3) Amsacrine 100 mg/m2 d1-5; cytarabine 200 mg/m2 continuous d1-5; etoposide 100 mg/m2 d1-5 (MACE), 4) Mitozantrone 10 mg/m2 daily by slow IV push on d1-5 inclusive (5 doses), cytosine arabinoside 1.0 mg/m2 12-hourly by 2h IV infusion on d1-3 inclusive (6 doses) (MidAC), 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE-ADE-MACE/Mytolarg-MidAC-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE), 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Amsacrine, cytarabine, etoposide (MACE)/Gemtuzumab Ozogamicin, 4) Mitozantrone, cytosine arabinoside (MidAC), 5) Ara-C ",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE-ADE-MACE/Mytolarg-MidAC-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE), 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Amsacrine, cytarabine, etoposide (MACE)/Gemtuzumab Ozogamicin, 4) Mitozantrone, cytosine arabinoside (MidAC), 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE/Mytolarg-ADE-MACE-MidAC-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE)/Gemtuzumab Ozogamicin, 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Amsacrine, cytarabine, etoposide (MACE), 4) Mitozantrone, cytosine arabinoside (MidAC), 5) Ara-C ",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE/Mytolarg-ADE-MACE-MidAC-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE)/Gemtuzumab Ozogamicin, 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Amsacrine, cytarabine, etoposide (MACE), 4) Mitozantrone, cytosine arabinoside (MidAC), 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE/Mytolarg-ADE-MACE/Mytolarg-MidAC-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE)/Gemtuzumab Ozogamicin, 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Amsacrine, cytarabine, etoposide (MACE)/Gemtuzumab Ozogamicin, 4) Mitozantrone, cytosine arabinoside (MidAC), 5) Ara-C ",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE/Mytolarg-ADE-MACE/Mytolarg-MidAC-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE)/Gemtuzumab Ozogamicin, 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Amsacrine, cytarabine, etoposide (MACE)/Gemtuzumab Ozogamicin, 4) Mitozantrone, cytosine arabinoside (MidAC), 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE-ADE-AraC3g-AraC3g-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE), 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Ara-C 3.0 g/m2, 4) Ara-C , 5) Ara-C 1.5 g/m2.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE-ADE-AraC3g-AraC3g-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE), 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Ara-C 3.0 g/m2, 4) Ara-C 3.0 g/m2, 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE-ADE-AraC3g/Mytolarg-AraC3g-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE), 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Ara-C 3.0 g/m2 (AraC3g)/Gemtuzumab Ozogamicin, 4) Ara-C 3.0 g/m2, 5) Ara-C 1.5 g/m2 ",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE-ADE-AraC3g/Mytolarg-AraC3g-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE), 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Ara-C 3.0 g/m2/Gemtuzumab Ozogamicin, 4) Ara-C 3.0 g/m2, 5) No futher treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE/Mytolarg-ADE-AraC3g-AraC3g-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE)/Gemtuzumab Ozogamicin, 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Ara-C 3.0 g/m2, 4) Ara-C 3.0 g/m2, 5) Ara-C 1.5 g/m2 ",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE/Mytolarg-ADE-AraC3g-AraC3g-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE)/Gemtuzumab Ozogamicin, 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Ara-C 3.0 g/m2, 4) Ara-C 3.0 g/m2, 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE/Mytolarg-ADE-AraC3g/Mytolarg-AraC3g-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE)/Gemtuzumab Ozogamicin, 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Ara-C 3.0 g/m2 /Gemtuzumab Ozogamicin, 4) Ara-C 3.0 g/m2, 5) Ara-C 1.5 g/m2 ",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:ADE/Mytolarg-ADE-AraC3g/Mytolarg-AraC3g-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Daunorubicin, cytarabine, etoposide (ADE)/Gemtuzumab Ozogamicin, 2) Daunorubicin, cytarabine, etoposide (ADE), 3) Ara-C 3.0 g/m2 /Gemtuzumab Ozogamicin, 4) Ara-C 3.0 g/m2, 5) No further treatement afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda-FLAGIda-MACE-MidAC-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine, cytosine arabinoside, G-CSF (FLAG-Ida), 2) Fluduarabine, cytosine arabinoside, G-CSF (FLAG-Ida), 3) Amsacrine, cytarabine, etoposide (MACE), 4) Mitozantrone, cytosine arabinoside (MidAC), 5) Ara-C 1.5 g/m2",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda-FLAGIda-MACE-MidAC-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine, cytosine arabinoside, G-CSF (FLAG-Ida), 2) Fluduarabine, cytosine arabinoside, G-CSF (FLAG-Ida), 3) Amsacrine, cytarabine, etoposide (MACE), 4) Mitozantrone, cytosine arabinoside (MidAC), 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda-FLAGIda-MACE/Mytolarg-MidAC-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine, cytosine arabinoside, G-CSF (FLAG-Ida), 2) Fluduarabine, cytosine arabinoside, G-CSF (FLAG-Ida), 3) Amsacrine, cytarabine, etoposide (MACE)/Gemtuzumab Ozogamicin, 4) Mitozantrone, cytosine arabinoside (MidAC), 5) Ara-C 1.5 g/m2 ",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda-FLAGIda-MACE/Mytolarg-MidAC-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine, cytosine arabinoside, G-CSF (FLAG-Ida), 2) Fluduarabine, cytosine arabinoside, G-CSF (FLAG-Ida), 3) Amsacrine, cytarabine, etoposide (MACE)/Gemtuzumab Ozogamicin, 4) Mitozantrone, cytosine arabinoside (MidAC), 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda/Mytolarg-FLAGIda-MACE-MidAC-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine, cytosine arabinoside, G-CSF  (FLAG-Ida)/Gemtuzumab Ozogamicin, 2) Fluduarabine, cytosine arabinoside, G-CSF (FLAG-Ida)/Gemtuzumab Ozogamicin, 3) Amsacrine, cytarabine, etoposide (MACE), 4) Mitozantrone, cytosine arabinoside (MidAC), 5) Ara-C 1.5 g/m2",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda/Mytolarg-FLAGIda-MACE-MidAC-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida)/gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 2) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida)/gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 3) Amsacrine 100 mg/m2 d1-5; cytarabine 200 mg/m2 continuous d1-5; etoposide 100 mg/m2 d1-5 (MACE), 4) Mitozantrone 10 mg/m2 daily by slow IV push on d1-5 inclusive (5 doses), cytosine arabinoside 1.0 mg/m2 12-hourly by 2h IV infusion on d1-3 inclusive (6 doses) (MidAC), 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda/Mytolarg-FLAGIda-MACE/Mytolarg-MidAC-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida)/gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 2) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 3) Amsacrine 100 mg/m2 d1-5; cytarabine 200 mg/m2 continuous d1-5; etoposide 100 mg/m2 d1-5 (MACE)/gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 4) Mitozantrone 10 mg/m2 daily by slow IV push on d1-5 inclusive (5 doses), cytosine arabinoside 1.0 mg/m2 12-hourly by 2h IV infusion on d1-3 inclusive (6 doses) (MidAC), 5) Ara-C 1.5 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (AraC).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda/Mytolarg-FLAGIda-MACE/Mytolarg-MidAC-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida)/gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 2) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 3) Amsacrine 100 mg/m2 d1-5; cytarabine 200 mg/m2 continuous d1-5; etoposide 100 mg/m2 d1-5 (MACE)/gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 4) Mitozantrone 10 mg/m2 daily by slow IV push on d1-5 inclusive (5 doses), cytosine arabinoside 1.0 mg/m2 12-hourly by 2h IV infusion on d1-3 inclusive (6 doses) (MidAC), 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda-FLAGIda-AraC3g-AraC3g-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 2) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 3) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g), 4) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g), 5) Ara-C 1.5 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (AraC).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda-FLAGIda-AraC3g-AraC3g-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 2) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 3) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g), 4) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g), 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda-FLAGIda-AraC3g/Mytolarg-AraC3g-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 2) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 3) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g)/gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 4) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g), 5) Ara-C 1.5 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (AraC).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda-FLAGIda-AraC3g/Mytolarg-AraC3g-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 2) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 3) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g)/gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 4) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g), 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda/Mytolarg-FLAGIda-AraC3g-AraC3g-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida)/gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 2) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 3) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g), 4) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g), 5) Ara-C 1.5 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (AraC).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda/Mytolarg-FLAGIda-AraC3g-AraC3g-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida)/gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 2) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 3) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g), 4) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g), 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda/Mytolarg-FLAGIda-AraC3g/Mytolarg-AraC3g-AraC": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida)/gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 2) Fuduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 3) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g)/ gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 4) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g), 5) Ara-C 1.5 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (AraC).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MRC AML15:FLAGIda/Mytolarg-FLAGIda-AraC3g/Mytolarg-AraC3g-No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida)/gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 2) Fluduarabine 30 mg/m2 IV d2-6 inclusive, cytosine arabinoside 2 g/m2 over 4h starting after fluduarabine on d2-6, G-CSF (lenograstin 263 \u03bcg (1 vial) SC daily d1-7 (FLAG-Ida), 3) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g)/ gemtuzumab ozogamicin 3 mg/m2 d1 (Gemtuzumab ozogamicin), 4) Ara-C 3.0 g/m2 d1 given IV over 4h 12 hourly on d1,3,5 (6 doses) (Ara-C3g), 5) No further treatment afterwards.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2004:AIET-AM-HA1M-HA2E-HA3-HA2E + Gemtuzumab Ozagamicin": {
                            "description": "Patients randomized with the following course sequence: 1) AIET: cytarabine, 6-thioguanine, etoposide, idarubicin 2) AM: cytarabine, mitoxantrone, 3) HA1M: cytarabine, mitoxantrone, 4) HA2E: cytarabine, etoposide 5) HA3: cytarabine (3g/m2), 6) HA2E: cytarabine (2g/m2), etoposide, 7) Gemtuzumab ozogamicin",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2004:AIET-AM-HA1M-HA2E-HA3-HA2E + No Further Therapy": {
                            "description": "Patients randomized with the following course sequence: 1) AIET: cytarabine, 6-thioguanine, etoposide, idarubicin 2) AM: cytarabine, mitoxantrone, 3) HA1M: cytarabine, mitoxantrone, 4) HA2E: cytarabine, etoposide 5) HA3: cytarabine (3g/m2), 6) HA2E: cytarabine (2g/m2), etoposide, 7) No further treatment",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:MEC-ADE-HAM-HA3E-FLA": {
                            "description": "Patients randomized with the following course sequence: 1) Mitoxantrone, etoposide, cytarabine (MEC), 2) Cytarabine, daunorubicin, etoposide (ADE), 3) Cytarabine, mitoxantrone (HAM), 4) Cytarabine (3000 mg/m2), etoposide (HA3E), 5) Fludarabine, cytarabine (FLA).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:DEC-ADE-HAM-HA3E-FLA": {
                            "description": "Patients randomized with the following course sequence: 1) Daunoxome, cytarabine, etoposide (DEC), 2) Cytarabine, daunorubicin, etoposide (ADE), 3) Cytarabine, mitoxantrone (HAM), 4) Cytarabine (3000 mg/m2), etoposide (HA3E), 5) Fludarabine, cytarabine (FLA).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:MEC-FLAD-HAM-HA3E-FLA": {
                            "description": "Patients randomized with the following course sequence: 1) Mitoxantrone, etoposide, cytarabine (MEC), 2) Fludarabine, high-dose cytarabine and Daunoxome (FLAD), 3) Cytarabine, mitoxantrone (HAM), 4) Cytarabine (3000 mg/m2), etoposide (HA3E), 5) Fludarabine, cytarabine (FLA).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:DEC -FLAD-HAM-HA3E-FLA": {
                            "description": "Patients randomized with the following course sequence: 1) Daunoxome, cytarabine, etoposide (DEC), 2) Fludarabine, high-dose cytarabine and Daunoxome (FLAD),, 3) Cytarabine, mitoxantrone (HAM), 4) Cytarabine (3000 mg/m2), etoposide (HA3E), 5) Fludarabine, cytarabine (FLA).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:MEC-ADE-HA3E-FLA (Low Risk)": {
                            "description": "Patients randomized with the following course sequence: 1) Mitoxantrone, etoposide, cytarabine (MEC), 2) Cytarabine, daunorubicin, etoposide (ADE), 3) Cytarabine (3000 mg/m2), etoposide (HA3E), 4) Fludarabine, cytarabine (FLA).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:DEC -ADE-HA3E-FLA (Low Risk)": {
                            "description": "Patients randomized with the following course sequence: 1) Daunoxome, cytarabine, etoposide (DEC), 2) Cytarabine, daunorubicin, etoposide (ADE), 3) Cytarabine (3000 mg/m2), etoposide (HA3E), 4) Fludarabine, cytarabine (FLA).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:MEC-FLAD-HA3E-FLA (Low Risk)": {
                            "description": "Patients randomized with the following course sequence: 1) Mitoxantrone, etoposide, cytarabine (MEC), 2) Fludarabine, high-dose cytarabine, daunoXome (FLAD), 3) Cytarabine (3000 mg/m2), etoposide (HA3E), 4) Fludarabine, cytarabine (FLA).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:DEC -FLAD-HA3E-FLA (Low Risk)": {
                            "description": "Patients randomized with the following course sequence: 1) Daunoxome, cytarabine, etoposide (DEC), 2) Fludarabine, high-dose cytarabine, daunoXome (FLAD), 3) Cytarabine (3000 mg/m2), etoposide (HA3E), 4) Fludarabine, cytarabine (FLA).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:MEC-ADE-HAM + SCT (High Risk 1)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) 1 group: 1) Mitoxantrone, cytarabine (MEC), 2) Low-dose cytarabine, daunorubicin, etoposide (ADE), 3) High-dose cytarabine, mitoxantrone (HAM), 4) Patients in the high-risk group should, whenever possible, receive an allogeneic SCT with an HLA matched related or unrelated donor. For high-risk patients the SCT should be done as soon as possible after course 3, but may be given after the fourth or fifth course if the donor is not available until then. The source of stem cells may be bone marrow, peripheral blood or cord blood. The recommended conditioning regimen is busulfan/cyclophosphamide/melphalan in patients who tolerate full conditioning. Autologous transplants should not be performed (SCT high risk 1).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:DEC -ADE-HAM + SCT (High Risk 1)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) 1 group: 1) Daunoxome, cytarabine (DEC), 2) 2) Low-dose cytarabine, daunorubicin, etoposide (ADE), 3) High-dose cytarabine, mitoxantrone (HAM), 4) Patients in the high-risk group should, whenever possible, receive an allogeneic SCT with an HLA matched related or unrelated donor. For high-risk patients the SCT should be done as soon as possible after course 3, but may be given after the fourth or fifth course if the donor is not available until then. The source of stem cells may be bone marrow, peripheral blood or cord blood. The recommended conditioning regimen is busulfan/cyclophosphamide/melphalan in patients who tolerate full conditioning. Autologous transplants should not be performed (SCT high risk 1).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:MEC-FLAD-HAM + SCT (High Risk 1)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) 1 group: 1) Mitoxantrone, etoposide, cytarabine (MEC), 2) Fludarabine, high-dose cytarabine daunoxome (FLAD), 3) High-dose cytarabine, mitoxantrone (HAM), 4) Patients in the high-risk group should, whenever possible, receive an allogeneic SCT with an HLA matched related or unrelated donor. For high-risk patients the SCT should be done as soon as possible after course 3, but may be given after the fourth or fifth course if the donor is not available until then. The source of stem cells may be bone marrow, peripheral blood or cord blood. The recommended conditioning regimen is busulfan/cyclophosphamide/melphalan in patients who tolerate full conditioning. Autologous transplants should not be performed (SCT high risk 1).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:DEC -FLAD-HAM + SCT (High Risk 1)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) 1 group: 1) Daunoxome, cytarabine (DEC), 2) Fludarabine, high-dose cytarabine daunoxome (FLAD), 3) High-dose cytarabine, mitoxantrone (HAM), 4) Patients in the high-risk group should, whenever possible, receive an allogeneic SCT with an HLA matched related or unrelated donor. For high-risk patients the SCT should be done as soon as possible after course 3, but may be given after the fourth or fifth course if the donor is not available until then. The source of stem cells may be bone marrow, peripheral blood or cord blood. The recommended conditioning regimen is busulfan/cyclophosphamide/melphalan in patients who tolerate full conditioning. Autologous transplants should not be performed (SCT high risk 1).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:MEC-ADE-HAM-HA3E + SCT (High Risk 2)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) 2 group: 1) Mitoxantrone, etoposide, cytarabine (MEC), 2) Low-dose cytarabine, daunorubicin, etoposide (ADE), 3) High-dose cytarabine, mitoxantrone (HAM), 4) Cytarabine (3000 mg/m2), etoposide (HA3E), 5) Patients in the high-risk group should, whenever possible, receive an allogeneic SCT with an HLA matched related or unrelated donor. For high-risk patients the SCT should be done as soon as possible after course 3, but may be given after the fourth or fifth course if the donor is not available until then. The source of stem cells may be bone marrow, peripheral blood or cord blood. The recommended conditioning regimen is busulfan/cyclophosphamide/melphalan in patients who tolerate full conditioning. Autologous transplants should not be performed (SCT high risk 2).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:DEC -ADE-HAM-HA3E+ SCT (High Risk 2)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) 2 group: 1) Daunoxome, cytarabine (DEC), 2) Low-dose cytarabine, daunorubicin, etoposide (ADE), 3) High-dose cytarabine, mitoxantrone (HAM), 4) Cytarabine (3000 mg/m2), etoposide (HA3E), 5) Patients in the high-risk group should, whenever possible, receive an allogeneic SCT with an HLA matched related or unrelated donor. For high-risk patients the SCT should be done as soon as possible after course 3, but may be given after the fourth or fifth course if the donor is not available until then. The source of stem cells may be bone marrow, peripheral blood or cord blood. The recommended conditioning regimen is busulfan/cyclophosphamide/melphalan in patients who tolerate full conditioning. Autologous transplants should not be performed (SCT high risk 2).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:MEC-FLAD-HAM-HA3E+ SCT (High Risk 2)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) 2 group: 1) Mitoxantrone, etoposide, cytarabine (MEC), 2) Fludarabine, high-dose cytarabine, daunoxome (FLAD), 3) High-dose cytarabine, mitoxantrone (HAM), 4) Cytarabine (3000 mg/m2), etoposide (HA3E), 5) Patients in the high-risk group should, whenever possible, receive an allogeneic SCT with an HLA matched related or unrelated donor) For high-risk patients the SCT should be done as soon as possible after course 3, but may be given after the fourth or fifth course if the donor is not available until then. The source of stem cells may be bone marrow, peripheral blood or cord blood. The recommended conditioning regimen is busulfan/cyclophosphamide/melphalan in patients who tolerate full conditioning. Autologous transplants should not be performed (SCT high risk 2).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:DEC -FLAD-HAM-HA3E+ SCT (High Risk 2)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) 2 group: 1) Daunoxome, cytarabine (DEC), 2) Fludarabine, high-dose cytarabine, daunoxome (FLAD), 3) High-dose cytarabine, mitoxantrone (HAM), 4) Cytarabine (3000 mg/m2), etoposide (HA3E), 5) Patients in the high-risk group should, whenever possible, receive an allogeneic SCT with an HLA matched related or unrelated donor) For high-risk patients the SCT should be done as soon as possible after course 3, but may be given after the fourth or fifth course if the donor is not available until then. The source of stem cells may be bone marrow, peripheral blood or cord blood. The recommended conditioning regimen is busulfan/cyclophosphamide/melphalan in patients who tolerate full conditioning. Autologous transplants should not be performed (SCT high risk 2).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:MEC-ADE-HAM-HA3E-FLA + SCT (High Risk 3)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) 2 group: 1) Mitoxantrone, etoposide, cytarabine (MEC), 2) Low-dose cytarabine, daunorubicin, etoposide (ADE), 3) High-dose cytarabine, mitoxantrone (HAM), 4) Cytarabine (3000 mg/m2), etoposide (HA3E), 5) Fludarabine, cytarabine (FLA), 6) Patients in the high-risk group should, whenever possible, receive an allogeneic SCT with an HLA matched related or unrelated donor. For high-risk patients the SCT should be done as soon as possible after course 3, but may be given after the fourth or fifth course if the donor is not available until then. The source of stem cells may be bone marrow, peripheral blood or cord blood. The recommended conditioning regimen is busulfan/cyclophosphamide/melphalan in patients who tolerate full conditioning. Autologous transplants should not be performed (SCT high risk 23.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:DEC -ADE-HAM-HA3E-FLA + SCT (High Risk 3)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) 2 group: 1) Daunoxome, cytarabine (DEC), 2) Low-dose cytarabine, daunorubicin, etoposide (ADE), 3) High-dose cytarabine, mitoxantrone (HAM), 4) Cytarabine (3000 mg/m2), etoposide (HA3E), 5) Fludarabine, cytarabine (FLA), 6) Patients in the high-risk group should, whenever possible, receive an allogeneic SCT with an HLA matched related or unrelated donor. For high-risk patients the SCT should be done as soon as possible after course 3, but may be given after the fourth or fifth course if the donor is not available until then. The source of stem cells may be bone marrow, peripheral blood or cord blood. The recommended conditioning regimen is busulfan/cyclophosphamide/melphalan in patients who tolerate full conditioning. Autologous transplants should not be performed (SCT high risk 3).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:MEC-FLAD-HAM-HA3E-FLA + SCT (High Risk 3)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) 2 group: 1) Mitoxantrone, etoposide, cytarabine (MEC), 2) Fludarabine, high-dose cytarabine daunoxome (FLAD), 3) High-dose cytarabine, mitoxantrone (HAM), 4) Cytarabine (3000 mg/m2), etoposide (HA3E), 5) Fludarabine, cytarabine (FLA), 6) Patients in the high-risk group should, whenever possible, receive an allogeneic SCT with an HLA matched related or unrelated donor. For high-risk patients the SCT should be done as soon as possible after course 3, but may be given after the fourth or fifth course if the donor is not available until then. The source of stem cells may be bone marrow, peripheral blood or cord blood. The recommended conditioning regimen is busulfan/cyclophosphamide/melphalan in patients who tolerate full conditioning. Autologous transplants should not be performed (SCT high risk 3).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:DEC -FLAD-HAM-HA3E-FLA + SCT (High Risk 3)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) 2 group: 1) Daunoxome, cytarabine (DEC), 2) Fludarabine, high-dose cytarabine daunoxome (FLAD), 3) High-dose cytarabine, mitoxantrone (HAM), 4) Cytarabine (3000 mg/m2), etoposide (HA3E), 5) Fludarabine, cytarabine (FLA), 6) Patients in the high-risk group should, whenever possible, receive an allogeneic SCT with an HLA matched related or unrelated donor. For high-risk patients the SCT should be done as soon as possible after course 3, but may be given after the fourth or fifth course if the donor is not available until then. The source of stem cells may be bone marrow, peripheral blood or cord blood. The recommended conditioning regimen is busulfan/cyclophosphamide/melphalan in patients who tolerate full conditioning. Autologous transplants should not be performed (SCT high risk 3).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:MEC-ADE-Off Protocol": {
                            "description": "Patients randomized with the following course sequence: 1) Mitoxantrone 5 mg/m2 as a 1 hour IV infusion day 6-10, Etoposide 150 mg/m2 as a 2 hour IV infusion day 1-5, Cytarabine 200 mg/m2 as a 12 hour IV infusion day 6-12 (MEC), 2) Low-dose cytarabine, daunorubicin and etoposide (ADE), 3) Although induction therapy in AML 2012 is intensified some patients will have resistant disease and the number is expected to be around 5%. These patients will be off protocol.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:DEC -ADE-Off Protocol": {
                            "description": "Patients randomized with the following course sequence: 1) DaunoXome 60 mg/m2 as a 1 hour IV infusion day 6,8 and 10, Etoposide 150 mg/m2 as a 2 hour IV infusion day 1-5, Cytarabine 200 mg/m2 as a 12 hour IV infusion day 6-12 (DEC), 2) Low-dose cytarabine, daunorubicin and etoposide (ADE), 3) Although induction therapy in AML 2012 is intensified some patients will have resistant disease and the number is expected to be around 5%. These patients will be off protocol.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:MEC-FLAD- Off Protocol": {
                            "description": "Patients randomized with the following course sequence: 1) Mitoxantrone, etoposide, cytarabine (MEC), 2) Fludarabine, high-dose cytarabine and Daunoxome (FLAD), 3) Although induction therapy in AML 2012 is intensified some patients will have resistant disease and the number is expected to be around 5%. These patients will be off protocol.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "NOPHO AML 2012:DEC -FLAD-Off Protocol": {
                            "description": "Patients randomized with the following course sequence: 1) Daunoxome, cytarabine, etoposide (DEC), 2) Fludarabine, high-dose cytarabine and Daunoxome (FLAD), 3) Although induction therapy in AML 2012 is intensified some patients will have resistant disease and the number is expected to be around 5%. These patients will be off protocol.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "DB - AML01:AIET-Post Recovery AM-HA2E+HA3+HA2E": {
                            "description": "Patients received treatment in the following course sequence: 1) Ara-C, idarubicin, etoposide, 6-thioguanin (AIET), 2) Post recovery Ara-C, mitoxantrone (AM), 3) High dose Ara-C 12 g/m2, etoposide 100 mg/m2 (HA2E), 4) High dose Ara-C 18 g/m2 (HA3), 5) High dose Ara-C 12 g/m2, etoposide 100 mg/m2 (HA2E).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "DB - AML01:AIET-Post Recovery FLA/Dnx-HA2E+HA3+HA2E": {
                            "description": "Patients received treatment in the following course sequence: 1) Ara-C, idarubicin, etoposide, 6-thioguanin (AIET), 2) Post recovery fludarabine, cytarabine/daunorubicin (FLA/Dnx), 3) High dose Ara-C 12 g/m2, etoposide 100 mg/m2 (HA2E), 4) High dose Ara-C 18 g/m2 (HA3), 5) High dose Ara-C 12 g/m2, etoposide 100 mg/m2 (HA2E).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "DB - AML01:AIET-Post Recovery AM-Off Protocol": {
                            "description": "Patients received treatment in the following course sequence: 1) Ara-C, idarubicin, etoposide, 6-thioguanin (AIET), 2) Post recovery Ara-C, mitoxantrone (AM), 3) Off protocol.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "DB - AML01:AIET-Post Recovery FLA/Dnx-Off Protocol": {
                            "description": "Patients received treatment in the following course sequence: 1) Ara-C, idarubicin, etoposide, 6-thioguanin (AIET), 2) Post recovery fludarabine, cytarabine/daunorubicin (FLA/Dnx), 3) Off protocol.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "DB - AML01:AIET-Immediate AM-HA2E+HA3+HA2E": {
                            "description": "Patients received treatment in the following course sequence: 1) Ara-C, idarubicin, etoposide, 6-thioguanin (AIET), 2) Immediate Ara-C, mitoxantrone (AM), 3) High dose Ara-C 12 g/m2, etoposide 100 mg/m2 (HA2E), 4) High dose Ara-C 18 g/m2 (HA3), 5) High dose Ara-C 12 g/m2, etoposide 100 mg/m2 (HA2E).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "DB - AML01:AIET-Immediate  FLA/Dnx-HA2E+HA3+HA2E": {
                            "description": "Patients received treatment in the following course sequence: 1) Ara-C, idarubicin, etoposide, 6-thioguanin (AIET), 2) Immediate fludarabine, cytarabine/daunorubicin (FLA/Dnx), 3) High dose Ara-C 12 g/m2, etoposide 100 mg/m2 (HA2E), 4) High dose Ara-C 18 g/m2 (HA3), 5) High dose Ara-C 12 g/m2, etoposide 100 mg/m2 (HA2E).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "DB - AML01:AIET-Immediate  AM-Off Protocol": {
                            "description": "Patients received treatment in the following course sequence: 1) Ara-C, idarubicin, etoposide, 6-thioguanin (AIET), 2) Immediate Ara-C, mitoxantrone (AM), 3) Off protocol.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "DB - AML01:AIET-Immediate  FLA/Dnx-Off Protocol": {
                            "description": "Patients received treatment in the following course sequence: 1) Ara-C, idarubicin, etoposide, 6-thioguanin (AIET), 2) Immediate fludarabine, cytarabine/daunorubicin (FLA/Dnx), 3) Off protocol.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AIEOP LAM 92:ICE(3+5+10) + ICE(3+5+10) + Consolidation": {
                            "description": "Patients received treatment in the following course sequence: 1) Idarubicin 12 mg/m2/day 1 h infusion on days 1, 3, 5; Etoposide 100 mg/m2/day 1 h i.v. infusion on days 1\u20135; Cytarabine 25 mg/m2/day i.v. push on day 1 followed by 100 mg/m2/day continuous i.v. infusion on days 1\u201310 (ICE (3+5+10)), 2) Idarubicin 12 mg/m2/day 1 h infusion on days 1, 3, 5; Etoposide 100 mg/m2/day 1 h i.v. infusion on days 1\u20135; Cytarabine 25 mg/m2/day i.v. push on day 1 followed by 100 mg/m2/day continuous i.v. infusion on days 1\u201310 (ICE (3+5+10)), 3) Consolidation: Various schemas mostly including highdose cytarabine.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AIEOP LAM 92:ICE(3+5+10) + ICE(2+3+7) + Consolidation": {
                            "description": "Patients received treatment in the following course sequence: 1) Idarubicin 12 mg/m2/day 1 h infusion on days 1, 3, 5; Etoposide 100 mg/m2/day 1 h i.v. infusion on days 1\u20135; Cytarabine 25 mg/m2/day i.v. push on day 1 followed by 100 mg/m2/day continuous i.v. infusion on days 1\u201310 (ICE (3+5+10)), 2) Iidarubicin 12 mg/m2/day 1 h infusion on days 1 and 3; Etoposide 100 mg/m2/day 1 h i.v. infusion on days 1\u20133; Cytarabine 25 mg/m2 i.v. push on day 1 followed by 100 mg/m2/day continuous i.v. infusion on days 1\u20137 (ICE 2+3+7)), 3) Consolidation: Various schemas mostly including highdose cytarabine.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AIEOP LAM 92:ICE(3+5+10) + ICE(3+5+10) + Consolidation + AUTO/ALLO SCT": {
                            "description": "Patients received treatment in the following course sequence: 1) Idarubicin 12 mg/m2/day 1 h infusion on days 1, 3, 5; Etoposide 100 mg/m2/day 1 h i.v. infusion on days 1\u20135; Cytarabine 25 mg/m2/day i.v. push on day 1 followed by 100 mg/m2/day continuous i.v. infusion on days 1\u201310 (ICE (3+5+10)), 2) Idarubicin 12 mg/m2/day 1 h infusion on days 1, 3, 5; Etoposide 100 mg/m2/day 1 h i.v. infusion on days 1\u20135; Cytarabine 25 mg/m2/day i.v. push on day 1 followed by 100 mg/m2/day continuous i.v. infusion on days 1\u201310 (ICE (3+5+10)), 3) Consolidation: Various schemas mostly including highdose cytarabine, 4) Allogeneic bone marrow transplantation if a sibling donor was available; autologous bone marrow transplant.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AIEOP LAM 92:ICE(3+5+10) + ICE(2+3+7) + Consolidation + AUTO/ALLO SCT": {
                            "description": "Patients received treatment in the following course sequence: 1) Idarubicin 12 mg/m2/day 1 h infusion on days 1, 3, 5; Etoposide 100 mg/m2/day 1 h i.v. infusion on days 1\u20135; Cytarabine 25 mg/m2/day i.v. push on day 1 followed by 100 mg/m2/day continuous i.v. infusion on days 1\u201310 (ICE (3+5+10)), 2) Iidarubicin 12 mg/m2/day 1 h infusion on days 1 and 3; Etoposide 100 mg/m2/day 1 h i.v. infusion on days 1\u20133; Cytarabine 25 mg/m2 i.v. push on day 1 followed by 100 mg/m2/day continuous i.v. infusion on days 1\u20137 (ICE 2+3+7)), 3) Consolidation: Various schemas mostly including highdose cytarabine, 4) Allogeneic bone marrow transplantation if a sibling donor was available; autologous bone marrow transplant.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AIEOP LAM 92:ICE(3+5+10) + ICE(3+5+10) + AUTO/ALLO SCT": {
                            "description": "Patients received treatment in the following course sequence: 1) Idarubicin 12 mg/m2/day 1 h infusion on days 1, 3, 5; Etoposide 100 mg/m2/day 1 h i.v. infusion on days 1\u20135; Cytarabine 25 mg/m2/day i.v. push on day 1 followed by 100 mg/m2/day continuous i.v. infusion on days 1\u201310 (ICE (3+5+10)), 2) Idarubicin 12 mg/m2/day 1 h infusion on days 1, 3, 5; Etoposide 100 mg/m2/day 1 h i.v. infusion on days 1\u20135; Cytarabine 25 mg/m2/day i.v. push on day 1 followed by 100 mg/m2/day continuous i.v. infusion on days 1\u201310 (ICE (3+5+10)), 3) Allogeneic bone marrow transplantation if a sibling donor was available; autologous bone marrow transplant.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AIEOP LAM 92:ICE(3+5+10) + ICE(2+3+7) + AUTO/ALLO SCT": {
                            "description": "Patients received treatment in the following course sequence: 1) Idarubicin 12 mg/m2/day 1 h infusion on days 1, 3, 5; Etoposide 100 mg/m2/day 1 h i.v. infusion on days 1\u20135; Cytarabine 25 mg/m2/day i.v. push on day 1 followed by 100 mg/m2/day continuous i.v. infusion on days 1\u201310 (ICE (3+5+10)), 2) Iidarubicin 12 mg/m2/day 1 h infusion on days 1 and 3; Etoposide 100 mg/m2/day 1 h i.v. infusion on days 1\u20133; Cytarabine 25 mg/m2 i.v. push on day 1 followed by 100 mg/m2/day continuous i.v. infusion on days 1\u20137 (ICE 2+3+7)), 3) Allogeneic bone marrow transplantation if a sibling donor was available; autologous bone marrow transplant.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "SCFE ELAM02:Induction + Consolidation 1 + Consolidation 2 + Consolidation 3": {
                            "description": "Patients randomized with the following course sequence: 1) Induction: 1 course of induction treatment (cytarabine and mitoxantrone), 2) Consolidation 1: Treatment (high-dose cytarabine), 3) Consolidation 2: Treatment (high-dose cytarabine), 4) Consolidation 3: Treatment (high-dose cytarabine).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "SCFE ELAM02:Induction + Consolidation 1 + Consolidation 2 + Consolidation 3 + IL2 Maintenance": {
                            "description": "Patients randomized with the following course sequence: 1) Induction: 1 course of induction treatment (cytarabine and mitoxantrone), 2) Consolidation 1: Treatment (high-dose cytarabine), 3) Consolidation 2: Treatment (high-dose cytarabine), 4) Consolidation 3: Treatment (high-dose cytarabine), 5) Patients not undergoing hematopoietic stem cell transplantation, still in complete remission (CR) after the third course of consolidation treatment, were eligible for randomization to 1 year of maintenance therapy with monthly courses of IL2 or no maintenance treatment.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "SCFE ELAM02:Induction + Consolidation 1 + Allo HSCT": {
                            "description": "Patients randomized with the following course sequence: 1) Induction: 1 course of induction treatment (cytarabine and mitoxantrone), 2) Consolidation 1: Treatment (high-dose cytarabine), 3) Allogeneic hematopoietic stem cell transplantation) HSCT was recommended for all patients in CR after course 2, except those with AML with t(8;21)(q22;q22), provided that an HLA-identical sibling donor was available and there was no active severe infection or organ failure) HSCT with a matched unrelated donor or unrelated cord blood was recommended for patients at high risk according to one of the following criteria: monosomy 7, 5q deletion, t(9;22)(q34;q11) or t(6;9)(p23;q34) and refractory disease after course 2.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:ADxE- AI-haM-HAE- Standard maintenance, 12 Gy (Standard Risk arm)": {
                            "description": "Patients randomized with the following course sequence for standard risk (SR) arm group: 1) Induction I: Cytarabine, L-CNR, etoposide (ADxE), 2) Induction II: Cytarabine [0.5g/m2], idarubicin (AI), 3) Consolidation: high-dose cytarabine [3g/m2], mitoxantrone (haM), 4) Intensification: high-dose cytarabine [3g/m2], etoposide (HAE), 5) Standard maintenance, 6) CNS-RT (central nerous system [cranial] irradiation) randomized to 12 Gy.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:ADxE- AI-haM-HAE- Standard maintenance, 18 Gy (Standard Risk arm)": {
                            "description": "Patients randomized with the following course sequence for standard risk (SR) arm group: 1) Induction I: Cytarabine, L-CNR, etoposide (ADxE), 2) Induction II: Cytarabine [0.5g/m2], idarubicin (AI), 3) Consolidation: high-dose cytarabine [3g/m2], mitoxantrone (haM), 4) Intensification: high-dose cytarabine [3g/m2], etoposide (HAE), 5) Standard maintenance, 6) CNS-RT (central nervous system [cranial] irradiation) randomized to 18 Gy.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:ADxE-HAM- AI/2CDA-haM, HAE- Standard maintenance, 12 Gy (High Risk arm)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) arm group: 1) Induction I: Cytarabine, L-CNR, etoposide (ADxE), 2) Induction II: High-dose cytarabine [3g/m2], mitoxantrone (HAM), 3) Consolidation: Cytarabine [0.5 g/m2], idarubicin, 2-chloro-2 deoxyadenosine (AI/2-CDA), 4) Intensification: High-dose cytarabine [3 g/m2], etoposide (haM, HAE), 5) Standard maintenance, 6) CNS-RT (central nervous system [cranial] irradiation) randomized to 12 Gy.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:ADxE-HAM- AI/2CDA-haM, HAE- Standard maintenance, 18 Gy (High Risk arm)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) arm group: 1) Induction I: Cytarabine, L-CNR, etoposide (ADxE), 2) Induction II: High-dose cytarabine [3g/m2], mitoxantrone (HAM), 3) Consolidation: Cytarabine [0.5 g/m2], idarubicin, 2-chloro-2 deoxyadenosine (AI/2-CDA), 4) Intensification: High-dose cytarabine [3 g/m2], etoposide (haM, HAE), 5) Standard maintenance, 6) CNS-RT (central nervous system [cranial] irradiation) randomized to 18 Gy.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:ADxE-HAM- AI-haM, HAE- Standard maintenance, 12 Gy (High Risk arm)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) arm group: 1) Induction I: Cytarabine, L-CNR, etoposide (ADxE), 2) Induction II: High-dose cytarabine [3g/m2], mitoxantrone (HAM), 3) Consolidation: Cytarabine [0.5 g/m2], idarubicin (AI), 4) Intensification: High-dose cytarabine [3 g/m2], etoposide (HAE), 5) Standard maintenance, 6) CNS-RT (central nervous system [cranial] irradiation) randomized to 12 Gy",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:ADxE-HAM- AI-haM, HAE- Standard maintenance, 18 Gy (High Risk arm)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) arm group: 1) Induction I: Cytarabine, L-CNR, etoposide (ADxE), 2) Induction II: High-dose cytarabine [3g/m2], mitoxantrone (HAM), 3) Consolidation: Cytarabine [0.5 g/m2], idarubicin (AI), 4) Intensification: High-dose cytarabine [3 g/m2], etoposide (HAE), 5) Standard maintenance, 6) CNS-RT (central nervous system [cranial] irradiation) randomized to 18 Gy.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:AIE- AI-haM-HAE- Standard maintenance, 12 Gy (Standard Risk arm)": {
                            "description": "Patients randomized with the following course sequence for standard risk (SR) arm group: 1) Induction I: Cytarabine, idarubicin, etoposide (AIE), 2) Induction II: Cytarabine [0.5g/m2], idarubicin (AI), 3) Consolidation: high-dose cytarabine [3g/m2], mitoxantrone (haM), 4) Intensification: high-dose cytarabine [3g/m2], etoposide (HAE), 5) Standard maintenance, 6) CNS-RT (central nerous system [cranial] irradiation) randomized to 12 Gy.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:AIE- AI-haM-HAE- Standard maintenance, 18 Gy(Standard Risk arm)": {
                            "description": "Patients randomized with the following course sequence for standard risk (SR) arm group: 1) Induction I: Cytarabine, idarubicin, etoposide (AIE), 2) Induction II: Cytarabine [0.5g/m2], idarubicin (AI), 3) Consolidation: high-dose cytarabine [3g/m2], mitoxantrone (haM), 4) Intensification: high-dose cytarabine [3g/m2], etoposide (HAE), 5) Standard maintenance, 6) CNS-RT (central nerous system [cranial] irradiation) randomized to 18 Gy.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:AIE-HAM- AI/2CDA-haM, HAE- Standard maintenance, 12 Gy (High Risk arm)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) arm group: 1) Induction I: Cytarabine, idarubicin, etoposide (AIE), 2) Induction II: High-dose cytarabine [3g/m2], mitoxantrone (HAM), 3) Consolidation: Cytarabine [0.5 g/m2], idarubicin, 2-chloro-2 deoxyadenosine (AI/2-CDA), 4) Intensification: High-dose cytarabine [3 g/m2], etoposide (haM, HAE), 5) Standard maintenance, 6) CNS-RT (central nervous system [cranial] irradiation) randomized to 12 Gy.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:AIE-HAM- AI/2CDA-haM, HAE- Standard maintenance, 18 Gy (High Risk arm)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) arm group: 1) Induction I: Cytarabine, idarubicin, etoposide (AIE), 2) Induction II: High-dose cytarabine [3g/m2], mitoxantrone (HAM), 3) Consolidation: Cytarabine [0.5 g/m2], idarubicin, 2-chloro-2 deoxyadenosine (AI/2-CDA), 4) Intensification: High-dose cytarabine [3 g/m2], etoposide (haM, HAE), 5) Standard maintenance, 6) CNS-RT (central nervous system [cranial] irradiation) randomized to 18 Gy.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:AIE-HAM- AI-haM, HAE- Standard maintenance, 12 Gy (High Risk arm)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) arm group: 1) Induction I: Cytarabine, idarubicin, etoposide (AIE), 2) Induction II: High-dose cytarabine [3g/m2], mitoxantrone (HAM), 3) Consolidation: Cytarabine [0.5 g/m2], idarubicin (AI), 4) Intensification: High-dose cytarabine [3 g/m2], etoposide (haM, HAE), 5) Standard maintenance, 6) CNS-RT (central nervous system [cranial] irradiation) randomized to 12 Gy.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:AIE-HAM- AI-haM, HAE- Standard maintenance, 18 Gy (High Risk arm)": {
                            "description": "Patients randomized with the following course sequence for high risk (HR) arm group: 1) Induction I: Cytarabine, idarubicin, etoposide (AIE), 2) Induction II: High-dose cytarabine [3g/m2], mitoxantrone (HAM), 3) Consolidation: Cytarabine [0.5 g/m2], idarubicin (AI), 4) Intensification: High-dose cytarabine [3 g/m2], etoposide (haM, HAE), 5) Standard maintenance, 6) CNS-RT (central nervous system [cranial] irradiation) randomized to 18 Gy.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:AIE-HAM- AI-haM, SCT": {
                            "description": "Patients randomized with the following course sequence: 1) Induction I: Cytarabine, idarubicin, etoposide (AIE), 2) Induction II: High-dose cytarabine [3g/m2], mitoxantrone (HAM), 3) Consolidation: Cytarabine [0.5 g/m2], idarubicin (AI), 4) Intensification: High-dose cytarabine [3 g/m2], etoposide (haM), 5) Allogeneic Stem Cell Transplantation (HR patients only).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:AIE-HAM- AI/2CDA-haM, SCT": {
                            "description": "Patients randomized with the following course sequence: 1) Induction I: Cytarabine, idarubicin, etoposide (AIE), 2) Induction II: High-dose cytarabine [3g/m2], mitoxantrone (HAM), 3) Consolidation: Cytarabine [0.5 g/m2], idarubicin, 2-chloro-2 deoxyadenosine (AI/2-CDA), 4) Intensification: High-dose cytarabine [3 g/m2], etoposide (haM), 5) Allogeneic Stem Cell Transplantation (HR patients only).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:ADxE-HAM- AI-haM, SCT": {
                            "description": "Patients randomized with the following course sequence: 1) Induction I: Cytarabine, L-CNR, etoposide (ADxE), 2) Induction II: High-dose cytarabine [3g/m2], mitoxantrone (HAM), 3) Consolidation: Cytarabine [0.5 g/m2], idarubicin (AI), 4) Intensification: High-dose cytarabine [3 g/m2], etoposide (haM), 5) Allogeneic Stem Cell Transplantation (HR patients only).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML-BFM 2004:ADxE-HAM- AI/2CDA-haM, SCT": {
                            "description": "Patients randomized with the following course sequence: 1) Induction I: Cytarabine, L-CNR, etoposide (ADxE), 2) Induction II: High-dose cytarabine [3g/m2], mitoxantrone (HAM), 3) Consolidation: Cytarabine [0.5 g/m2], idarubicin, 2-chloro-2 deoxyadenosine (AI/2-CDA), 4) Intensification: High-dose cytarabine [3 g/m2], etoposide (haM), 5) Allogeneic Stem Cell Transplantation (HR patients only).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM Registry 2012:ADxE- AI-haM-HAE- Standard Maintenance (Standard Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for standard risk (SR) arm group: 1) Cytarabine, daunorubicin, etoposide (ADxE), 2) Cytarabine, idarubicin (AI), 3) Cytarabine, mitoxantrone (haM), 4) Cytarabine, etoposide (HAE), 5) Standard Maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM Registry 2012:ADxE-HAM- AI-haM, HAE- Standard Maintenance (Intermediate Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for intermediate risk (IR) arm group: 1) Cytarabine, daunorubicin, etoposide (ADxE), 2) Cytarabine, mitoxantrone (HAM), 3) Cytarabine, idarubicin (AI), 4) Cytarabine, mitoxantrone (haM), 5) Cytarabine, etoposide (HAE), 6) Standard Maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM Registry 2012:ADxE-HAM- AI-haM, SCT (High Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for high risk (HR) arm group: 1) Cytarabine, daunorubicin, etoposide (ADxE), 2) Cytarabine, mitoxantrone (HAM), 3) Cytarabine, idarubicin (AI), 4) Cytarabine, mitoxantrone (haM), 5) Stem Cell Transplantation.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:CDxA- AI-haM, AI- HAE -Short Maintenance (Standard Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for standard risk (SR) arm group: 1) 2-chloro-2-deoxyadenosine (CDxA), 2) Cytarabine and idarubicin (AI), 3) High-dose cytarabine (1\u2009g/m2) and mitoxantrone (haM), 4) Cytarabine and idarubicine (AI), 5) High-dose cytarabine (3\u2009g/m2) and etoposide (HAE), 6) Short maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:CDxA- AI-haM, AI- HAE - Standard Maintenance (Standard Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for standard risk (SR) arm group: 1) 2-chloro-2-deoxyadenosine (CDxA), 2) Cytarabine and idarubicin (AI), 3) High-dose cytarabine (1\u2009g/m2) and mitoxantrone (haM), 4) Cytarabine and idarubicine (AI), 5) High-dose cytarabine (3\u2009g/m2) and etoposide (HAE), 6) Standard maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:CDxA- HAM- AI- haM-HAE -Short Maintenance (Standard Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for standard risk (SR) arm group: 1) 2-chloro-2-deoxyadenosine (CDxA), 2) High-dose cytarabine (3\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2), AI cytarabine (500\u2009\u2009mg/m2), idarubicin (7\u2009\u2009mg/m2)(HAM), 3) Cytarabine and idarubicine (AI), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM), 5) High-dose cytarabine (3\u2009g/m2) and etoposide (HAE), 6) Short maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:CDxA- HAM- AI- haM-HAE -Standard Maintenance (Standard Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for standard risk (SR) arm group: 1)  2-chloro-2-deoxyadenosine (CDxA), 2) High-dose cytarabine (3\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2), AI cytarabine (500\u2009\u2009mg/m2), idarubicin (7\u2009\u2009mg/m2)(HAM), 3) Cytarabine and idarubicine (AI), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM), 5) High-dose cytarabine (3\u2009g/m2) and etoposide (HAE), 5) Standard maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:ADxE - AI-haM, AI- HAE -Short Maintenance (Standard Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for standard risk (SR) arm group: 1) Cytarabine (100\u2009\u2009mg/m2), liposomal daunorubicin (80\u2009mg/m2), etoposide (150\u2009\u2009mg/m2) (ADxE), 2) Cytarabine and idarubicin (AI), 3) High-dose cytarabine (1\u2009g/m2) and mitoxantrone (haM), 4) Cytarabine and idarubicine (AI), 5) High-dose cytarabine (3\u2009g/m2) and etoposide (HAE), 6) Short maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:ADxE - AI-haM, AI- HAE - Standard Maintenance (Standard Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for standard risk (SR) arm group: 1) ytarabine (100\u2009\u2009mg/m2), liposomal daunorubicin (80\u2009mg/m2), etoposide (150\u2009\u2009mg/m2) (ADxE), 2) Cytarabine and idarubicin (AI), 3) High-dose cytarabine (1\u2009g/m2) and mitoxantrone (haM), 4) Cytarabine and idarubicine (AI), 5) High-dose cytarabine (3\u2009g/m2) and etoposide (HAE), 6) Standard maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:ADxE - HAM- AI- haM-HAE -Short Maintenance (Standard Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for standard risk (SR) arm group: 1) Cytarabine (100\u2009\u2009mg/m2), liposomal daunorubicin (80\u2009mg/m2), etoposide (150\u2009\u2009mg/m2) (ADxE), 2) High-dose cytarabine (3\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (HAM), 3) Cytarabine and idarubicine (AI), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM), 5) High-dose cytarabine (3\u2009g/m2) and etoposide (HAE), 6) Short maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:ADxE - HAM- AI- haM-HAE -Standard Maintenance (Standard Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for standard risk (SR) arm group: 1) Cytarabine (100\u2009\u2009mg/m2), liposomal daunorubicin (80\u2009mg/m2), etoposide (150\u2009\u2009mg/m2) (ADxE), 2) High-dose cytarabine (3\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (HAM), 3) Cytarabine and idarubicine (AI), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM), 5) High-dose cytarabine (3\u2009g/m2) and etoposide (HAE), 6) Standard maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:CDxA-HAM- AI-haM- HAE-Short Maintenance (Intermediate Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for intermediate risk (IR) arm group: 1) 2-chloro-2-deoxyadenosine (CDxA), 2) High-dose cytarabine (3\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (HAM), 3) Cytarabine and idarubicine (AI), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM), 5) High-dose cytarabine (3\u2009g/m2) and etoposide (HAE), 6) Short maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:CDxA-HAM- AI-haM- HAE -Standard Maintenance (Intermediate Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for intermediate risk (IR) arm group: 1) 2-chloro-2-deoxyadenosine (CDxA), 2) High-dose cytarabine (3\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (HAM), 3) Cytarabine and idarubicine (AI), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM), 5) High-dose cytarabine (3\u2009g/m2) and etoposide (HAE), 6) Standard maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:ADxE- HAM- AI-haM- HAE-Short Maintenance (Intermediate Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for intermediate risk (IR) arm group: 1) Cytarabine (100\u2009\u2009mg/m2), daunorubicin (60\u2009\u2009mg/m2), etoposide (150\u2009\u2009mg/m2) (ADxE), 2) High-dose cytarabine (3\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (HAM), 3) Cytarabine and idarubicine (AI), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM), 5) High-dose cytarabine (3\u2009g/m2) and etoposide (HAE), 6) Short maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:ADxE- HAM- AI-haM- HAE-Standard Maintenance (Intermediate Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for intermediate risk (IR) arm group: 1) Cytarabine (100\u2009\u2009mg/m2), daunorubicin (60\u2009\u2009mg/m2), etoposide (150\u2009\u2009mg/m2) (ADxE), 2) High-dose cytarabine (3\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (HAM), 3) Cytarabine and idarubicine (AI), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM), 5) High-dose cytarabine (3\u2009g/m2) and etoposide (HAE), 6) Standard maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:CDxA- HAM Sorafenib, AI Sorafenib, haM Sorafenib, Short Maintenance (Intermediate Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for intermediate risk (IR) arm group: 1) 2-chloro-2-deoxyadenosine (CDxA), 2) High-dose cytarabine (1\u2009g/m2) and mitoxantrone (HAM Sorafenib), 3) Cytarabine and idarubicine (AI Sorafenib), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM Sorafenib), 5) Short maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:CDxA- HAM Sorafenib, AI Sorafenib, haM Sorafenib, Standard Maintenance (Intermediate Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for intermediate risk (IR) arm group: 1) 2-chloro-2-deoxyadenosine (CDxA), 2) High-dose cytarabine (1\u2009g/m2) and mitoxantrone (HAM Sorafenib), 3) Cytarabine and idarubicine (AI Sorafenib), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM Sorafenib), 5) Standard maintenance.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:CDxA- HAM Sorafenib, AI Sorafenib, haM Sorafenib, Stem Cell Transplantation (High Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for high risk (HR) arm group: 1) 2-chloro-2-deoxyadenosine (CDxA), 2) High-dose cytarabine (1\u2009g/m2) and mitoxantrone (HAM Sorafenib), 3) Cytarabine and idarubicine (AI Sorafenib), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM Sorafenib), 5) Stem Cell Transplantation.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:CDxA-HAM, AI, haM, Stem Cell Transplantation(High Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for high risk (HR) arm group: 1) 2-chloro-2-deoxyadenosine (CDxA), 2) High-dose cytarabine (1\u2009g/m2) and mitoxantrone (HAM), 3) Cytarabine and idarubicine (AI), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM), 5) Stem cell Transplantation.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:ADxE- HAM Sorafenib, AI Sorafenib, haM Sorafenib, Stem Cell Transplantation (High Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for high risk (HR) arm group: 1) Cytarabine (100\u2009\u2009mg/m2), liposomal daunorubicin (80\u2009mg/m2), etoposide (150\u2009\u2009mg/m2) (ADxE), 2) High-dose cytarabine (3\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (HAM Sorafenib), 3) Cytarabine and idarubicine (AI Sorafenib), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM Sorafenib), 5) Stem Cell Transplantation.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "AML BFM 2012:ADxE- HAM, AI, haM, Stem Cell Transplantation (High Risk Arm)": {
                            "description": "Patients received treatment in the following course sequence for high risk (HR) arm group: 1) Cytarabine (100\u2009\u2009mg/m2), liposomal daunorubicin (80\u2009mg/m2), etoposide (150\u2009\u2009mg/m2) (ADxE), 2) High-dose cytarabine (3\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (HAM), 3) Cytarabine and idarubicine (AI), 4) Intermediate-dose cytarabine (1\u2009\u2009g/m2), mitoxantrone (10\u2009\u2009mg/m2) (haM), 5) Stem Cell Transplantation.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "SJCRH AML02:HDAC-ADE+GO-C1-C2-C3": {
                            "description": "Patients randomized with the following course sequence: 1) High-dose cytarabine (HDAC), 2) Daunomycin, cytarabine and etoposide (ADE), 3) Gemtuzumab ozogamicin (GO), 4) Consolidation I, 5) Consolidation II, 6) Consolidation III",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "SJCRH AML02:HDAC-ADE-C1-C2-C3": {
                            "description": "Patients randomized with the following course sequence: 1) High-dose cytarabine (HDAC), 2) Daunomycin, cytarabine and etoposide (ADE), 3) Consolidation I, 4) Consolidation II, 5) Consolidation III",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "SJCRH AML02:HDAC-ADE+GO-SCT": {
                            "description": "Patients randomized with the following course sequence: 1) High-dose cytarabine (HDAC), 2) Daunomycin, cytarabine and etoposide (ADE), 3) Gemtuzumab ozogamicin (GO), 4) Stem Cell Transplant (SCT)",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "SJCRH AML02:HDAC-ADE-SCT": {
                            "description": "Patients randomized with the following course sequence: 1) High-dose cytarabine (HDAC), 2) Daunomycin, cytarabine and etoposide (ADE), 3) Stem Cell Transplant (SCT)",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "SJCRH AML02:LDAC-ADE+GO-C1-C2-C3": {
                            "description": "Patients randomized with the following course sequence: 1) Low-dose cytarabine (LDAC), 2) Daunomycin, cytarabine and etoposide (ADE), 3) Gemtuzumab ozogamicin (GO), 4) Consolidation I, 5) Consolidation II, 6) Consolidation III",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "SJCRH AML02:LDAC-ADE-C1-C2-C3": {
                            "description": "Patients randomized with the following course sequence: 1) Low-dose cytarabine (LDAC), 2) Daunomycin, cytarabine and etoposide (ADE), 3) Consolidation I, 4) Consolidation II, 5) Consolidation III",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "SJCRH AML02:LDAC-ADE+GO-SCT": {
                            "description": "Patients randomized with the following course sequence: 1) Low-dose cytarabine (LDAC), 2) Daunomycin, cytarabine and etoposide (ADE), 3) Gemtuzumab ozogamicin (GO), 4) Stem Cell Transplant (SCT)",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "SJCRH AML02:LDAC-ADE-SCT": {
                            "description": "Patients randomized with the following course sequence: 1) Low-dose cytarabine (LDAC), 2) Daunomycin, cytarabine and etoposide (ADE), 3) Stem Cell Transplant (SCT)",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "PPLLSG AML-98:SR": {
                            "description": "Patients received treatment in the following course sequence for standard risk (SR) group: 1) AIE: cytarabine, idarubicin, etoposide, 2) Consolidation phase 1: 6-thioguanine, prednisone, cytarabine, vincristine, idarubicin, 3) Consolidation phase 2: 6-thioguanine, cytarabine, cyclophosphamide, CNS irradiation, 4) Maintenance: thioguanine, cytarabine, doxorubicin, 5)Thioguanine, cytarabine ",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "PPLLSG AML-98:HR": {
                            "description": "Patients received treatment in the following course sequence for high risk (HR) group: 1) AIE: cytarabine, idarubicin, etoposide, 2) AI: cytarabine, idarubicin, 3) AE: cytarabine, etoposide, 4) Consolidation phase 1: 6-thioguanine, prednisone, cytarabine, vincristine, idarubicin, 5) Short post-remission block: 6-thioguanine, cytarabine, cyclophosphamide, AIE: cytarabine, idarubicin, etoposide, 6) Maintenance: thioguanine, cytarabine, doxorubicin, 7) Received therapy for 1 year (about 18 months of therapy together with intensive courses).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "JACLS AML99:LR": {
                            "description": "Patients received treatment in the following course sequence for low risk (LR) group: 1) Low-risk children were defined as those with t(8;21) and a WBC lower than 50,000/\u03bcL, inv(16), or an age younger than 2 years without high-risk factors) Consolidation therapy consisted of five courses and triple intrathecal therapy was given as a part of each course) Low-risk children were treated only with chemotherapy, regardless the availability of a suitable HSCT donor.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "JACLS AML99:IR": {
                            "description": "Patients received treatment in the following course sequence for intermediate risk (IR) group: 1) Intermediate-risk children were those who were not in either a low-risk or high-risk group) Consolidation therapy consisted of five courses and triple intrathecal therapy was given as a part of each course) Matched related BMT was recommended for intermediate-risk children with a HLA-matched-related donor (MRD).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "JACLS AML99:HR": {
                            "description": "Patients received treatment in the following course sequence for high risk (HR) group: 1) High-risk children were those with CR after consolidation course 1 or induction C or with abnormalities of monosomy 7,7 5q-7, t(16;21),8 t(9;22) (Philadelphia chromosome [Ph1])) Consolidation therapy consisted of six courses and triple intrathecal therapy was given as a part of each course) All high-risk children were allocated to Allo-HSCT in the first remission, including unrelated bone marrow transplantation (BMT).",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "JPLSG AML05:JACLS": {
                            "description": "Patients received treatment in the following courses sequence: 1) For Low Risk group (LR), 3 courses of intensification multi-agent combination chemotherapy, 2) For Intermediate Risk group (IR), 3 courses of intensification multi-agent combination chemotherapy, 3) For High Risk group (HR), 1 to 3 courses of intensification multi-agent combination chemotherapy followed by allogeneic hematopoietic stem cell transplantation.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                }
            },
            "time_period": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "SUBMITTER_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "An ID provided by the data contributor that identifies a unique time period and that is referenced throughout subsequent tabels in the TIME_PERIOD_SUBMITTER_ID variables.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "PARENT_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The SUBMITTER_ID of the time period in whose context a subsequent time period takes place. For example, multiple treatment courses occuring the \"Initial Diagnosis\" period would each reference the SUBMITTER_ID of the \"Initial Diagnosis\" period as their PARENT_SUBMITTER_ID.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "TIME_PERIOD_TYPE": {
                    "type": "Enum",
                    "tier": "",
                    "description": "The type of time period being reported.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Disease Phase": {
                            "description": "The stage or period of an individual's disease.",
                            "codes": [
                                "ncit:C168878"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Course": {
                            "description": "The type of protocol treatment course administered with respect to Course Timing.",
                            "codes": [
                                "ncit:C187095"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "DISEASE_PHASE": {
                    "type": "Enum",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "ncit:C168878"
                    ],
                    "implementation_notes": [
                        "Note: Disease Phase could be \"Initial Diagnosis\" phase, or a \"Relapse\" phase, etc..."
                    ],
                    "mappings": [
                        "[aml_v1.7].[Disease Phase Timing].[DISEASE_PHASE] skos:exactMatch [aml_v2.0].[Time Period].[DISEASE_PHASE]"
                    ],
                    "permissible_values": {
                        "Initial Diagnosis": {
                            "description": "The first diagnosis of the individual's condition.",
                            "codes": [
                                "ncit:C156813"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Relapse": {
                            "description": "The return of a disease after a period of remission.",
                            "codes": [
                                "ncit:C38155"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "COURSE": {
                    "type": "Enum",
                    "tier": "",
                    "description": "The protocol treatment \"course\" during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "ncit:C168807"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Course Timing].[COURSE] skos:exactMatch [aml_v2.0].[Time Period].[COURSE]"
                    ],
                    "permissible_values": {
                        "Prephase": {
                            "description": "A chemotherapy treatment administered prior to the definitive chemotherapy treatment.",
                            "codes": [
                                "ncit:C168826"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Induction": {
                            "description": "The first choice of treatment for a particular type of cancer.",
                            "codes": [
                                "ncit:C158876"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Intensification": {
                            "description": "A second round of intense chemotherapy as part of consolidation therapy.",
                            "codes": [
                                "ncit:C173105"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Consolidation": {
                            "description": "Treatment that is given after initial therapy to kill any remaining cancer cells.",
                            "codes": [
                                "ncit:C15679"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Stem Cell Transplant Conditioning": {
                            "description": "A regimen that can be used as a conditioning regimen for hematopoietic stem cell transplantation (HSCT).",
                            "codes": [
                                "ncit:C168794"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Maintenance": {
                            "description": "Continuation of treatment for an extended period of time to prevent relapse.",
                            "codes": [
                                "ncit:C15688"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Palliative Treatment": {
                            "description": "The patient- and family-centered active holistic care of patients with advanced, progressive disease. Essential components of Palliative Care are: pain and symptom control, communication regarding treatment and alternatives, prognosis, and available services, rehabilitation services, care that addresses treatment and palliative concerns, intellectual, emotional, social, and spiritual needs, terminal care, support in bereavement. The goal of Palliative Care is an achievement of the best quality of life for patients and their families.",
                            "codes": [
                                "ncit:C15292"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "TIME_PERIOD_NUMBER": {
                    "type": "Integer",
                    "tier": "",
                    "description": "This variable indicates the ordinal numbering of time periods of the same TIME_PERIOD_TYPE within its various subgroups (e.g., Relapse 1, Relapse 2, Relapse 3, etc.). The observations across domains can therefore be organized longitudinally without the need for specific dates.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Disease Phase Timing].[DISEASE_PHASE_NUMBER] skos:broadMatch [aml_v2.0].[Time Period].[TIME_PERIOD_NUMBER] ",
                        " [aml_v1.7].[Course Timing].[COURSE_NUMBER] skos:broadMatch [aml_v2.0].[Time Period].[TIME_PERIOD_NUMBER]"
                    ]
                },
                "YEAR_AT_START": {
                    "type": "Integer",
                    "tier": "",
                    "description": "The year at the start of the indicated time period.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Disease Phase Timing].[YEAR_AT_DISEASE_PHASE] skos:broadMatch [aml_v2.0].[Time Period].[YEAR_AT_START]"
                    ]
                },
                "AGE_AT_START": {
                    "type": "Integer",
                    "tier": "",
                    "description": "The age (in days) of the patient at the start of the reported time period.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Disease Phase Timing].[AGE_AT_DISEASE_PHASE] skos:broadMatch [aml_v2.0].[Time Period].[AGE_AT_START] ",
                        " [aml_v1.7].[Course Timing].[AGE_AT_COURSE_START] skos:broadMatch [aml_v2.0].[Time Period].[AGE_AT_START]"
                    ]
                },
                "AGE_AT_END": {
                    "type": "Integer",
                    "tier": "",
                    "description": "The age (in days) of the patient at the end of the reported time period.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Course Timing].[AGE_AT_COURSE_END] skos:exactMatch [aml_v2.0].[Time Period].[AGE_AT_END]"
                    ]
                },
                "AGE_AT_COURSE_ANC_500": {
                    "type": "Integer",
                    "tier": "",
                    "description": "The age (in days) of the subject when the subject's neutrophil count exceeded 500 (ANC/mm3)",
                    "codes": [
                        "ncit:C168852"
                    ],
                    "implementation_notes": [
                        "Note: This variable is used as a proxy for the age at course end, when appropriate."
                    ],
                    "mappings": [
                        "[aml_v1.7].[Course Timing].[AGE_AT_COURSE_ANC_500] skos:exactMatch [aml_v2.0].[Time Period].[AGE_AT_COURSE_ANC_500]"
                    ]
                }
            },
            "off_protocol_therapy/study": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_OFF": {
                    "type": "Integer",
                    "tier": "",
                    "description": "Age of subject (in days) when subject was off therapy or study.",
                    "codes": [
                        "ncit:C172678"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "OFF_TYPE": {
                    "type": "Enum",
                    "tier": "",
                    "description": "The code used to designate that the subject went off therapy or off the study.",
                    "codes": [
                        "ncit:C173256"
                    ],
                    "implementation_notes": [
                        "Off protocol therapy means they have stopped protocol treatment, but are still being followed in the study"
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Protocol Therapy": {
                            "description": "No longer receiving protocol therapy.",
                            "codes": [
                                "ncit:C173257"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Study": {
                            "description": "No longer participating in a study; not being followed and will not be retreated.",
                            "codes": [
                                "ncit:C29851"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "REASON_OFF": {
                    "type": "Enum",
                    "tier": "",
                    "description": "The reason a subject went off the therapy or study.",
                    "codes": [
                        "ncit:C173519"
                    ],
                    "implementation_notes": [
                        "If multiple reasons \"off protocol therapy\" or \"off study\", include one observation per reason."
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Death": {
                            "description": "Specifies whether the life of an entity has ceased.",
                            "codes": [
                                "ncit:C93546"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Lost to Follow-Up": {
                            "description": "The subject was not available for follow-up procedures.",
                            "codes": [
                                "ncit:C70740"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Completion of Planned Therapy": {
                            "description": "The end of the planned treatment.",
                            "codes": [
                                "ncit:C168935"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Physician Decision": {
                            "description": "A position, opinion or judgment reached after consideration by a physician with reference to subject.",
                            "codes": [
                                "ncit:C48250"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Withdrawal of Consent": {
                            "description": "When the permission to do something is rescinded or withdrawn.",
                            "codes": [
                                "ncit:C48271"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Subject/Guardian Refused Further Treatment": {
                            "description": "The subject or their guardian has refused further treatment.",
                            "codes": [
                                "ncit:C168934"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Disease Progression": {
                            "description": "A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.",
                            "codes": [
                                "ncit:C35571"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Relapse": {
                            "description": "The return of a disease after a period of remission.",
                            "codes": [
                                "ncit:C38155"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Adverse Event": {
                            "description": "Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).",
                            "codes": [
                                "ncit:C41331"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Secondary Malignancy": {
                            "description": "A malignant neoplasm that arises from a pre-existing lower grade lesion, or as a result of a primary lesion that has spread to secondary sites, or due to a complication of a cancer treatment.",
                            "codes": [
                                "ncit:C4968"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            }
        },
        "demographics": {
            "demographics": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "SEX": {
                    "type": "Enum",
                    "tier": "",
                    "description": "The assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female.",
                    "codes": [
                        "ncit:C28421"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Male": {
                            "description": "A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both.",
                            "codes": [
                                "ncit:C20197"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Female": {
                            "description": "A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both.",
                            "codes": [
                                "ncit:C16576"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "RACE": {
                    "type": "Enum",
                    "tier": "",
                    "description": "A geographic ancestral origin category that is assigned to a population group based mainly on physical characteristics that are thought to be distinct and inherent.",
                    "codes": [
                        "ncit:C17049"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "American Indian or Alaska Native": {
                            "description": "A person having origins in any of the original peoples of North and South America (including Central America) and who maintains tribal affiliation or community attachment. (OMB)",
                            "codes": [
                                "ncit:C41259"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Asian": {
                            "description": "A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. (OMB)",
                            "codes": [
                                "ncit:C41260"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Black or African American": {
                            "description": "A person having origins in any of the Black racial groups of Africa. Terms such as \"Haitian\" or \"Negro\" can be used in addition to \"Black or African American\". (OMB)",
                            "codes": [
                                "ncit:C16352"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Multiracial": {
                            "description": "Having ancestors of several or various races.",
                            "codes": [
                                "ncit:C67109"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Native Hawaiian or Other Pacific Islander": {
                            "description": "A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. (OMB)",
                            "codes": [
                                "ncit:C41219"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "White": {
                            "description": "A person having origins in any of the original peoples of Europe, the Middle East, or North Africa. (OMB)",
                            "codes": [
                                "ncit:C41261"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "ETHNICITY": {
                    "type": "Enum",
                    "tier": "",
                    "description": "A social group characterized by a distinctive social and cultural tradition that is maintained from generation to generation. Members share a common history and origin and a sense of identification with the group. They have similar and distinctive features in their lifestyle habits and shared experiences. They often have a common genetic heritage which may be reflected in their experience of health and disease.",
                    "codes": [
                        "ncit:C16564"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Hispanic or Latino": {
                            "description": "A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. The term, \"Spanish origin,\" can be used in addition to \"Hispanic or Latino.\" (OMB)",
                            "codes": [
                                "ncit:C17459"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Hispanic or Latino": {
                            "description": "A person not of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.",
                            "codes": [
                                "ncit:C41222"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "medical_history": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "CONDITION": {
                    "type": "Enum",
                    "tier": "",
                    "description": "A health condition or medical problem that was diagnosed or treated before a specific date.",
                    "codes": [
                        "ncit:C54056"
                    ],
                    "implementation_notes": [
                        "If subject had multiple prior medical conditions, include one observation per condition."
                    ],
                    "mappings": [
                        "[aml_v1.7].[Medical History].[MEDICAL_HISTORY] skos:exactMatch [aml_v2.0].[Medical History].[CONDITION]"
                    ],
                    "permissible_values": {
                        "Trisomy 21": {
                            "description": "A chromosomal abnormality consisting of the presence of a third copy of chromosome 21 in somatic cells.",
                            "codes": [
                                "ncit:C43224"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Trisomy 21 Mosaicism": {
                            "description": "The presence of cells with and without three copies of chromosome 21 in either somatic or germinal tissue.",
                            "codes": [
                                "ncit:C142099"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "survival_characteristics": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_LKSS": {
                    "type": "Integer",
                    "tier": "",
                    "description": "Age of subject (in days) at the last known survival status.",
                    "codes": [
                        "ncit:C168844"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "LKSS": {
                    "type": "Enum",
                    "tier": "",
                    "description": "The individual's last known survival status.",
                    "codes": [
                        "ncit:C168931"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Alive": {
                            "description": "Showing characteristics of life; displaying signs of life.",
                            "codes": [
                                "ncit:C37987"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Dead": {
                            "description": "The cessation of life.",
                            "codes": [
                                "ncit:C28554"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "AGE_LOST_TO_FOLLOW_UP": {
                    "type": "Integer",
                    "tier": "",
                    "description": "Age of subject (in days) when the subject was lost to follow-up.",
                    "codes": [
                        "ncit:C172679"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "CAUSE_OF_DEATH": {
                    "type": "Enum",
                    "tier": "",
                    "description": "The circumstance or condition that results in the death of a living being.",
                    "codes": [
                        "ncit:C81239"
                    ],
                    "implementation_notes": [
                        "If multiple causes of death, include one observation per cause of death. However, only one cause of death can have the varaiable CAUSE_OF_DEATH_RANKING=Primary. ",
                        " Only fill in this variable if LKSS is \"Dead\""
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Disease Progression": {
                            "description": "An indication that the subject has died due to the progression of their disease.",
                            "codes": [
                                "ncit:C168970"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Pre-Treatment Disease Complications": {
                            "description": "A complication of the disease that existed prior to treatment.",
                            "codes": [
                                "ncit:C168876"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Post-Treatment Disease Complications": {
                            "description": "A complication of the disease that occurred after treatment.",
                            "codes": [
                                "ncit:C168877"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Treatment-Related Mortality": {
                            "description": "A death that is considered to be causally linked to a treatment.",
                            "codes": [
                                "ncit:C166165"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unrelated to Disease or Treatment": {
                            "description": "The cause of death of the subject is unrelated to the disease or treatment that was given.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "TRM_TYPE": {
                    "type": "Enum",
                    "tier": "",
                    "description": "The type of treatment related to the mortality of the subject.",
                    "codes": [
                        "ncit:C173260"
                    ],
                    "implementation_notes": [
                        "If multiple treatment types, include one observation per treatment type. ",
                        " Only fill in this variable if LKSS is \"Dead\" and CAUSE_OF_DEATH is \"Treatment-related mortality\""
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Stem Cell Transplant": {
                            "description": "A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.",
                            "codes": [
                                "ncit:C15431"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Immunotherapy": {
                            "description": "Therapy designed to induce changes in a patient's immune status in order to treat disease.",
                            "codes": [
                                "ncit:C15262"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Chemotherapy": {
                            "description": "The use of synthetic or naturally-occurring chemicals for the treatment of diseases.",
                            "codes": [
                                "ncit:C15632"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "CAUSE_OF_DEATH_DETAIL": {
                    "type": "Enum",
                    "tier": "",
                    "description": "Specific details of the cause of death.",
                    "codes": [
                        "ncit:C168868"
                    ],
                    "implementation_notes": [
                        "If multiple cause of death details, include one observation per cause of death detail. ",
                        " Only fill in this variable if LKSS is \"Dead\""
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Hemorrhage": {
                            "description": "In medicine, loss of blood from damaged blood vessels. A hemorrhage may be internal or external, and usually involves a lot of bleeding in a short time.",
                            "codes": [
                                "ncit:C26791"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Cardiac Failure": {
                            "description": "Inability of the heart to pump blood at an adequate rate to meet tissue metabolic requirements. Clinical symptoms of heart failure include: unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention or rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray presumed to be cardiac dysfunction.",
                            "codes": [
                                "ncit:C50577"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Bacterial Infection": {
                            "description": "An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.",
                            "codes": [
                                "ncit:C2890"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Viral Infection": {
                            "description": "Any disease caused by a virus.",
                            "codes": [
                                "ncit:C3439"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Fungal Infection": {
                            "description": "An infection caused by a fungus.",
                            "codes": [
                                "ncit:C3245"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Infection, Not Otherwise Specified": {
                            "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.",
                            "codes": [
                                "ncit:C128320"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Sinusoidal Obstruction Syndrome": {
                            "description": "A disorder characterized by inflammation and damage of the hepatic sinusoidal endothelial cells of the hepatic venules that leads to venular occlusion and hepatocellular necrosis. It is most often a conditioning-related toxicity that results as a complication of hematopoietic stem cell transplantation (HSCT). It has also been described in populations of individuals who have ingested pyrrolizidine plant alkaloids. The clinical signs and symptoms include hyperbilirubinemia, hepatomegaly, and fluid retention.",
                            "codes": [
                                "ncit:C26793"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Graft Versus Host Disease": {
                            "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.",
                            "codes": [
                                "ncit:C3063"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "CAUSE_OF_DEATH_RANKING": {
                    "type": "Enum",
                    "tier": "",
                    "description": "Assigning a weighted relevance to the cause of death.",
                    "codes": [
                        "ncit:C168932"
                    ],
                    "implementation_notes": [
                        "There may be multiple contributory causes of death, but only one primary cause of death. ",
                        " Only fill in this variable if LKSS is \"Dead\""
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Primary": {
                            "description": "The first significant event which ultimately led to death.",
                            "codes": [
                                "ncit:C99531"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Contributory": {
                            "description": "Any factor contributing to the cause of death.",
                            "codes": [
                                "ncit:C168948"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            }
        },
        "testing": {
            "vitals_and_anthropometrics": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_MEASUREMENT": {
                    "type": "Integer",
                    "tier": "To-do",
                    "description": "The age (in days) of the subject when the vitals measurement was taken.",
                    "codes": [
                        "ncit:C154628"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Vitals].[AGE_AT_VITALS] skos:exactMatch [aml_v2.0].[Vitals And Anthropometrics].[AGE_AT_MEASUREMENT]"
                    ]
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "MEASUREMENT_TYPE": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The measurement type of the vital sign or anthropomorphic measurement.",
                    "codes": [
                        "ncit:C49672"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Vitals].[VITALS_TEST] skos:exactMatch [aml_v2.0].[Vitals And Anthropometrics].[MEASUREMENT_TYPE]"
                    ],
                    "permissible_values": {
                        "Weight": {
                            "description": "The weight of a subject.",
                            "codes": [
                                "ncit:C81328"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Height": {
                            "description": "The vertical measurement or distance from the base to the top of a subject or participant.",
                            "codes": [
                                "ncit:C164634"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "BMI": {
                            "description": "The result of a body mass index measurement.",
                            "codes": [
                                "ncit:C138901"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "RESULT_TEXT": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The string/text result of the vitals or anthropomorphic measurement.",
                    "codes": [
                        "ncit:C173522"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Vitals].[VITALS_RESULT] skos:exactMatch [aml_v2.0].[Vitals And Anthropometrics].[RESULT_TEXT]"
                    ]
                },
                "RESULT_NUMERIC": {
                    "type": "Decimal",
                    "tier": "To-do",
                    "description": "The numeric result of the vitals or anthropomorphic measurement.",
                    "codes": [
                        "ncit:C173268"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Vitals].[VITALS_RESULT_NUMERIC] skos:exactMatch [aml_v2.0].[Vitals And Anthropometrics].[RESULT_NUMERIC]"
                    ]
                },
                "RESULT_UNIT": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The unit of the numeric vital sign or anthropomorphic measurement.",
                    "codes": [
                        "ncit:C49675"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Vitals].[VITALS_RESULT_UNIT] skos:exactMatch [aml_v2.0].[Vitals And Anthropometrics].[RESULT_UNIT]"
                    ],
                    "permissible_values": {
                        "kg": {
                            "description": "A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds.",
                            "codes": [
                                "ncit:C28252"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "cm": {
                            "description": "A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.",
                            "codes": [
                                "ncit:C49668"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "kg/m2": {
                            "description": "The SI derived unit of spread rate of a substance by mass, used also as a measure of area density and as a dose calculation unit.",
                            "codes": [
                                "ncit:C49671"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "function_test": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_FUNCTION_TEST": {
                    "type": "Integer",
                    "tier": "To-do",
                    "description": "The age (in days) of the subject at the time of the function test.",
                    "codes": [
                        "ncit:C185624"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "TEST": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The function test used on the subject.",
                    "codes": [
                        "ncit:C186304"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Function Test].[FUNCTION_CATEGORY] skos:exactMatch [aml_v2.0].[Function Test].[TEST]"
                    ],
                    "permissible_values": {
                        "Echocardiogram": {
                            "description": "A test that uses high-frequency sound waves (ultrasound) to create an image of the heart.",
                            "codes": [
                                "ncit:C16525"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "MEASUREMENT_TYPE": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The measurement type used to perform the function test on the subject.",
                    "codes": [
                        "ncit:C185625"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Function Test].[FUNCTION_TEST] skos:exactMatch [aml_v2.0].[Function Test].[MEASUREMENT_TYPE]"
                    ],
                    "permissible_values": {
                        "Ejection Fraction": {
                            "description": "The fraction of the left ventricular end diastolic volume ejected with each beat. The left ventricular ejection fraction is equal to the left ventricular stroke volume divided by the left ventricular end diastolic volume.",
                            "codes": [
                                "ncit:C99524"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Shortening Fraction": {
                            "description": "The fraction of the left ventricle diastolic dimension that is lost during systole; the measurement is calculated using the following formula: (end-diastolic dimension - end-systolic dimension) / end-diastolic dimension; the quotient is then multiplied by one hundred to be expressed as a percent.",
                            "codes": [
                                "ncit:C38020"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "RESULT_TEXT": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The string/text result of the function test.",
                    "codes": [
                        "ncit:C187025"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Function Test].[FUNCTION_RESULT] skos:exactMatch [aml_v2.0].[Function Test].[RESULT_TEXT]"
                    ]
                },
                "RESULT_NUMERIC": {
                    "type": "Decimal",
                    "tier": "To-do",
                    "description": "The numeric result of the function test.",
                    "codes": [
                        "ncit:C185629"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Function Test].[FUNCTION_RESULT_NUMERIC] skos:exactMatch [aml_v2.0].[Function Test].[RESULT_NUMERIC]"
                    ]
                },
                "RESULT_UNIT": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The unit of the numeric measurement of the function test.",
                    "codes": [
                        "ncit:C186305"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Function Test].[FUNCTION_RESULT_UNIT] skos:exactMatch [aml_v2.0].[Function Test].[RESULT_UNIT]"
                    ],
                    "permissible_values": {
                        "%": {
                            "description": "A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).",
                            "codes": [
                                "ncit:C48570"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "laboratory_test": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_LAB": {
                    "type": "Integer",
                    "tier": "To-do",
                    "description": "The age (in days) of the subject at the time of the laboratory test.",
                    "codes": [
                        "ncit:C172691"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "CATEGORY": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The category of laboratory test performed on the subject.",
                    "codes": [
                        "ncit:C83017"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Labs].[LAB_CATEGORY] skos:exactMatch [aml_v2.0].[Laboratory Test].[CATEGORY]"
                    ],
                    "permissible_values": {
                        "Bone Marrow Analysis": {
                            "description": "A laboratory analysis of a sample of bone marrow.",
                            "codes": [
                                "ncit:C173273"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Cerebrospinal Fluid Analysis": {
                            "description": "A laboratory analysis of a sample of cerebrospinal fluid.",
                            "codes": [
                                "ncit:C173272"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Peripheral Blood Analysis": {
                            "description": "A laboratory analysis of a sample of peripheral blood.",
                            "codes": [
                                "ncit:C173271"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "TEST": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "A medical procedure that involves testing a sample of blood, urine, or other substance from the body. Tests can help determine a diagnosis, plan treatment, check to see if treatment is working, or monitor the disease over time.",
                    "codes": [
                        "ncit:C117142"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Labs].[LAB_TEST] skos:exactMatch [aml_v2.0].[Laboratory Test].[TEST]"
                    ],
                    "permissible_values": {
                        "Auer Rods": {
                            "description": "The determination of the number of Auer rods present in a biospecimen.",
                            "codes": [
                                "ncit:C74657"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Blasts": {
                            "description": "The determination of the number of blast cells present in a blood sample.",
                            "codes": [
                                "ncit:C74605"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Hemoglobin": {
                            "description": "A quantitative measurement of the amount of hemoglobin present in a biospecimen.",
                            "codes": [
                                "ncit:C64848"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Platelets": {
                            "description": "The determination of the number of platelets in a biospecimen.",
                            "codes": [
                                "ncit:C51951"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "RBC": {
                            "description": "The determination of the number of erythrocytes in a biospecimen.",
                            "codes": [
                                "ncit:C51946"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "WBC": {
                            "description": "A test to determine the number of leukocytes in a biospecimen.",
                            "codes": [
                                "ncit:C51948"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "SPECIMEN": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The type of a material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes. This includes particular types of cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory substances.",
                    "codes": [
                        "ncit:C70713"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Labs].[LAB_SPEC_TYPE] skos:exactMatch [aml_v2.0].[Laboratory Test].[SPECIMEN]"
                    ],
                    "permissible_values": {
                        "Blood": {
                            "description": "A small volume of blood removed for testing or storage.",
                            "codes": [
                                "ncit:C17610"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Bone Marrow": {
                            "description": "The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.",
                            "codes": [
                                "ncit:C12431"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Cerebrospinal Fluid": {
                            "description": "The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord.",
                            "codes": [
                                "ncit:C12692"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "METHOD": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "A systematic course of action that is performed in order to complete a laboratory test.",
                    "codes": [
                        "ncit:C83312"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Labs].[LAB_METHOD] skos:exactMatch [aml_v2.0].[Laboratory Test].[METHOD]"
                    ],
                    "permissible_values": {
                        "Flow Cytometry": {
                            "description": "A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.",
                            "codes": [
                                "ncit:C16585"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Morphology Method": {
                            "description": "The technique used to administer the morphologic assessment.",
                            "codes": [
                                "ncit:C117624"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "RESULT_TEXT": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The string/text result of the laboratory test.",
                    "codes": [
                        "ncit:C36292"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Labs].[LAB_RESULT] skos:exactMatch [aml_v2.0].[Laboratory Test].[RESULT_TEXT]"
                    ]
                },
                "RESULT_NUMERIC": {
                    "type": "Decimal",
                    "tier": "To-do",
                    "description": "The numeric result of the laboratory test.",
                    "codes": [
                        "ncit:C70952"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Labs].[LAB_RESULT_NUMERIC] skos:exactMatch [aml_v2.0].[Laboratory Test].[RESULT_NUMERIC]"
                    ]
                },
                "RESULT_UNIT": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The unit of the numeric result of the laboratory test.",
                    "codes": [
                        "ncit:C173274"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Labs].[LAB_RESULT_UNIT] skos:exactMatch [aml_v2.0].[Laboratory Test].[RESULT_UNIT]"
                    ],
                    "permissible_values": {
                        "%": {
                            "description": "A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).",
                            "codes": [
                                "ncit:C48570"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "count/mm3": {
                            "description": "A count of items per cubic millimeter of sample.",
                            "codes": [
                                "ncit:C173275"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "g/dL": {
                            "description": "A unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one deciliter (100 milliliters). The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one gram occupies the volume one deciliter.",
                            "codes": [
                                "ncit:C64783"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "U/L": {
                            "description": "An arbitrary unit of substance concentration equal to the concentration at which one liter of mixture contains one unit of a substance.",
                            "codes": [
                                "ncit:C67456"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "mm/h": {
                            "description": "A unit of both speed (scalar) and velocity (vector), defined as the distance of one millimeter travelled per unit time equal to one hour.",
                            "codes": [
                                "ncit:C67419"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "mg/L": {
                            "description": "A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter.",
                            "codes": [
                                "ncit:C64572"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "TRAUMATIC_TAP": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "Did the subject's cerebrospinal fluid (CSF) sample contain more than 10 red blood cells per mm\u00b3 due to contamination?",
                    "codes": [
                        "ncit:C168879"
                    ],
                    "implementation_notes": [
                        "Notes: Traumatic tap is defined as cerebrospinal fluid with greater than 10 RBC/mm3. Note: Only fill in this variable if LAB_SAMPLE_SOURCE is \"CSF\""
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "molecular_analysis": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_MOLECULAR_ANALYSIS": {
                    "type": "Integer",
                    "tier": "n/a",
                    "description": "Age of subject (in days) when molecular analysis was performed.",
                    "codes": [
                        "ncit:C168848"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "MOLECULAR_ANALYSIS_METHOD": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "A request to enter the specific molecular analysis method used to detect abnormalities in the study.",
                    "codes": [
                        "ncit:C158954"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Karyotype": {
                            "description": "The preparation, analysis, and interpretation of a karyotype, the representation of the chromosome set of a cell.",
                            "codes": [
                                "ncit:C16768"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Fluorescence In Situ Hybridization": {
                            "description": "A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.",
                            "codes": [
                                "ncit:C17563"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Reverse Transcriptase-Polymerase Chain Reaction": {
                            "description": "A laboratory procedure in which an RNA strand is first transcribed into a DNA complement and then subjected to PCR amplification. Transcribing an RNA strand into a DNA complement is termed reverse transcription and is done by the enzyme reverse transcriptase.",
                            "codes": [
                                "ncit:C18136"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Next Generation Sequencing": {
                            "description": "Technologies that facilitate the rapid determination of the DNA sequence of large numbers of strands or segments of DNA.",
                            "codes": [
                                "ncit:C101293"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Capillary Electropheresis": {
                            "description": "An electrophoresis procedure, in which a sample is introduced into a capillary tube and the components are separated by the application of high voltage. Due to the large surface to volume ratio, cooling is more efficient, allowing use of higher voltages. As a result, separation occurs more quickly and sensitivity is increased. The technique allows for separation of proteins, nucleic acids, and carbohydrates.",
                            "codes": [
                                "ncit:C17637"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Gel Electropheresis": {
                            "description": "Gel electrophoresis is a method of separating large molecules (such as DNA fragments or proteins) from a mixture of similar molecules by electrophoretic filtration through a gelatinous matrix. Subject to an electric field, each molecule in the sample mixture migrates through the matrix at a different rate, depending mainly on electrical charge and size, resulting in spatial separation within the matrix of each molecular species in the sample mixture. Agarose and acrylamide in a cylindrical tube or slab gel are commonly used media for electrophoresis of proteins and nucleic acids.",
                            "codes": [
                                "ncit:C18091"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "ISCN": {
                    "type": "String",
                    "tier": "n/a",
                    "description": "The International System for Human Cytogenetic Nomenclature for the karyotype.",
                    "codes": [
                        "ncit:C173278"
                    ],
                    "implementation_notes": [
                        "Only fill in this variable if MOLECULAR_ANALYSIS_METHOD is \"Karyotype\""
                    ],
                    "mappings": []
                },
                "INDEPEN_AB": {
                    "type": "Integer",
                    "tier": "n/a",
                    "description": "The number of independent aberrations found in the karyotype during analysis.",
                    "codes": [
                        "ncit:C173279"
                    ],
                    "implementation_notes": [
                        "Only fill in this variable if MOLECULAR_ANALYSIS_METHOD is \"Karyotype\""
                    ],
                    "mappings": []
                },
                "NUM_METAPHASES": {
                    "type": "Integer",
                    "tier": "n/a",
                    "description": "The number of cells in metaphase during karyotype analysis.",
                    "codes": [
                        "ncit:C168918"
                    ],
                    "implementation_notes": [
                        "Only fill in this variable if MOLECULAR_ANALYSIS_METHOD is \"Karyotype\""
                    ],
                    "mappings": []
                },
                "MOLECULAR_ABNORMALITY": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "A molecular or cytogenic abnormality which occurs in either human disease states or disease models.",
                    "codes": [
                        "ncit:C3910"
                    ],
                    "implementation_notes": [
                        "If multiple molecular abnormalities, include one observation per molecular abnormality."
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "RUNX1-RUNX1T1 Fusion": {
                            "description": "A fusion gene (~4.3 kb) that results from a chromosomal translocation t(8;21)(q22;q22) which fuses the first 5 exons of the RUNX1 gene to exon 2 of the RUNX1T1 gene. This rearrangement is associated with acute myeloid leukemia.",
                            "codes": [
                                "ncit:C99294"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Trisomy 3": {
                            "description": "A chromosomal abnormality consisting of the presence of a third copy of chromosome 3 in somatic cells.",
                            "codes": [
                                "ncit:C36425"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(v;q23,3); KMT2A": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Biallelic CEBPA Gene Mutation": {
                            "description": "The presence of mutations in both alleles of the CEBPA gene.",
                            "codes": [
                                "ncit:C157569"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "CEBPA Gene Mutation": {
                            "description": "Mutation of the CEBPA gene encoding CCAAT/enhancer binding protein alpha. It is seen in acute myeloid leukemias usually associated with a normal karyotype.",
                            "codes": [
                                "ncit:C38372"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "CEBPA Mutation - Mutation Unspecified": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "CKIT Mutation - Ex17": {
                            "description": "A molecular genetic abnormality indicating the presence of a mutation in exon 17 of the KIT gene located within 4q11-q12.",
                            "codes": [
                                "ncit:C116396"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "CKIT Mutation - Ex8": {
                            "description": "A molecular genetic abnormality indicating the presence of a mutation in exon 8 of the KIT gene located within 4q11-q12.",
                            "codes": [
                                "ncit:C128660"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "CKIT Mutation - Unspecified": {
                            "description": "A molecular genetic abnormality that refers to mutation of the c-kit (CD117) proto-oncogene. It is associated with the development of gastrointestinal stromal tumor and gastrointestinal autonomic nerve tumor. It has also been described in acute myeloid leukemias, dysgerminomas, and seminomas.",
                            "codes": [
                                "ncit:C39712"
                            ],
                            "implementation_notes": [
                                "t(9;11)(p21.3;q23.3)"
                            ],
                            "mappings": []
                        },
                        "del(13q)": {
                            "description": "A cytogenetic abnormality that refers to the loss of all or part of the long arm of chromosome 13 (13q).",
                            "codes": [
                                "ncit:C36497"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "del(13q)(13q14-21)": {
                            "description": "A cytogenetic abnormality that refers to deletion of chromosome bands 14-21 on the long arm of chromosome 13.",
                            "codes": [
                                "ncit:C168770"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "del(17p)": {
                            "description": "A cytogenetic abnormality that refers to the loss of all or part of the short arm of chromosome 17 (17p).",
                            "codes": [
                                "ncit:C36499"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "del(5q)(5q31-q32)": {
                            "description": "A cytogenetic abnormality that refers to deletion of chromosome bands 31-32 on the long arm of chromosome 5.",
                            "codes": [
                                "ncit:C168769"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "der.12p": {
                            "description": "A cytogenetic abnormality involving the rearrangement of two or more other chromosomes with the short arm of chromosome 12 (12p).",
                            "codes": [
                                "ncit:C173542"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "ETV6-MN1 Fusion": {
                            "description": "A fusion gene that results from a chromosomal translocation t(12;22)(p13;q11-12) that fuses the 5' portion of the ETV6 gene to the 3' portion of the MN1 gene. This rearrangement is associated with both acute myeloid leukemia and refractory anemia with excess blasts.",
                            "codes": [
                                "ncit:C99678"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "FLT3 D835N Pathogenic Variant": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "FLT3 Internal Tandem Duplication": {
                            "description": "A genetic abnormality that arises from duplications of the juxtamembrane portion of the gene and results in constitutive activation of the FLT3 receptor tyrosine kinase protein in early hematopoietic progenitor cells. It is associated with acute myelogenous leukemia where it appears to correlate with a poor prognosis.",
                            "codes": [
                                "ncit:C67494"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "FLT3 Tyrosine Kinase Domain Point Mutation": {
                            "description": "Single nucleotide mutations in the tyrosine kinase domain encoded by the human FLT3 gene that are associated with acute myeloid leukemia and poor prognosis.",
                            "codes": [
                                "ncit:C67495"
                            ],
                            "implementation_notes": [
                                "t(6;9)(p23;q34.1)"
                            ],
                            "mappings": []
                        },
                        "GATA1 Mutation": {
                            "description": "A change in the nucleotide sequence of the GATA1 gene.",
                            "codes": [
                                "ncit:C82340"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "inv(16)(p13.3q24.3) / CBFA2T3-GLIS2": {
                            "description": "A pericentric chromosomal inversion that involves chromosome 16. It is associated with CBFA2T3/GLIS2 fusions and pediatric acute megakaryoblastic leukemia.",
                            "codes": [
                                "ncit:C167195"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "inv(16)(p13q22)": {
                            "description": "A chromosomal inversion that involves chromosome 16. It is associated with the development of acute myeloid leukemia CBFB-MYH11, acute myelomonocytic leukemia with abnormal eosinophils, and granulocytic sarcoma.",
                            "codes": [
                                "ncit:C36373"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "inv(3)(q21.3;q26.2)": {
                            "description": "A cytogenetic abnormality that refers to a paracentric inversion involving breakpoints on the long (q23.1 and q26.2) of chromosome 3. It is associated with acute myeloid leukemia.",
                            "codes": [
                                "ncit:C36407"
                            ],
                            "implementation_notes": [
                                "t(v;11q23.3)"
                            ],
                            "mappings": []
                        },
                        "K-RAS Mutation": {
                            "description": "A change in the nucleotide sequence of the KRAS gene.",
                            "codes": [
                                "ncit:C41361"
                            ],
                            "implementation_notes": [
                                "t(11;17)(q23;q12-21)"
                            ],
                            "mappings": []
                        },
                        "MLL Other Partner": {
                            "description": "A chromosomal abnormality consisting of the translocation of genetic material from any one of several chromosomes to the 11q23.3 region, resulting in an MLL gene rearrangement.",
                            "codes": [
                                "ncit:C36517"
                            ],
                            "implementation_notes": [
                                "t(8;16)(p11.2;p13.3)"
                            ],
                            "mappings": []
                        },
                        "MLL Rearrangement": {
                            "description": "A molecular abnormality indicating rearrangement of the MLL (KMT2A) gene.",
                            "codes": [
                                "ncit:C122623"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "MLL-MLLT10(AF10) Fusion": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "MLL-MLLT3 Fusion": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Monoallelic CEBPA Gene Mutation": {
                            "description": "The presence of mutations in only one allele of the CEBPA gene.",
                            "codes": [
                                "ncit:C168774"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Monosomy 5": {
                            "description": "A cytogenetic aneuploidy abnormality that refers to the presence of one chromosome 5 only. It is associated with the development of refractory anemia with excess blasts, refractory anemia with multilineage dysplasia, and refractory anemia with multilineage dysplasia and ringed sideroblasts.",
                            "codes": [
                                "ncit:C36523"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Monosomy 7": {
                            "description": "A chromosomal abnormality consisting of the absence of one of the copies of chromosome 7 in somatic cells.",
                            "codes": [
                                "ncit:C36411"
                            ],
                            "implementation_notes": [
                                "split"
                            ],
                            "mappings": []
                        },
                        "N-RAS Mutation": {
                            "description": "A change in the structure of the NRAS gene.",
                            "codes": [
                                "ncit:C41381"
                            ],
                            "implementation_notes": [
                                "split"
                            ],
                            "mappings": []
                        },
                        "Non-KMT2A MLLT10": {
                            "description": "An indication that a cytogenetic rearrangement involving MLLT10 but not involving KMT2A was detected in a sample.",
                            "codes": [
                                "ncit:C168771"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "NPM1 Mutation": {
                            "description": "Mutation of the nucleophosmin gene. It is seen in acute myeloid leukemias usually associated with a normal karyotype.",
                            "codes": [
                                "ncit:C168774"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "PML-RARA Fusion": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "t(9;22)(q34.1;q11.2)"
                            ],
                            "mappings": []
                        },
                        "PTPN11 Mutation": {
                            "description": "Mutation of the protein tyrosine phosphatase, non-receptor type 11 gene. It is seen in cases of juvenile myelomonocytic leukemia.",
                            "codes": [
                                "ncit:C82612"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "RUNX1 Mutation": {
                            "description": "A change in the nucleotide sequence of the RUNX1 gene.",
                            "codes": [
                                "ncit:C38362"
                            ],
                            "implementation_notes": [
                                "GATA2/MECOM Fusion Gene"
                            ],
                            "mappings": []
                        },
                        "t(1;11)(q21;q23) / MLL-MLLT11(AF1Q)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q21) of chromosome 1 and the long arm (q23) of chromosome 11. It is associated with KMT2A (MLL)/MLLT11 (AF1Q) fusions, acute myeloid leukemia and some cases of acute lymphoblastic leukemia.",
                            "codes": [
                                "ncit:C168759"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(1;22)(RBM15-MKL1)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the short arm (p13.3) of chromosome 1 and the long arm (q13.1) of chromosome 22. It is associated with RBM15/MRTFA (MKL1) fusions and acute megakaryocytic leukemia.",
                            "codes": [
                                "ncit:C36417"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(10;11)(p11.2;q23)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the short arm (p11.2) of chromosome 10 and the long arm (q23) of chromosome 11. It is associated with KMT2A (MLL)/ABI1 fusions and acute myeloid leukemia.",
                            "codes": [
                                "ncit:C168758"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(10;11)(p12;q23) / MLL-MLLT10(AF10)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of chromosome 10p12 with chromosome 11q23. It is associated with acute myeloid leukemia in childhood.",
                            "codes": [
                                "ncit:C132102"
                            ],
                            "implementation_notes": [
                                "t(1;22)(p13.3;q13.1)"
                            ],
                            "mappings": []
                        },
                        "t(11;15)(p15;q35) / NUP98/JARID1A": {
                            "description": "A cytogenetic abnormality that refers to the translocation of chromosome 11p15 with chromosome 15q35. It results in the formation of NUP98/JARID1A fusion gene. It is associated with the development of acute myeloid leukemia with t(11;15)(p15;q35); NUP98-JARID1A.",
                            "codes": [
                                "ncit:C131505"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(11;17)(AF17)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q23) of chromosome 11 and the long arm (q12-21) of chromosome 19. It is associated with KMT2A (MLL) fusions, including those with MLLT6 (AF17), and acute myeloid leukemia.",
                            "codes": [
                                "ncit:C168760"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(11;19)(q23;p13.1) / (MLL-ELL)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q23) of chromosome 11 and the short arm (p13.1) of chromosome 19. It is associated with the development of acute myeloid leukemia with variant MLL translocations and topoisomerase II inhibitor-related acute myeloid leukemia.",
                            "codes": [
                                "ncit:C36371"
                            ],
                            "implementation_notes": [
                                "KMT2A Gene Rearrangement"
                            ],
                            "mappings": []
                        },
                        "t(11;19)(q23;p13.3) / (MLL-ENL)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q23.3) of chromosome 11 and the short arm (p13.3) of chromosome 19. It is associated with KMT2A (MLL)/MLLT1 (ENL) fusions and acute myeloid leukemia.",
                            "codes": [
                                "ncit:C36372"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(11;19)(q23;p13) / (MLL-ENL)/(MLL-ELL)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q23) of chromosome 11 and the short arm (p13) of chromosome 19. It is associated with KMT2A (MLL) fusions, including those with MLLT1 (ENL) and ELL, and acute myeloid leukemia.",
                            "codes": [
                                "ncit:C168764"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(15;17)(q24;q21)": {
                            "description": "A chromosomal translocation associated with creation of a fusion between the PML and RARA genes. It is seen in variants of acute promyelocytic leukemia.",
                            "codes": [
                                "ncit:C27758"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(16;16)(p13.1;q22)": {
                            "description": "A chromosomal translocation that involves chromosome 16. It is often associated with the development of acute myeloid leukemia CBFB-MYH11, acute myelomonocytic leukemia with abnormal eosinophils, and granulocytic sarcoma.",
                            "codes": [
                                "ncit:C27759"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(16;21)(p11;q22) / FUS/ERG": {
                            "description": "A chromosomal translocation involving the FUS gene on chromosome 16p11 and the ERG gene on chromosome 21q22.",
                            "codes": [
                                "ncit:C36616"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(16;21)(q24;q22) / RUNX1-CBFA2T3": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q24) of chromosome 16 and the long arm (q22) of chromosome 22. It is associated with RUNX1/CBFA2T3 fusions, myelodysplastic syndromes and acute myeloid leukemia.",
                            "codes": [
                                "ncit:C168773"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(2;12)": {
                            "description": "A cytogenetic abnormality that involves a translocation between chromosomes 2 and 12.",
                            "codes": [
                                "ncit:C173543"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(3;12)(q23;p12.3) / ETV6/EVI1": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q23) of chromosome 3 and the shot arm (p12.3) of chromosome 12. It is associated with ETV6/MECOM (EVI1) fusions, myeloproliferative disorders, myelodysplastic syndromes and acute myelogenous leukemia.",
                            "codes": [
                                "ncit:C168766"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(3;3)(q21;q26.2)": {
                            "description": "A cytogenetic abnormality that refers to the translocation where both breakpoints are on the long arm (q23.1 and q26.2) of chromosome 3. It is associated with acute myeloid leukemia.",
                            "codes": [
                                "ncit:C36406"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(3;5)(q25;q34) / NPM1/MLF1": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q25) of chromosome 3 and the long arm (q34) of chromosome 5. It is associated with the development of acute myeloid leukemia arising from myelodysplastic syndrome, acute myeloid leukemia with multilineage dysplasia, and acute myeloid leukemia with myelodysplasia-related changes.",
                            "codes": [
                                "ncit:C36415"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(4;11)(q21;q23) / MLL-MLLT2(AF4)": {
                            "description": "A chromosomal abnormality consisting of the translocation of 4q21 with 11q23.",
                            "codes": [
                                "ncit:C36365"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(5;11)(q35;p15) / NSD1/NUP98": {
                            "description": "A cytogenetic abnormality that refers to the translocation of chromosome 11p15 with chromosome 5q35. It results in the formation of NUP98/NSD1 fusion gene. It is associated with the development of acute myeloid leukemia with t(5;11)(q35;p15); NUP98-NSD1.",
                            "codes": [
                                "ncit:C131503"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(6;11)(q27;q23) / MLL-MLLT4(AF6)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q27) of chromosome 6 and the long arm (q23) of chromosome 11. It is associated with the development of de novo acute myeloid leukemia.",
                            "codes": [
                                "ncit:C36610"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(6;9)(p23;q34) (DEK/NUP214)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the short arm (p23) of chromosome 6 and the long arm (q34.1) of chromosome 9. It is associated with DEK/NUP214 fusions, acute myeloid leukemia and myelodysplastic syndromes.",
                            "codes": [
                                "ncit:C36532"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(7;12)(q36;p13) / HLXB9(MNX1)/ETV6(TEL)": {
                            "description": "A chromosomal translocation involving the ETV6 gene on chromosome 12p13 and HLXB9 gene on chromosome 7q36.",
                            "codes": [
                                "ncit:C122689"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(8;16)MOZ/CBP": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the short arm (p11.2) of chromosome 8 and the short arm (p13.3) of chromosome 16. It is associated with KAT6A/CREBBP fusions and acute myeloid leukemia.",
                            "codes": [
                                "ncit:C167194"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(8;21)(q22;q22) RUNX1/ETO": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(9;11)(p22;q23) / MLL-MLLT3(AF9)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the short arm (p21.3) of chromosome 9 and the long arm (q23.3) of chromosome 11. It is associated with the development of acute myeloid leukemia with the MLLT3-MLL fusion gene transcript.",
                            "codes": [
                                "ncit:C36370"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(9;22)(q34;q11.2) / ABL/BCR": {
                            "description": "A translocation between chromosomes 9 and 22 that is associated with the Philadelphia chromosome.",
                            "codes": [
                                "ncit:C13271"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "TCF3-PBX1 Fusion": {
                            "description": "A fusion gene that results from a chromosomal translocation t(1;19)(q23;p13) which fuses intron 13 of the TCF3 gene with exon 2 of the PBX1 gene. This rearrangement is associated with pre-B cell acute lymphoblastic leukemia.",
                            "codes": [
                                "ncit:C99291"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Trisomy 21": {
                            "description": "A chromosomal abnormality consisting of the presence of a third copy of chromosome 21 in somatic cells.",
                            "codes": [
                                "ncit:C43224"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Trisomy 8": {
                            "description": "A chromosomal abnormality consisting of the presence of a third copy of chromosome 8 in somatic cells.",
                            "codes": [
                                "ncit:C36396"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Wild Type": {
                            "description": "The naturally-occurring, normal, non-mutated version of a gene or genome.",
                            "codes": [
                                "ncit:C62195"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "WT1 Mutation": {
                            "description": "A change in the nucleotide sequence of the WT1 gene.",
                            "codes": [
                                "ncit:C146726"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "CHROMOSOME": {
                    "type": "String",
                    "tier": "n/a",
                    "description": "One of the bodies in the cell nucleus that is the bearer of genes, has the form of a delicate chromatin filament during interphase, contracts to form a compact cylinder segmented into two arms by the centromere during metaphase and anaphase stages of cell division, and is capable of reproducing its physical and chemical structure through successive cell divisions.",
                    "codes": [
                        "ncit:C13202"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "GENE1": {
                    "type": "String",
                    "tier": "n/a",
                    "description": "The gene symbol that represents either a single gene that has a mutation or the gene that comprises the 5' portion of the coding sequence involved in a fusion gene mutation.",
                    "codes": [
                        "ncit:C173595"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "GENE2": {
                    "type": "String",
                    "tier": "n/a",
                    "description": "The gene symbol that represents the gene that comprises the 3' portion of the coding sequence for a fusion gene.",
                    "codes": [
                        "ncit:C171253"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "VARIANT_TYPE": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The category or type of variation or abnormality present in an amino acid or nucleic acid sequence.",
                    "codes": [
                        "ncit:C173544"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Translocation": {
                            "description": "A genetic exchange where a piece of one chromosome is transfered to another chromosome.",
                            "codes": [
                                "ncit:C3420"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Inversion": {
                            "description": "A structural change in genomic DNA where the 5' to 3' order of a nucleotide sequence is completely reversed to the 3' to 5' order relative to its adjacent sequences. This inversion is termed either pericentric, if it includes the centromere of a chromosome, or pancentric, if it excludes the centromere. An inversion mutation abnormality may be heritable or occur somatically.",
                            "codes": [
                                "ncit:C45589"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Mutation": {
                            "description": "Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer.",
                            "codes": [
                                "ncit:C45576"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Single Nucleotide Variant": {
                            "description": "A variation of a single nucleotide at a specific location of the genome due to base substitution, which is found at any frequency in the population.",
                            "codes": [
                                "ncit:C164674"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Copy Number Alteration": {
                            "description": "Variation in the number of copies of a particular sequence within the genetic material of an individual. Large-scale copy number polymorphisms are common and widely distributed in the human genome.",
                            "codes": [
                                "ncit:C40207"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Rearrangement": {
                            "description": "Any change in the structure of one or more chromosomes.",
                            "codes": [
                                "ncit:C36541"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Gain": {
                            "description": "A cytogenetic abnormality that refers to gain of an entire chromosome, a chromosome arm or a chromosomal band.",
                            "codes": [
                                "ncit:C36438"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Insertion": {
                            "description": "A chromosomal rearrangement in which a segment a segment of DNA is added internally to a chromosome.",
                            "codes": [
                                "ncit:C6828"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Deletion": {
                            "description": "Any rearrangement to the genomic content that results in the loss of one or more nucleotides of DNA. Deletions are generally irreversible rearrangements. They may alter the reading frame of a gene, or may result in loss of large chromosomal regions.",
                            "codes": [
                                "ncit:C19296"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "GENETIC_SEQ": {
                    "type": "String",
                    "tier": "n/a",
                    "description": "A variation in the nucleic acid sequence of a specific gene.",
                    "codes": [
                        "ncit:C97927"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "AA_MUTATION": {
                    "type": "String",
                    "tier": "n/a",
                    "description": "A variation in the amino acid sequence of a specific gene product.",
                    "codes": [
                        "ncit:C97928"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "MOLECULAR_ABNORMALITY_RESULT": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "An indicator for whether a molecular analysis procedure was performed and whether the assay detected a molecular abnormality.",
                    "codes": [
                        "ncit:C173596"
                    ],
                    "implementation_notes": [
                        "This variable indicates the result of testing for the molecular abnormality listed in MOLECULAR_ABNORMALITY"
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Positive": {
                            "description": "A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.",
                            "codes": [
                                "ncit:C38758"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Negative": {
                            "description": "A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.",
                            "codes": [
                                "ncit:C38757"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Done": {
                            "description": "Indicates a task, process or examination that has either not been initiated or not been completed.",
                            "codes": [
                                "ncit:C49484"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "ALLELIC_RATIO": {
                    "type": "Integer",
                    "tier": "n/a",
                    "description": "The determination of the ratio of variant alleles to wild-type alleles present in a sample.",
                    "codes": [
                        "ncit:C173545"
                    ],
                    "implementation_notes": [
                        "Only fill in this variable if the information is available."
                    ],
                    "mappings": []
                }
            }
        },
        "disease_attributes": {
            "diagnosis": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_DIAG_ASSESSMENT": {
                    "type": "Integer",
                    "tier": "To-do",
                    "description": "The age (in days) of the subject at the time of this diagnostic assessment.",
                    "codes": [
                        "ncit:C175004"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "DIAGNOSIS_BASIS": {
                    "type": "Enum",
                    "tier": "",
                    "description": "The type of diagnosis used for determining the medical condition.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Histological": {
                            "description": "Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.",
                            "codes": [
                                "ncit:C25526"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Integrated": {
                            "description": "Combining things, people, or ideas of different types in one effective unit, group, or system.",
                            "codes": [
                                "ncit:C165682"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "DIAGNOSIS": {
                    "type": "Enum",
                    "tier": "",
                    "description": "The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.",
                    "codes": [
                        "ncit:C15220"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "M0": {
                            "description": "Acute Myeloid Leukemia with Minimal Differentiation",
                            "codes": [
                                "ncit:C8460"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[FAB_TYPE].[M0] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[M0]"
                            ]
                        },
                        "M1": {
                            "description": "Acute Myeloid Leukemia without Maturation",
                            "codes": [
                                "ncit:C3249"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[FAB_TYPE].[M1] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[M1]"
                            ]
                        },
                        "M2": {
                            "description": "Acute Myeloid Leukemia with Maturation",
                            "codes": [
                                "ncit:C3250"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[FAB_TYPE].[M2] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[M2]"
                            ]
                        },
                        "M3": {
                            "description": "Acute Promyelocytic Leukemia with PML-RARA",
                            "codes": [
                                "ncit:C3182"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[FAB_TYPE].[M3] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[M3]"
                            ]
                        },
                        "M3 Variant": {
                            "description": "Acute promyelocytic leukemia in which the promyelocytes in the peripheral blood have paucity or absence of cytoplasmic granules and characteristic bilobed nuclei.",
                            "codes": [
                                "ncit:C27757"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[FAB_TYPE].[M3 Variant] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[M3 Variant]"
                            ]
                        },
                        "M4": {
                            "description": "Acute Myelomonocytic Leukemia",
                            "codes": [
                                "ncit:C7463"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[FAB_TYPE].[M4] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[M4]"
                            ]
                        },
                        "M4eo": {
                            "description": "Acute Myelomonocytic Leukemia with Abnormal Eosinophils",
                            "codes": [
                                "ncit:C9020"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[FAB_TYPE].[M4eo] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[M4eo]"
                            ]
                        },
                        "M5": {
                            "description": "Acute Monocytic Leukemia",
                            "codes": [
                                "ncit:C4861"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[FAB_TYPE].[M5] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[M5]"
                            ]
                        },
                        "M6": {
                            "description": "Acute Erythroid Leukemia",
                            "codes": [
                                "ncit:C8923"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[FAB_TYPE].[M6] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[M6]"
                            ]
                        },
                        "M7": {
                            "description": "Acute Megakaryoblastic Leukemia",
                            "codes": [
                                "ncit:C3170"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[FAB_TYPE].[M7] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[M7]"
                            ]
                        },
                        "AML, NOS": {
                            "description": "Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.",
                            "codes": [
                                "ncit:C27753"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[FAB_TYPE].[AML, NOS] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[AML, NOS]"
                            ]
                        },
                        "WHO >> Version 4 >> AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1": {
                            "description": "An acute myeloid leukemia with t(8;21)(q22; q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate.",
                            "codes": [
                                "ncit:C9288"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1]"
                            ]
                        },
                        "WHO >> Version 4 >> AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11": {
                            "description": "An acute myeloid leukemia with monocytic and granulocytic differentiation and the presence of a characteristically abnormal eosinophil component in the bone marrow. This type of acute myeloid leukemia has a favorable prognosis. (WHO, 2001)",
                            "codes": [
                                "ncit:C9287"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11]"
                            ]
                        },
                        "WHO >> Version 4 >> APL with PML-RARA": {
                            "description": "An acute promyelocytic leukemia with PML-RARA fusion occurring in children.",
                            "codes": [
                                "ncit:C7968"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  APL with PML-RARA] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  APL with PML-RARA]"
                            ]
                        },
                        "WHO >> Version 4 >> AML with t(9;11)(p21.3;q23.3); KMT2A-MLLT3": {
                            "description": "An acute myeloid leukemia associated with t(9;11)(p21.3;q23.3) and MLLT3-MLL (KMT2A) fusion protein expression. Morphologically it usually has monocytic features. It may present at any age but it is more commonly seen in children. Patients may present with disseminated intravascular coagulation.",
                            "codes": [
                                "ncit:C82403"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  AML with t(9;11)(p21.3;q23.3); KMT2A-MLLT3] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  AML with t(9;11)(p21.3;q23.3); KMT2A-MLLT3]"
                            ]
                        },
                        "WHO >> Version 5 >> AML with KMT2A Rearrangement": {
                            "description": "An acute myeloid leukemia associated with t(6;9)(p23;q34.1) resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It affects both children and adults and it usually has an unfavorable clinical outcome.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 5  AML with KMT2A Rearrangement] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 5  AML with KMT2A Rearrangement]"
                            ]
                        },
                        "WHO >> Version 4 >> AML with t(6;9)(p23;q34.1);DEK-NUP214": {
                            "description": "An acute myeloid leukemia associated with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.",
                            "codes": [
                                "ncit:C82423"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  AML with t(6;9)(p23;q34.1);DEK-NUP214] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  AML with t(6;9)(p23;q34.1);DEK-NUP214]"
                            ]
                        },
                        "WHO >> Version 4 >> AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM": {
                            "description": "An acute myeloid leukemia associated with t(1;22)(p13.3;q13.1) resulting in the expression of RBM15-MKL1 fusion protein. It affects infants and children and usually shows megakaryocytic maturation.",
                            "codes": [
                                "ncit:C82426"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM]"
                            ]
                        },
                        "WHO >> Version 4 >> AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1": {
                            "description": "A rare, de novo acute myeloid leukemia in which the blasts harbor BCR-ABL1 translocation in the absence of a history and clinical and laboratory features of chronic myelogenous leukemia.",
                            "codes": [
                                "ncit:C82427"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1]"
                            ]
                        },
                        "WHO >> Version 4 >> Provisional Entity: AML with BCR-ABL1": {
                            "description": "An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.",
                            "codes": [
                                "ncit:C129785"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  Provisional Entity: AML with BCR-ABL1] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  Provisional Entity: AML with BCR-ABL1]"
                            ]
                        },
                        "WHO >> Version 4 >> AML with Mutated NPM1": {
                            "description": "An acute myeloid leukemia with double mutations of the CEBPA gene.",
                            "codes": [
                                "ncit:C82431"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  AML with Mutated NPM1] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  AML with Mutated NPM1]"
                            ]
                        },
                        "WHO >> Version 4 >> AML with Biallelic Mutations of CEBPA": {
                            "description": "De novo acute myeloid leukemia with RUNX1 gene mutation, not associated with myelodysplastic syndrome-related cytogenetic abnormalities.",
                            "codes": [
                                "ncit:C129782"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  AML with Biallelic Mutations of CEBPA] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  AML with Biallelic Mutations of CEBPA]"
                            ]
                        },
                        "WHO >> Version 4 >> Provisional Entity: AML with Mutated RUNX1": {
                            "description": "An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood, and either a previous history of myelodysplastic syndrome, multilineage dysplasia or myelodysplastic syndrome-related cytogenetic abnormalities. There is no history of prior cytotoxic therapy for an unrelated disorder, and there is absence of the cytogenetic abnormalities that are present in acute myeloid leukemia with recurrent genetic abnormalities.",
                            "codes": [
                                "ncit:C129786"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  Provisional Entity: AML with Mutated RUNX1] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  Provisional Entity: AML with Mutated RUNX1]"
                            ]
                        },
                        "WHO >> Version 4 >> AML with Myelodysplasia-related Changes": {
                            "description": "Acute myeloid leukemias, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms arising as a result of the mutagenic effect of chemotherapy agents and/or radiation that are used for the treatment of neoplastic or non-neoplastic disorders.",
                            "codes": [
                                "ncit:C7600"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  AML with Myelodysplasia-related Changes] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  AML with Myelodysplasia-related Changes]"
                            ]
                        },
                        "WHO >> Version 4 >> Therapy-Related Myeloid Neoplasms": {
                            "description": "Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.",
                            "codes": [
                                "ncit:C27912"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  Therapy-Related Myeloid Neoplasms] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  Therapy-Related Myeloid Neoplasms]"
                            ]
                        },
                        "WHO >> Version 4 >> AML with Minimal Differentiation": {
                            "description": "Acute Myeloid Leukemia without Maturation",
                            "codes": [
                                "ncit:C8460"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  AML with Minimal Differentiation] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  AML with Minimal Differentiation]"
                            ]
                        },
                        "WHO >> Version 4 >> AML without Maturation": {
                            "description": "Acute Myeloid Leukemia with Maturation",
                            "codes": [
                                "ncit:C3249"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  AML without Maturation] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  AML without Maturation]"
                            ]
                        },
                        "WHO >> Version 4 >> AML with Maturation": {
                            "description": "Acute Myelomonocytic Leukemia",
                            "codes": [
                                "ncit:C3250"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  AML with Maturation] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  AML with Maturation]"
                            ]
                        },
                        "WHO >> Version 4 >> Acute Myelomonocytic Leukemia": {
                            "description": "Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features.",
                            "codes": [
                                "ncit:C7463"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  Acute Myelomonocytic Leukemia] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  Acute Myelomonocytic Leukemia]"
                            ]
                        },
                        "WHO >> Version 4 >> Acute Monoblastic/Monocytic Leukemia": {
                            "description": "Acute erythroid leukemia characterized by the presence of immature erythroid cells in the bone marrow (at least 80% of the cellular component), without evidence of a significant myeloblastic cell population present.",
                            "codes": [
                                "ncit:C7318"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  Acute Monoblastic/Monocytic Leukemia] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  Acute Monoblastic/Monocytic Leukemia]"
                            ]
                        },
                        "WHO >> Version 4 >> Pure Erythroid Leukemia": {
                            "description": "Acute Megakaryoblastic Leukemia",
                            "codes": [
                                "ncit:C7467"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  Pure Erythroid Leukemia] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  Pure Erythroid Leukemia]"
                            ]
                        },
                        "WHO >> Version 4 >> Acute Megakaryoblastic Leukemia": {
                            "description": "A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.",
                            "codes": [
                                "ncit:C3170"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  Acute Megakaryoblastic Leukemia] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  Acute Megakaryoblastic Leukemia]"
                            ]
                        },
                        "WHO >> Version 4 >> Acute Basophilic Leukemia": {
                            "description": "An acute myeloid leukemia characterized by bone marrow fibrosis without preexisting primary myelofibrosis.",
                            "codes": [
                                "ncit:C3164"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  Acute Basophilic Leukemia] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  Acute Basophilic Leukemia]"
                            ]
                        },
                        "WHO >> Version 4 >> Acute Panmyelosis with Myelofibrosis": {
                            "description": "A tumor mass composed of myeloblasts or immature myeloid cells. It occurs in extramedullary sites or the bone. (WHO, 2001)",
                            "codes": [
                                "ncit:C4344"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  Acute Panmyelosis with Myelofibrosis] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  Acute Panmyelosis with Myelofibrosis]"
                            ]
                        },
                        "WHO >> Version 4 >> Myeloid Sarcoma": {
                            "description": "Myeloid neoplasms occurring in individuals with Down syndrome. There is an increased risk of acute leukemias in both children and adults with Down syndrome. In particular, the incidence of acute myeloid leukemia in Down syndrome children of less than five years of age is particularly high, it is usually an acute megakaryoblastic leukemia, and is associated with GATA1 gene mutation. This group of disorders also includes the entity transient abnormal myelopoiesis which occurs in neonates and is associated with GATA1 gene mutation.",
                            "codes": [
                                "ncit:C3520"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  Myeloid Sarcoma] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  Myeloid Sarcoma] ",
                                " [aml_v1.7].[Myeloid Sarcoma Involvement].[MYELOID_SARCOMA].[Yes] skos:exactMatch [aml_v2.0].[Diagnosis].[Myeloid Sarcoma]"
                            ]
                        },
                        "WHO >> Version 4 >> Myeloid Proliferations Related to Down Syndrome": {
                            "description": "A myeloid proliferation occurring in newborns with Down syndrome.  It is clinically and morphologically indistinguishable from acute myeloid leukemia and is associated with GATA1 mutations.  The blasts display morphologic and immunophenotypic features of megakaryocytic lineage.  In the majority of patients the myeloid proliferation undergoes spontaneous remission.",
                            "codes": [
                                "ncit:C82338"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  Myeloid Proliferations Related to Down Syndrome] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  Myeloid Proliferations Related to Down Syndrome]"
                            ]
                        },
                        "WHO >> Version 4 >> Transient Abnormal Myelopoiesis (TAM)": {
                            "description": "Acute myeloid leukemia or myelodysplastic syndrome occurring in children with Down syndrome. The acute myeloid leukemia is usually an acute megakaryoblastic leukemia, and is associated with GATA1 gene mutation.",
                            "codes": [
                                "ncit:C82339"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  Transient Abnormal Myelopoiesis (TAM)] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[WHO  Version 4  Transient Abnormal Myelopoiesis (TAM)]"
                            ]
                        },
                        "WHO >> Version 4 >> Myeloid Leukemia Associated with Down Syndrome": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C43223"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[WHO_AML].[WHO  Version 4  Myeloid Leukemia Associated with Down Syndrome] skos:exactMatch [aml_v2.0].[Diagnosis].[WHO  Version 4  Myeloid Leukemia Associated with Down Syndrome]"
                            ]
                        },
                        "CNS1": {
                            "description": "The status of central nervous system leukemia at diagnosis, where there is an absence of blasts on a cerebral spinal fluid cytospin preparation, regardless of the number of white blood cells.",
                            "codes": [
                                "ncit:C116833"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[CNS_DISEASE_STATUS].[CNS1] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[CNS1]"
                            ]
                        },
                        "CNS2": {
                            "description": "The status of central nervous system leukemia at diagnosis, where there are less than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts; or greater than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is considered negative by Steinherz/Bleyer algorithm.",
                            "codes": [
                                "ncit:C116834"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[CNS_DISEASE_STATUS].[CNS2] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[CNS2]"
                            ]
                        },
                        "CNS3": {
                            "description": "The status of central nervous system leukemia at diagnosis, where there are more than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts; with or without clinical signs of CNS leukemia.",
                            "codes": [
                                "ncit:C116835"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Disease Characteristics].[CNS_DISEASE_STATUS].[CNS3] skos:exactMatch [aml_v2.0].[Diagnosis].[DIAGNOSIS].[CNS3]"
                            ]
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "MPAL": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "An acute leukemia of ambiguous lineage. It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.",
                    "codes": [
                        "ncit:C82179"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Disease Characteristics].[MPAL] skos:exactMatch [aml_v2.0].[Diagnosis].[MPAL]"
                    ],
                    "permissible_values": {
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "MLDS": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "Does the subject have myelodysplastic syndrome?",
                    "codes": [
                        "ncit:C43223"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Disease Characteristics].[MLDS] skos:exactMatch [aml_v2.0].[Diagnosis].[MLDS]"
                    ],
                    "permissible_values": {
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "TAM": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "Does the patient have transient abnormal myelopoiesis (TAM)? TAM is a myeloid proliferation occurring in newborns with Down syndrome. It is clinically and morphologically indistinguishable from acute myeloid leukemia and is associated with GATA1 mutations. The blasts display morphologic and immunophenotypic features of megakaryocytic lineage. In the majority of patients the myeloid proliferation undergoes spontaneous remission.",
                    "codes": [
                        "ncit:C82339"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Disease Characteristics].[TAM] skos:exactMatch [aml_v2.0].[Diagnosis].[TAM]"
                    ],
                    "permissible_values": {
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "SECONDARY_AML": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "Did an acute myeloid leukemia arise from prior myelodysplastic syndrome, myeloproliferative neoplasm, or myelodysplastic/myeloproliferative neoplasm, or as a result of previous exposure to alkylating agents or topoisomerase II inhibitors?",
                    "codes": [
                        "ncit:C25765"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Disease Characteristics].[SECONDARY_AML] skos:exactMatch [aml_v2.0].[Diagnosis].[SECONDARY_AML]"
                    ],
                    "permissible_values": {
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "disease_site_assessment": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_SITE_ASSESSMENT": {
                    "type": "Integer",
                    "tier": "Optional",
                    "description": "",
                    "codes": [
                        "ncit:C175004"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "DETECTION_METHOD": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The method used to detect the extent of the disease involvement.",
                    "codes": [
                        "ncit:C173262"
                    ],
                    "implementation_notes": [
                        "If there were multiple detection methods, include one observation per detection method. If disease site provided, detection method should be linked to each disease site. If no disease sites provided, detection method should be linked to overall disease."
                    ],
                    "mappings": [
                        "[aml_v1.7].[Disease Characteristics].[DETECTION_METHOD] skos:exactMatch [aml_v2.0].[Disease Site Assessment].[DETECTION_METHOD]"
                    ],
                    "permissible_values": {
                        "Cerebrospinal Fluid Results": {
                            "description": "The results of cerebrospinal fluid laboratory tests.",
                            "codes": [
                                "ncit:C168884"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Clinical Signs or Symptoms": {
                            "description": "Objective evidence of disease perceptible to the examining practitioner (sign) and subjective evidence of disease perceived by the patient (symptom).",
                            "codes": [
                                "ncit:C100104"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Bone Marrow Results": {
                            "description": "The results of bone marrow laboratory tests.",
                            "codes": [
                                "ncit:C190021"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Imaging": {
                            "description": "Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.",
                            "codes": [
                                "ncit:C17369"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "SITE": {
                    "type": "Enum",
                    "tier": "Mandatory",
                    "description": "The anatomic site of the disease.",
                    "codes": [
                        "ncit:C173263"
                    ],
                    "implementation_notes": [
                        "Note: If multiple sites of disease involvement, include one observation per site."
                    ],
                    "mappings": [
                        "[aml_v1.7].[Disease Characteristics].[DISEASE_SITE] skos:exactMatch [aml_v2.0].[Disease Site Assessment].[SITE]"
                    ],
                    "permissible_values": {
                        "Bone Marrow": {
                            "description": "The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.",
                            "codes": [
                                "ncit:C12431"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Central Nervous System": {
                            "description": "The part of the nervous system that consists of the brain, spinal cord, and meninges.",
                            "codes": [
                                "ncit:C12438"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Bone": {
                            "description": "Connective tissue that forms the skeletal components of the body.",
                            "codes": [
                                "ncit:C12366"
                            ],
                            "implementation_notes": [
                                "D4CGNote: Only use when DIAGNOSIS = \"Myeloid Sarcoma\""
                            ],
                            "mappings": [
                                "[aml_v1.7].[Myeloid Sarcoma Involvement].[MYELOID_SARCOMA_SITE].[Bone] skos:exactMatch [aml_v2.0].[Disease Site Assessment].[SITE].[Bone]"
                            ]
                        },
                        "Orbit": {
                            "description": "The bony cavity of the skull which contains the eye, anterior portion of the optic nerve, ocular muscles and ocular adnexa. Seven bones contribute to the structure of the orbit: the frontal, maxillary, zygomatic, sphenoid, lacrimal, ethmoid, and palatine bones.",
                            "codes": [
                                "ncit:C12347"
                            ],
                            "implementation_notes": [
                                "D4CGNote: Only use when DIAGNOSIS = \"Myeloid Sarcoma\""
                            ],
                            "mappings": [
                                "[aml_v1.7].[Myeloid Sarcoma Involvement].[MYELOID_SARCOMA_SITE].[Orbit] skos:exactMatch [aml_v2.0].[Disease Site Assessment].[SITE].[Orbit]"
                            ]
                        },
                        "Skin": {
                            "description": "An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.",
                            "codes": [
                                "ncit:C12470"
                            ],
                            "implementation_notes": [
                                "D4CGNote: Only use when DIAGNOSIS = \"Myeloid Sarcoma\""
                            ],
                            "mappings": [
                                "[aml_v1.7].[Myeloid Sarcoma Involvement].[MYELOID_SARCOMA_SITE].[Skin] skos:exactMatch [aml_v2.0].[Disease Site Assessment].[SITE].[Skin]"
                            ]
                        },
                        "Testes": {
                            "description": "Either of the paired male reproductive glands that produce the male germ cells and the male hormones.",
                            "codes": [
                                "ncit:C12412"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            }
        },
        "treatment": {
            "medication": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_MEDICATION_START": {
                    "type": "Integer",
                    "tier": "To-do",
                    "description": "The age (in days) of the subject at the start of this medication treatment.",
                    "codes": [
                        "ncit:C172698"
                    ],
                    "implementation_notes": [
                        "Note: In the case of \"Intrathecal Chemotherapy,\" the age at the start is based on intention-to-treat."
                    ],
                    "mappings": [
                        "[aml_v1.7].[Total Dose].[AGE_AT_TOTAL_DOSE_START] skos:exactMatch [aml_v2.0].[Medication].[AGE_AT_MEDICATION_START]"
                    ]
                },
                "AGE_AT_MEDICATION_END": {
                    "type": "Integer",
                    "tier": "To-do",
                    "description": "The age (in days) of the subject at the end of this medication treatment.",
                    "codes": [
                        "ncit:C172686"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Total Dose].[AGE_AT_TOTAL_DOSE_END] skos:exactMatch [aml_v2.0].[Medication].[AGE_AT_MEDICATION_END]"
                    ]
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "CATEGORY": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "A classification of medication agents.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Chemotherapeutic Agent": {
                            "description": "A substance that inhibits the maturation, growth or spread of tumor cells.",
                            "codes": [
                                "ncit:C274"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Concomitant Agent": {
                            "description": "A pharmaceutical agent other than agent(s) tested in a given protocol that is administered to or used by a subject either prior to or during the study. Supportive care and essential ancillary medications required by a treatment regimen should be clearly identified. A protocol's complete instructions including appropriate indication, dosage, administration route, schedule, restrictions to use, and any other relevant data should be explicitly stated. Concept also refers to substance(s) used prior or during the study that are not specified by the protocol.",
                            "codes": [
                                "ncit:C70902"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "ADMINISTRATION_STATUS": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The status of the medication administration.",
                    "codes": [
                        "ncit:C173297"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Medication Administered": {
                            "description": "An indication that medication was administered.",
                            "codes": [
                                "ncit:C173298"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Medication Not Administered": {
                            "description": "An indication that medication was not administered.",
                            "codes": [
                                "ncit:C173299"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "ROUTE": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The intended area to be affected by the choice of a particular route of administration of a medication.",
                    "codes": [
                        "ncit:C186559"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Systemic": {
                            "description": "Immunotherapy that is disseminated throughout the body via the bloodstream.",
                            "codes": [
                                "ncit:C173291"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Intrathecal": {
                            "description": "Immunotherapy that is administered into the cerebrospinal fluid.",
                            "codes": [
                                "ncit:C173292"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "MEDICATION": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "A dosage form that contains one or more active and/or inactive ingredients. Medications come in many dosage forms, including tablets, capsules, liquids, creams, and patches. They can also be given in different ways, such as by mouth, by infusion into a vein, or by drops that are put into the ear or eye. The form with the active ingredient is used to prevent, diagnose, treat, or relieve symptoms of a disease or abnormal condition. A medication that does not contain an active ingredient and is used in research studies is called a placebo. Also called drug product.",
                    "codes": [
                        "ncit:C459"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Total Dose].[ANTINEOPLASTIC_AGENT] skos:exactMatch [aml_v2.0].[Medication].[MEDICATION]"
                    ],
                    "permissible_values": {
                        "Amsacrine": {
                            "description": "An aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis.",
                            "codes": [
                                "ncit:C240",
                                "rxcui:739"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Arsenic Trioxide": {
                            "description": "A small-molecule arsenic compound with antineoplastic activity. The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)",
                            "codes": [
                                "ncit:C1005",
                                "rxcui:18330"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Bortezomib": {
                            "description": "A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.",
                            "codes": [
                                "ncit:C1851",
                                "rxcui:358258"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Busulfan": {
                            "description": "A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties. Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA. Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)",
                            "codes": [
                                "ncit:C321",
                                "rxcui:1828"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Cladribine": {
                            "description": "A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.",
                            "codes": [
                                "ncit:C1336",
                                "rxcui:44157"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Clofarabine": {
                            "description": "A second generation purine nucleoside analog with antineoplastic activity.",
                            "codes": [
                                "ncit:C26638",
                                "rxcui:44151"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Cyclophosphamide": {
                            "description": "A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.",
                            "codes": [
                                "ncit:C405",
                                "rxcui:3002"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Cytarabine": {
                            "description": "An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)",
                            "codes": [
                                "ncit:C408",
                                "rxcui:3041"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Daunorubicin": {
                            "description": "An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.",
                            "codes": [
                                "ncit:C62091",
                                "rxcui:3109"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Daunorubicin (Liposomal)": {
                            "description": "A liposome-encapsulated form of the citrate salt of the anthracycline antineoplastic antibiotic daunorubicin. Daunorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Liposomal delivery of doxorubicin citrate improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.",
                            "codes": [
                                "ncit:C2213",
                                "rxcui:214468"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Daunorubicin and Cytarabine (Liposomal)": {
                            "description": "A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids.",
                            "codes": [
                                "ncit:C67504",
                                "rxcui:2017575"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Dexrazoxane": {
                            "description": "A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.",
                            "codes": [
                                "ncit:C1333"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Concomitant Medication].[MEDICATION].[Dexrazoxane] skos:exactMatch [aml_v2.0].[Medication].[MEDICATION].[Dexrazoxane]"
                            ]
                        },
                        "Doxorubicin": {
                            "description": "An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.",
                            "codes": [
                                "ncit:C456",
                                "rxcui:3639"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Etoposide": {
                            "description": "A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum. Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)",
                            "codes": [
                                "ncit:C491",
                                "rxcui:4179"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Fludarabine": {
                            "description": "A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth. (NCI04)",
                            "codes": [
                                "ncit:C1094"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Gemtuzumab Ozogamicin": {
                            "description": "A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)",
                            "codes": [
                                "ncit:C1806",
                                "rxcui:1294580"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Gilteritinib": {
                            "description": "An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246), with potential antineoplastic activity. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL and ALK. This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and reduces tumor cell proliferation in cancer cell types that overexpress these RTKs. FLT3, AXL and ALK, overexpressed or mutated in a variety of cancer cell types, play a key role in tumor cell growth and survival.",
                            "codes": [
                                "ncit:C116722",
                                "rxcui:2105806"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Hydrocortisone Sodium Succinate": {
                            "description": "The sodium salt of hydrocortisone succinate with glucocorticoid property. Hydrocortisone sodium succinate is chemically similar to the endogenous hormone that stimulates anti-inflammatory and immunosuppressive activities, in addition to exhibiting minor mineralocorticoid effects. This agent binds to intracellular glucocorticoid receptors and is translocated into the nucleus, where it initiates the transcription of glucocorticoid-responsive genes, such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation.",
                            "codes": [
                                "ncit:C1819",
                                "rxcui:235483"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Idarubicin": {
                            "description": "A semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin.",
                            "codes": [
                                "ncit:C562",
                                "rxcui:5650"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Melphalan": {
                            "description": "A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.",
                            "codes": [
                                "ncit:C633",
                                "rxcui:6718"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Methotrexate": {
                            "description": "An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.",
                            "codes": [
                                "ncit:C642",
                                "rxcui:6851"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Midostaurin": {
                            "description": "A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.",
                            "codes": [
                                "ncit:C1872",
                                "rxcui:1919083"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Quizartinib": {
                            "description": "An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.",
                            "codes": [
                                "ncit:C68936"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Sorafenib": {
                            "description": "A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.",
                            "codes": [
                                "ncit:C61948",
                                "rxcui:495881"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Thiotepa": {
                            "description": "A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.",
                            "codes": [
                                "ncit:C875",
                                "rxcui:10473"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Tretinoin": {
                            "description": "A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis. This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types. The oral form of tretinoin has teratogenic and embryotoxic properties.",
                            "codes": [
                                "ncit:C900",
                                "rxcui:110753"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "NUMBER_DOSES": {
                    "type": "Decimal",
                    "tier": "To-do",
                    "description": "Number of times a dose of the medication was administered between the AGE_AT_MEDICATION_START and AGE_AT_MEDICATION_END values.",
                    "codes": [
                        "ncit:C173293"
                    ],
                    "implementation_notes": [
                        "Note: Number of doses of chemotherapy agent administered over the indicated start and end time points Note: Only fill in this variable if this information is available."
                    ],
                    "mappings": []
                },
                "TOTAL_DOSE_ADMINISTERED": {
                    "type": "Decimal",
                    "tier": "To-do",
                    "description": "Total amount of medication administered between the AGE_AT_MEDICATION_START and AGE_AT_MEDICATION values. Assuming all doses administered are the same amount of medication, this value should be equal to the amount of medication given at each dose multiplied by the number of doses.",
                    "codes": [
                        "ncit:C94394"
                    ],
                    "implementation_notes": [
                        "Note: Total dose of the chemotherapy agent administered to the subject over the indicated start and end time points. Note: Only fill in this variable if this information is available."
                    ],
                    "mappings": []
                },
                "TOTAL_DOSE_INTENDED": {
                    "type": "Decimal",
                    "tier": "To-do",
                    "description": "This is the total amount of medication that was intended to be administered either by trial protocol, by prescription, or other indicator at the time point of AGE_AT_MEDICATION_START. Often, this will be equal to TOTAL_DOSE_ADMINISTERED. If TOTAL_DOSE_ADMINISTERED and TOTAL_DOSE_INTENDED are different, this indicates a deviation from the protocol or plan and may be due to a variety of factors including patient intolerance, patient non-adherence, etc.",
                    "codes": [
                        "ncit:C173294"
                    ],
                    "implementation_notes": [
                        "Note: Intention-to-treat total dose of the chemotherapy agent over the indicated start and end time points. Note: Only fill in this variable if this information is available."
                    ],
                    "mappings": []
                },
                "TOTAL_DOSE_UNIT": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The units of the total dose administered to the subject.",
                    "codes": [
                        "ncit:C17395"
                    ],
                    "implementation_notes": [
                        "Note: Unit for TOTAL_DOSE_ADMINISTERED and TOTAL_DOSE_INTENDED must be the same."
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "mg/m2": {
                            "description": "A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.",
                            "codes": [
                                "ncit:C67402"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "radiation_therapy": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_RT_START": {
                    "type": "Integer",
                    "tier": "To-do",
                    "description": "The age (in days) of the subject at the start of this radiation treatment.",
                    "codes": [
                        "ncit:C172695"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "AGE_AT_RT_END": {
                    "type": "Integer",
                    "tier": "To-do",
                    "description": "The age (in days) of the subject at the end of this radiation treatment.",
                    "codes": [
                        "ncit:C172696"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "SITE": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The anatomic site of the radiation therapy.",
                    "codes": [
                        "ncit:C173281"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Radiation Therapy].[RT_SITE] skos:exactMatch [aml_v2.0].[Radiation Therapy].[SITE]"
                    ],
                    "permissible_values": {
                        "Cranium": {
                            "description": "The bones that form the head, made up of the bones of the braincase and face.",
                            "codes": [
                                "ncit:C12789"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "DOSE": {
                    "type": "Decimal",
                    "tier": "To-do",
                    "description": "The total radiation dose administered.",
                    "codes": [
                        "ncit:C173282"
                    ],
                    "implementation_notes": [
                        "Note: Total dose of radiation over the period encompassed by AGE_AT_RT_START to _AGE_AT_RT_END"
                    ],
                    "mappings": [
                        "[aml_v1.7].[Radiation Therapy].[RT_DOSE] skos:exactMatch [aml_v2.0].[Radiation Therapy].[DOSE]"
                    ]
                },
                "DOSE_UNIT": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "A unit of measurement of the dose of radiation received or absorbed.",
                    "codes": [
                        "ncit:C18068"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Radiation Therapy].[RT_UNIT] skos:exactMatch [aml_v2.0].[Radiation Therapy].[DOSE_UNIT]"
                    ],
                    "permissible_values": {
                        "Gy": {
                            "description": "A SI derived unit of absorbed radiation dose. One gray is equal to an absorbed dose of one joule per kilogram of matter, or to 100 rads.",
                            "codes": [
                                "ncit:C18063"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "stem_cell_transplant": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_SCT": {
                    "type": "Integer",
                    "tier": "n/a",
                    "description": "Age of subject (in days) at the time of stem-cell transplantation.",
                    "codes": [
                        "ncit:C168853"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": []
                },
                "SCT_TYPE": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "Type of stem-cell transplantation the subject received.",
                    "codes": [
                        "ncit:C168864"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Autologous, Single": {
                            "description": "An autologous stem cell transplant performed once. In this procedure, a patient's own stem cells are collected, stored, and then reinfused after intensive chemotherapy or radiation therapy. The purpose is to restore the bone marrow and blood cell production that the aggressive treatment has destroyed.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Autologous, Tandem": {
                            "description": "Therapy that combines cytoreductive-therapy from high-dose therapy and autologous hematopoietic cell transplantation with adoptive immunotherapy (from autologous hematopoietic cell transplantation) as a treatment strategy for multiple myeloma.",
                            "codes": [
                                "ncit:C116466"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Autologous, NOS": {
                            "description": "Stem cell transfer or transplantation in which the patient is their own donor.",
                            "codes": [
                                "ncit:C201465"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Stem Cell Transplant].[SCT_TYPE].[Autologous] skos:exactMatch [aml_v2.0].[Stem Cell Transplant].[SCT_TYPE].[Autologous, NOS]"
                            ]
                        },
                        "Allogeneic": {
                            "description": "A clinical treatment in which hematopoietic stem cells (HSCs) are transferred from one genetically dissimilar individual to another.",
                            "codes": [
                                "ncit:C46089"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "STEM_CELL_SOURCE": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The source of the stem cells for the stem cell transplant.",
                    "codes": [
                        "ncit:C168870"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Stem Cell Transplant].[SCT_SOURCE] skos:exactMatch [aml_v2.0].[Stem Cell Transplant].[STEM_CELL_SOURCE]"
                    ],
                    "permissible_values": {
                        "Bone Marrow": {
                            "description": "The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.",
                            "codes": [
                                "ncit:C12431"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Peripheral Blood": {
                            "description": "Blood drawn from a limb.",
                            "codes": [
                                "ncit:C173496"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Cord Blood": {
                            "description": "Blood present in the umbilical vessels at the time of delivery. If cryopreserved at birth, cord blood can serve as a source of hematopoietic progenitor cells for transplantation to a patient later diagnosed and treated for a hematopoietic disorder.",
                            "codes": [
                                "ncit:C13300"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Stem Cell Mixture": {
                            "description": "A mixture of different sources of stem cells.",
                            "codes": [
                                "ncit:C168886"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "DONOR_RELATIONSHIP": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The biological relationship between the stem cell donor and the recipients.",
                    "codes": [
                        "ncit:C168869"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Stem Cell Transplant].[SCT_DONOR_RELATIONSHIP] skos:exactMatch [aml_v2.0].[Stem Cell Transplant].[DONOR_RELATIONSHIP]"
                    ],
                    "permissible_values": {
                        "Biological Sibling": {
                            "description": "A person's brother or sister with whom they share a genetic makeup inherited from one or both of their shared biological parents.",
                            "codes": [
                                "ncit:C100809"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Biological Parent": {
                            "description": "The male who supplied the sperm or the female who supplied the egg which resulted in one's conception.",
                            "codes": [
                                "ncit:C166114"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Biological Relative": {
                            "description": "A person related by descent rather than by marriage or law.",
                            "codes": [
                                "ncit:C71384"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Biologically Unrelated": {
                            "description": "A person who is biologically unrelated to another individual.",
                            "codes": [
                                "ncit:C130053"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "HLA_MATCH": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "A process in which blood or tissue samples are analyzed to determine their human leukocyte antigen (HLA) profiles so that transplant materials can be transferred into a patient with the same or similar profile.",
                    "codes": [
                        "ncit:C169009"
                    ],
                    "implementation_notes": [
                        "the term should be about the HLA matching result (ie match status), not the process - NCI will massage this term's definition (HLA Match status)"
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Match": {
                            "description": "The state when a recipient and their donor have the same alleles for tissue markers. A full match includes HLA-A, HLA-B, HLA-C, and HLA-DRB1. HLA match typing may also include alleles in the HLA-DQ serogroup.",
                            "codes": [
                                "ncit:C129972"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Non-Match": {
                            "description": "The state when a recipient of a hematopoietic stem cell transplant is not fully matched with their donor for HLA-A, HLA-B, HLA-C, and HLA-DRB1.",
                            "codes": [
                                "ncit:C126298"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "NUMBER_HLA": {
                    "type": "Integer",
                    "tier": "n/a",
                    "description": "The number of human leukocyte antigens that were evaluated.",
                    "codes": [
                        "ncit:C173301"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "NUMBER_MATCHES": {
                    "type": "Integer",
                    "tier": "n/a",
                    "description": "The number of human leukocyte antigens that matched between the donor and the recipient.",
                    "codes": [
                        "ncit:C173302"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "HLA_A_RESULT": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The extent of HLA-A matching between the donor and the recipient.",
                    "codes": [
                        "ncit:C168923"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Both Alleles Matched": {
                            "description": "Both alleles match for one HLA locus",
                            "codes": [
                                "ncit:C168821"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "One Allele Mismatched": {
                            "description": "One allele matches for one HLA locus.",
                            "codes": [
                                "ncit:C168819"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Two Alleles Mismatched": {
                            "description": "A mismatch exists at both alleles.",
                            "codes": [
                                "ncit:C168820"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "HLA_B_RESULT": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The extent of HLA-B matching between the donor and the recipient.",
                    "codes": [
                        "ncit:C168924"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Both Alleles Matched": {
                            "description": "Both alleles match for one HLA locus",
                            "codes": [
                                "ncit:C168821"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "One Allele Mismatched": {
                            "description": "One allele matches for one HLA locus.",
                            "codes": [
                                "ncit:C168819"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Two Alleles Mismatched": {
                            "description": "A mismatch exists at both alleles.",
                            "codes": [
                                "ncit:C168820"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "HLA_C_RESULT": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The extent of HLA-C matching between the donor and the recipient.",
                    "codes": [
                        "ncit:C168925"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Both Alleles Matched": {
                            "description": "Both alleles match for one HLA locus",
                            "codes": [
                                "ncit:C168821"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "One Allele Mismatched": {
                            "description": "One allele matches for one HLA locus.",
                            "codes": [
                                "ncit:C168819"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Two Alleles Mismatched": {
                            "description": "A mismatch exists at both alleles.",
                            "codes": [
                                "ncit:C168820"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "HLA_DRB1_RESULT": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The extent of HLA-DRB1 matching between the donor and the recipient.",
                    "codes": [
                        "ncit:C168926"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Both Alleles Matched": {
                            "description": "Both alleles match for one HLA locus",
                            "codes": [
                                "ncit:C168821"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "One Allele Mismatched": {
                            "description": "One allele matches for one HLA locus.",
                            "codes": [
                                "ncit:C168819"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Two Alleles Mismatched": {
                            "description": "A mismatch exists at both alleles.",
                            "codes": [
                                "ncit:C168820"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "HLA_DQ_RESULT": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The extent of HLA-DQ matching between the donor and the recipient.",
                    "codes": [
                        "ncit:C168927"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Both Alleles Matched": {
                            "description": "Both alleles match for one HLA locus",
                            "codes": [
                                "ncit:C168821"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "One Allele Mismatched": {
                            "description": "One allele matches for one HLA locus.",
                            "codes": [
                                "ncit:C168819"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Two Alleles Mismatched": {
                            "description": "A mismatch exists at both alleles.",
                            "codes": [
                                "ncit:C168820"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "CONDITIONING_TYPE": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "Type of conditioning the subject received prior to stem-cell transplantation.",
                    "codes": [
                        "ncit:C169014"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Stem Cell Transplant].[SCT_CONDITIONING_TYPE] skos:exactMatch [aml_v2.0].[Stem Cell Transplant].[CONDITIONING_TYPE]"
                    ],
                    "permissible_values": {
                        "Myeloablative": {
                            "description": "A conditioning regimen with high doses of chemotherapy or radiation to eliminate host hematopoietic stem cells prior to restitution via transplantation.",
                            "codes": [
                                "ncit:C131679"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Reduced Intensity Conditioning/Reduced Toxicity Conditioning": {
                            "description": "A method of preparation for stem cell transplant that uses less than standard doses of chemotherapy and radiation prior to the transfer of stem cells, with the goal of providing protection against graft vs. host disease, while simultaneously minimizing the toxic effects of the conditioning treatment.",
                            "codes": [
                                "ncit:C116471"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Non-Myeloablative": {
                            "description": "A modification of the standard method of allogeneic hematopoietic stem cell transplantation developed to allow for the therapy to be extended to a patient population that is unable to tolerate treatment with the conventional procedure due to its toxicity.",
                            "codes": [
                                "ncit:C62714"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "PRIOR_TBI": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.",
                    "codes": [
                        "ncit:C15350"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Stem Cell Transplant].[SCT_TBI] skos:exactMatch [aml_v2.0].[Stem Cell Transplant].[PRIOR_TBI]"
                    ],
                    "permissible_values": {
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "transfusion_medicine_procedures": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_TMP_START": {
                    "type": "Integer",
                    "tier": "To-do",
                    "description": "The age (in days) of the subject at the start of the transfusion medicine procedure.",
                    "codes": [
                        "ncit:C172697"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "TYPE": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "An infusion or replacement of blood components.",
                    "codes": [
                        "ncit:C173057"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Transfusion Medicine Procedure].[TMP_TYPE] skos:exactMatch [aml_v2.0].[Transfusion Medicine Procedure].[TYPE]"
                    ],
                    "permissible_values": {
                        "Exchange Transfusion": {
                            "description": "Withdrawn blood is exchanged for other blood or blood components and returned to the subject.",
                            "codes": [
                                "ncit:C173284"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Therapeutic Apheresis": {
                            "description": "Withdrawal of blood from a subject and removal of any pathogenic components before returning the remainder to the subject.",
                            "codes": [
                                "ncit:C173286"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Simple Transfusion": {
                            "description": "Transfusion of blood into the body without removing any of the patient's blood volume.",
                            "codes": [
                                "ncit:C173285"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "PRODUCT": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The type of product intended for transfusion.",
                    "codes": [
                        "ncit:C173287"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Transfusion Medicine Procedure].[TMP_PRODUCT] skos:exactMatch [aml_v2.0].[Transfusion Medicine Procedure].[PRODUCT]"
                    ],
                    "permissible_values": {
                        "RBC": {
                            "description": "Red blood cells remaining after separating plasma from human blood, or collected by apheresis.",
                            "codes": [
                                "ncit:C133280"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Platelets": {
                            "description": "Platelets collected from a single donor and suspended in a specified volume of original plasma.",
                            "codes": [
                                "ncit:C133278"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "WBC": {
                            "description": "White blood cells intended as source material for further manufacturing use.",
                            "codes": [
                                "ncit:C133281"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "cellular_immunotherapy": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_CIMT_START": {
                    "type": "Integer",
                    "tier": "To-do",
                    "description": "The age (in days) of the subject at the time of cellular immunotherapy.",
                    "codes": [
                        "ncit:C173195"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "TYPE": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The type of cellular immunotherapy.",
                    "codes": [
                        "ncit:C173289"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Cellular Immunotherapy].[CIMT_TYPE] skos:exactMatch [aml_v2.0].[Cellular Immunotherapy].[TYPE]"
                    ],
                    "permissible_values": {
                        "Donor Lymphocyte Infusion": {
                            "description": "The infusion of donor lymphocytes following hematopoietic stem cell transplantation for the purpose of augmenting the host immune response or preventing the rejection of the graft.",
                            "codes": [
                                "ncit:C16145"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Chimeric Antigen Receptor T-cell Therapy": {
                            "description": "Treatment that uses T-cells that have been engineered to contain a chimeric antigen receptor (CAR) that specifically targets a particular antigen.",
                            "codes": [
                                "ncit:C126102"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            }
        },
        "response": {
            "minimal_residual_disease": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "AGE_AT_MRD_ASSESSMENT": {
                    "type": "Integer",
                    "tier": "To-do",
                    "description": "The age (in days) of the subject at the minimal residual disease assessment.",
                    "codes": [
                        "ncit:C168855"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": []
                },
                "METHOD": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "Modality used to determine minimal residual disease.",
                    "codes": [
                        "ncit:C168933"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Minimal Residual Disease].[MRD_METHOD] skos:exactMatch [aml_v2.0].[Minimal Residual Disease].[METHOD]"
                    ],
                    "permissible_values": {
                        "Flow Cytometry, NOS": {
                            "description": "A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.",
                            "codes": [
                                "ncit:C16585"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Minimal Residual Disease].[MRD_METHOD].[Flow Cytometry] skos:exactMatch [aml_v2.0].[Minimal Residual Disease].[METHOD].[Flow Cytometry, NOS]"
                            ]
                        },
                        "Flow Cytometry, Leukemia-Associated Immunophenotypes": {
                            "description": "A technique with leukemia-associated immunophenotypes for counting, examining or sorting microscopic particles suspended in a stream of fluid based on tagging the population of interest with antibody-based reagents.",
                            "codes": [
                                "ncit:C168812"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Minimal Residual Disease].[FLOW_CYTOMETRY_TYPE].[Leukemia-Associated Immunophenotypes] skos:exactMatch [aml_v2.0].[Minimal Residual Disease].[METHOD].[Flow Cytometry, Leukemia-Associated Immunophenotypes]"
                            ]
                        },
                        "Flow Cytometry, Different-From-Normal": {
                            "description": "The use of flow cytometry to detect whether material or cells in a sample or specimen is sorted differently than a normal control analyte.",
                            "codes": [
                                "ncit:C168956"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New VD"
                            ]
                        },
                        "Molecular Real-time Quantitative PCR": {
                            "description": "An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.",
                            "codes": [
                                "ncit:C51962"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[aml_v1.7].[Minimal Residual Disease].[MRD_METHOD].[Molecular Real-Time Quantitative Polymerase Chain Reaction] skos:exactMatch [aml_v2.0].[Minimal Residual Disease].[METHOD].[Molecular Real-time Quantitative PCR]"
                            ]
                        },
                        "Next Generation Sequencing": {
                            "description": "Technologies that facilitate the rapid determination of the nucleotide sequence of large numbers of strands or segments of DNA or RNA.",
                            "codes": [
                                "ncit:C101293"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "RESULT_TEXT": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The string/text result of the minimal residual disease test.",
                    "codes": [
                        "ncit:C124433"
                    ],
                    "implementation_notes": [
                        "Note: String result can include anything that is not a single numeric result, i.e. \"Positive\", \"Negative\", \"Present\", \"Absent\", \"Yes\", \"No\", \"Elevated,\" \"Depressed\", \"Above threshold\", \"Below threshold\", ranges, as well as bucketed categories, etc... Note: Only fill in this variable when the available data is anything EXCEPT a single numeric value, and include the entire available data as a string, including units if applicable"
                    ],
                    "mappings": [
                        "[aml_v1.7].[Minimal Residual Disease].[MRD_RESULT] skos:exactMatch [aml_v2.0].[Minimal Residual Disease].[RESULT_TEXT]"
                    ]
                },
                "RESULT_NUMERIC": {
                    "type": "Decimal",
                    "tier": "To-do",
                    "description": "The numeric result of the minimal residual disease.",
                    "codes": [
                        "ncit:C168951"
                    ],
                    "implementation_notes": [
                        "Note: Only fill in this variable if the available data is a single numeric value."
                    ],
                    "mappings": [
                        "[aml_v1.7].[Minimal Residual Disease].[MRD_RESULT_NUMERIC] skos:exactMatch [aml_v2.0].[Minimal Residual Disease].[RESULT_NUMERIC]"
                    ]
                },
                "RESULT_UNIT": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "The units used for the numeric result of the minimal residual disease test.",
                    "codes": [
                        "ncit:C173304"
                    ],
                    "implementation_notes": [
                        "Note: Only fill in this variable if a numeric result is provided in MRD_RESULT_NUMERIC."
                    ],
                    "mappings": [
                        "[aml_v1.7].[Minimal Residual Disease].[MRD_RESULT_UNIT] skos:exactMatch [aml_v2.0].[Minimal Residual Disease].[RESULT_UNIT]"
                    ],
                    "permissible_values": {
                        "%": {
                            "description": "A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).",
                            "codes": [
                                "ncit:C48570"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "SENSITIVITY": {
                    "type": "Decimal",
                    "tier": "To-do",
                    "description": "Sensitivity of modality used to determine minimal residual disease.",
                    "codes": [
                        "ncit:C168957"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Minimal Residual Disease].[MRD_SENSITIVTY] skos:exactMatch [aml_v2.0].[Minimal Residual Disease].[SENSITIVITY]"
                    ]
                },
                "SPECIMEN": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "Source of sample used for minimal residual disease assessment.",
                    "codes": [
                        "ncit:C168958"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Minimal Residual Disease].[MRD_SAMPLE_SOURCE] skos:exactMatch [aml_v2.0].[Minimal Residual Disease].[SPECIMEN]"
                    ],
                    "permissible_values": {
                        "Bone Marrow": {
                            "description": "The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.",
                            "codes": [
                                "ncit:C12431"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Blood": {
                            "description": "A small volume of blood removed for testing or storage.",
                            "codes": [
                                "ncit:C17610"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "MOLECULAR_MARKERS": {
                    "type": "Enum",
                    "tier": "To-do",
                    "description": "Minimal residual disease molecular markers",
                    "codes": [
                        "ncit:C168895"
                    ],
                    "implementation_notes": [
                        "Note: If multiple MRD markers, include one observation per marker."
                    ],
                    "mappings": [
                        "[aml_v1.7].[Minimal Residual Disease].[MRD_MOLECULAR_MARKERS] skos:exactMatch [aml_v2.0].[Minimal Residual Disease].[MOLECULAR_MARKERS]"
                    ],
                    "permissible_values": {
                        "inv(16)(p13q22)": {
                            "description": "A chromosomal inversion that involves chromosome 16. It is associated with the development of acute myeloid leukemia CBFB-MYH11, acute myelomonocytic leukemia with abnormal eosinophils, and granulocytic sarcoma.",
                            "codes": [
                                "ncit:C36373"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(16;16)(p13.1;q22)": {
                            "description": "A chromosomal translocation that involves chromosome 16. It is often associated with the development of acute myeloid leukemia CBFB-MYH11, acute myelomonocytic leukemia with abnormal eosinophils, and granulocytic sarcoma.",
                            "codes": [
                                "ncit:C27759"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(15;17)(q24;q21)": {
                            "description": "A chromosomal translocation associated with creation of a fusion between the PML and RARA genes. It is seen in variants of acute promyelocytic leukemia.",
                            "codes": [
                                "ncit:C27758"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(9;11)(p22;q23) / MLL-MLLT3(AF9)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the short arm (p21.3) of chromosome 9 and the long arm (q23.3) of chromosome 11. It is associated with the development of acute myeloid leukemia with the MLLT3-MLL fusion gene transcript.",
                            "codes": [
                                "ncit:C36370"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(10;11)(p12;q23) / MLL-MLLT10(AF10)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of chromosome 10p12 with chromosome 11q23. It is associated with acute myeloid leukemia in childhood.",
                            "codes": [
                                "ncit:C132102"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(10;11)(p11.2;q23)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the short arm (p11.2) of chromosome 10 and the long arm (q23) of chromosome 11. It is associated with KMT2A (MLL)/ABI1 fusions and acute myeloid leukemia.",
                            "codes": [
                                "ncit:C168758"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(1;11)(q21;q23) / MLL-MLLT11(AF1Q)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q21) of chromosome 1 and the long arm (q23) of chromosome 11. It is associated with KMT2A (MLL)/MLLT11 (AF1Q) fusions, acute myeloid leukemia and some cases of acute lymphoblastic leukemia.",
                            "codes": [
                                "ncit:C168759"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(4;11)(q21;q23) / MLL-MLLT2(AF4)": {
                            "description": "A chromosomal abnormality consisting of the translocation of 4q21 with 11q23.",
                            "codes": [
                                "ncit:C36365"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(6;11)(q27;q23) / MLL-MLLT4(AF6)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q27) of chromosome 6 and the long arm (q23) of chromosome 11. It is associated with the development of de novo acute myeloid leukemia.",
                            "codes": [
                                "ncit:C36610"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(6;9)(p23;q34) DEK/NUP214": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the short arm (p23) of chromosome 6 and the long arm (q34.1) of chromosome 9. It is associated with DEK/NUP214 fusions, acute myeloid leukemia and myelodysplastic syndromes.",
                            "codes": [
                                "ncit:C36532"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(11;19)(q23;p13)(MLL-ENL)/(MLL-ELL)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q23) of chromosome 11 and the short arm (p13) of chromosome 19. It is associated with KMT2A (MLL) fusions, including those with MLLT1 (ENL) and ELL, and acute myeloid leukemia.",
                            "codes": [
                                "ncit:C168764"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(11;19)(q23;p13.1)(MLL-ELL)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q23) of chromosome 11 and the short arm (p13.1) of chromosome 19. It is associated with the development of acute myeloid leukemia with variant MLL translocations and topoisomerase II inhibitor-related acute myeloid leukemia.",
                            "codes": [
                                "ncit:C36371"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(11;19)(q23;p13.3)(MLL-ENL)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q23.3) of chromosome 11 and the short arm (p13.3) of chromosome 19. It is associated with KMT2A (MLL)/MLLT1 (ENL) fusions and acute myeloid leukemia.",
                            "codes": [
                                "ncit:C36372"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "MLL Other partner": {
                            "description": "A chromosomal abnormality consisting of the translocation of genetic material from any one of several chromosomes to the 11q23.3 region, resulting in an MLL gene rearrangement.",
                            "codes": [
                                "ncit:C36517"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(11;17)(AF17)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q23) of chromosome 11 and the long arm (q12-21) of chromosome 19. It is associated with KMT2A (MLL) fusions, including those with MLLT6 (AF17), and acute myeloid leukemia.",
                            "codes": [
                                "ncit:C168760"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(8;16)MOZ/CBP": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the short arm (p11.2) of chromosome 8 and the short arm (p13.3) of chromosome 16. It is associated with KAT6A/CREBBP fusions and acute myeloid leukemia.",
                            "codes": [
                                "ncit:C167194"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Monosomy 7": {
                            "description": "A chromosomal abnormality consisting of the absence of one of the copies of chromosome 7 in somatic cells.",
                            "codes": [
                                "ncit:C36411"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Monosomy 5": {
                            "description": "A cytogenetic aneuploidy abnormality that refers to the presence of one chromosome 5 only. It is associated with the development of refractory anemia with excess blasts, refractory anemia with multilineage dysplasia, and refractory anemia with multilineage dysplasia and ringed sideroblasts.",
                            "codes": [
                                "ncit:C36523"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Trisomy 8": {
                            "description": "A chromosomal abnormality consisting of the presence of a third copy of chromosome 8 in somatic cells.",
                            "codes": [
                                "ncit:C36396"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "der.12p": {
                            "description": "A cytogenetic abnormality involving the rearrangement of two or more other chromosomes with the short arm of chromosome 12 (12p).",
                            "codes": [
                                "ncit:C173542"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(2;12)": {
                            "description": "A cytogenetic abnormality that involves a translocation between chromosomes 2 and 12.",
                            "codes": [
                                "ncit:C173543"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(5;11)(q35;p15) NSD1/NUP98": {
                            "description": "A cytogenetic abnormality that refers to the translocation of chromosome 11p15 with chromosome 5q35. It results in the formation of NUP98/NSD1 fusion gene. It is associated with the development of acute myeloid leukemia with t(5;11)(q35;p15); NUP98-NSD1.",
                            "codes": [
                                "ncit:C131503"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(7;12)(q36;p13) HLXB9(MNX1)/ETV6(TEL)": {
                            "description": "A chromosomal translocation involving the ETV6 gene on chromosome 12p13 and HLXB9 gene on chromosome 7q36.",
                            "codes": [
                                "ncit:C122689"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(9;22)(q34;q11.2) ABL/BCR": {
                            "description": "A translocation between chromosomes 9 and 22 that is associated with the Philadelphia chromosome.",
                            "codes": [
                                "ncit:C13271"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "inv(3)(q21;q21.2)": {
                            "description": "A cytogenetic abnormality that refers to a paracentric inversion involving breakpoints on the long (q23.1 and q26.2) of chromosome 3. It is associated with acute myeloid leukemia.",
                            "codes": [
                                "ncit:C36407"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(3;3)(q21;q26.2)": {
                            "description": "A cytogenetic abnormality that refers to the translocation where both breakpoints are on the long arm (q23.1 and q26.2) of chromosome 3. It is associated with acute myeloid leukemia.",
                            "codes": [
                                "ncit:C36406"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(3;12)(q23;p12.3)(ETV6/EVI1)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q23) of chromosome 3 and the shot arm (p12.3) of chromosome 12. It is associated with ETV6/MECOM (EVI1) fusions, myeloproliferative disorders, myelodysplastic syndromes and acute myelogenous leukemia.",
                            "codes": [
                                "ncit:C168766"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "del(5q)(5q31-q32)": {
                            "description": "A cytogenetic abnormality that refers to deletion of chromosome bands 31-32 on the long arm of chromosome 5.",
                            "codes": [
                                "ncit:C168769"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(1;22)(RBM15-MKL1)": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the short arm (p13.3) of chromosome 1 and the long arm (q13.1) of chromosome 22. It is associated with RBM15/MRTFA (MKL1) fusions and acute megakaryocytic leukemia.",
                            "codes": [
                                "ncit:C36417"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "del(13q)(13q 14 - 21)": {
                            "description": "A cytogenetic abnormality that refers to deletion of chromosome bands 14-21 on the long arm of chromosome 13.",
                            "codes": [
                                "ncit:C168770"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "del(17p)": {
                            "description": "A cytogenetic abnormality that refers to the loss of all or part of the short arm of chromosome 17 (17p).",
                            "codes": [
                                "ncit:C36499"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Any MLL rearrangement": {
                            "description": "A molecular abnormality indicating rearrangement of the MLL (KMT2A) gene.",
                            "codes": [
                                "ncit:C122623"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "non-KMT2A MLLT10": {
                            "description": "An indication that a cytogenetic rearrangement involving MLLT10 but not involving KMT2A was detected in a sample.",
                            "codes": [
                                "ncit:C168771"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "inv(16)(p13.3q24.3)/CBFA2T3-GLIS2": {
                            "description": "A pericentric chromosomal inversion that involves chromosome 16. It is associated with CBFA2T3/GLIS2 fusions and pediatric acute megakaryoblastic leukemia.",
                            "codes": [
                                "ncit:C167195"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(11;15)(p15;q35)/NUP98/JARID1A": {
                            "description": "A cytogenetic abnormality that refers to the translocation of chromosome 11p15 with chromosome 15q35. It results in the formation of NUP98/JARID1A fusion gene. It is associated with the development of acute myeloid leukemia with t(11;15)(p15;q35); NUP98-JARID1A.",
                            "codes": [
                                "ncit:C131505"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(16;21)(q24;q22)RUNX1-CBFA2T3": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q24) of chromosome 16 and the long arm (q22) of chromosome 22. It is associated with RUNX1/CBFA2T3 fusions, myelodysplastic syndromes and acute myeloid leukemia.",
                            "codes": [
                                "ncit:C168773"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(3;5)(q25;q34)NPM1/MLF1": {
                            "description": "A cytogenetic abnormality that refers to the translocation of the long arm (q25) of chromosome 3 and the long arm (q34) of chromosome 5. It is associated with the development of acute myeloid leukemia arising from myelodysplastic syndrome, acute myeloid leukemia with multilineage dysplasia, and acute myeloid leukemia with myelodysplasia-related changes.",
                            "codes": [
                                "ncit:C36415"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(16;21)(p11;q22)FUS/ERG": {
                            "description": "A chromosomal translocation involving the FUS gene on chromosome 16p11 and the ERG gene on chromosome 21q22.",
                            "codes": [
                                "ncit:C36616"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "NPM1 mutation": {
                            "description": "Mutation of the nucleophosmin gene. It is seen in acute myeloid leukemias usually associated with a normal karyotype.",
                            "codes": [
                                "ncit:C82429"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "CEBPA mutation - monoallelic": {
                            "description": "The presence of mutations in only one allele of the CEBPA gene.",
                            "codes": [
                                "ncit:C168774"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "CEBPA mutation - biallelic": {
                            "description": "The presence of mutations in both alleles of the CEBPA gene.",
                            "codes": [
                                "ncit:C157569"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "CEBPA mutation - mutation unspecified": {
                            "description": "Mutation of the CEBPA gene encoding CCAAT/enhancer binding protein alpha. It is seen in acute myeloid leukemias usually associated with a normal karyotype.",
                            "codes": [
                                "ncit:C38372"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "FLT3 internal tandem duplication": {
                            "description": "A genetic abnormality that arises from duplications of the juxtamembrane portion of the gene and results in constitutive activation of the FLT3 receptor tyrosine kinase protein in early hematopoietic progenitor cells. It is associated with acute myelogenous leukemia where it appears to correlate with a poor prognosis.",
                            "codes": [
                                "ncit:C67494"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "FLT3-TKD": {
                            "description": "Single nucleotide mutations in the tyrosine kinase domain encoded by the human FLT3 gene that are associated with acute myeloid leukemia and poor prognosis.",
                            "codes": [
                                "ncit:C67495"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "WT1 mutation": {
                            "description": "A change in the nucleotide sequence of the WT1 gene.",
                            "codes": [
                                "ncit:C146726"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "CKIT mutation - ex17": {
                            "description": "A molecular genetic abnormality indicating the presence of a mutation in exon 17 of the KIT gene located within 4q11-q12.",
                            "codes": [
                                "ncit:C116396"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "CKIT mutation - ex8": {
                            "description": "A molecular genetic abnormality indicating the presence of a mutation in exon 8 of the KIT gene located within 4q11-q12.",
                            "codes": [
                                "ncit:C128660"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "CKIT mutation - unspecified": {
                            "description": "A molecular genetic abnormality that refers to mutation of the c-kit (CD117) proto-oncogene. It is associated with the development of gastrointestinal stromal tumor and gastrointestinal autonomic nerve tumor. It has also been described in acute myeloid leukemias, dysgerminomas, and seminomas.",
                            "codes": [
                                "ncit:C39712"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "GATA1 mutation": {
                            "description": "A change in the nucleotide sequence of the GATA1 gene.",
                            "codes": [
                                "ncit:C82340"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "RUNX1 mutation": {
                            "description": "A change in the nucleotide sequence of the RUNX1 gene.",
                            "codes": [
                                "ncit:C38362"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "PTPN11 mutation": {
                            "description": "Mutation of the protein tyrosine phosphatase, non-receptor type 11 gene. It is seen in cases of juvenile myelomonocytic leukemia.",
                            "codes": [
                                "ncit:C82612"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "N-RAS mutation": {
                            "description": "A change in the structure of the NRAS gene.",
                            "codes": [
                                "ncit:C41381"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(3;5)(q25;q34)NPM1/MLF2": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(3;5)(q25;q34)NPM1/MLF3": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "K-RAS mutation": {
                            "description": "A change in the nucleotide sequence of the KRAS gene.",
                            "codes": [
                                "ncit:C41361"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "t(8;21)": {
                            "description": "A cytogenetic abnormality that involves a translocation between chromosomes 8 and 21.",
                            "codes": [
                                "ncit:C119608"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "subject_response": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_RESPONSE": {
                    "type": "Integer",
                    "tier": "n/a",
                    "description": "Age of subject (in days) when the response assessment was made.",
                    "codes": [
                        "ncit:C168856"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "RESPONSE_CATEGORY": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The category used to assess the response to therapy.",
                    "codes": [
                        "ncit:C173306"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Overall Response": {
                            "description": "An assessment of the overall response of the disease to the therapy.",
                            "codes": [
                                "ncit:C96613"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Bone Marrow Response": {
                            "description": "The response of the bone marrow to the treatment.",
                            "codes": [
                                "ncit:C173307"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Central Nervous System Response": {
                            "description": "The response of the central nervous system to treatment.",
                            "codes": [
                                "ncit:C168952"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Myeloid Sarcoma Response": {
                            "description": "The response of the myeloid sarcoma to the treatment.",
                            "codes": [
                                "ncit:C168965"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "RESPONSE": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.",
                    "codes": [
                        "ncit:C50995"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Complete Remission": {
                            "description": "The disappearance of all signs of cancer in response to treatment.",
                            "codes": [
                                "ncit:C4870"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Non-Response": {
                            "description": "A response defined as a non-response in the protocol.",
                            "codes": [
                                "ncit:C173526"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "BM_PCT_BLASTS_AT_RESPONSE": {
                    "type": "Integer",
                    "tier": "n/a",
                    "description": "The percent of cells that were blasts in the subject's bone marrow used to make the response assessment.",
                    "codes": [
                        "ncit:C168959"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "BM_ANALYSIS_METHOD_AT_RESPONSE": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The modality used to determine the bone marrow percent blasts.",
                    "codes": [
                        "ncit:C168960"
                    ],
                    "implementation_notes": [
                        "Only fill in the variable if a value is available for BM_PCT_BLASTS_AT_RESPONSE"
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Morphology": {
                            "description": "A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.",
                            "codes": [
                                "ncit:C35867"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Flow Cytometry": {
                            "description": "A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.",
                            "codes": [
                                "ncit:C16585"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "ANC_AT_RESPONSE": {
                    "type": "Integer",
                    "tier": "n/a",
                    "description": "The absolute neutrophil count used to make the response assessment.",
                    "codes": [
                        "ncit:C168961"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "ANC_THRESHOLD_AT_RESPONSE": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "Subject exceeded an absolute neutrophil count threshold of >= 500 (ANC/mm3) at the time of the response assessment.",
                    "codes": [
                        "ncit:C168962"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "PLATELET_COUNT_AT_RESPONSE": {
                    "type": "Integer",
                    "tier": "n/a",
                    "description": "The platelet count used to make the response assessment.",
                    "codes": [
                        "ncit:C168963"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "PLATELET_THRESHOLD_AT_RESPONSE": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "Subject exceeded a platelet count threshold of >=50,000 (platelets/mm3) at the time of the response assessment.",
                    "codes": [
                        "ncit:C168964"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            }
        },
        "events": {
            "adverse_events": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_AE": {
                    "type": "Integer",
                    "tier": "n/a",
                    "description": "Age of subject (in days) at the onset of the adverse event.",
                    "codes": [
                        "ncit:C172677"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "AGE_AT_AE_RESOLVED": {
                    "type": "Integer",
                    "tier": "To-do",
                    "description": "The age (in days) of the subject when this adverse event was resolved.",
                    "codes": [
                        "ncit:C175043"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "TIME_PERIOD_SUBMITTER_ID": {
                    "type": "String",
                    "tier": "To-do",
                    "description": "This is the SUBMITTER_ID of the time period (defined in the \"Time Period\" table) during which this observation takes place.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "ADVERSE_EVENT": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).",
                    "codes": [
                        "ncit:C41331"
                    ],
                    "implementation_notes": [
                        "For AML, COG will omit multiorgan failure, hemorrhage, and neurotoxcity. Infection for AML COG will be CRF question about sterile site"
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Left Ventricular Systolic Dysfunction": {
                            "description": "The degree of impairment of the left cardiac ventricle to contract efficiently. (ACC)",
                            "codes": [
                                "ncit:C64251"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Infection": {
                            "description": "The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.",
                            "codes": [
                                "ncit:C128320"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Sinusoidal Obstruction Syndrome": {
                            "description": "A disorder characterized by inflammation and damage of the hepatic sinusoidal endothelial cells of the hepatic venules that leads to venular occlusion and hepatocellular necrosis. It is most often a conditioning-related toxicity that results as a complication of hematopoietic stem cell transplantation (HSCT). It has also been described in populations of individuals who have ingested pyrrolizidine plant alkaloids. The clinical signs and symptoms include hyperbilirubinemia, hepatomegaly, and fluid retention.",
                            "codes": [
                                "ncit:C26793"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Typhlitis": {
                            "description": "Inflammation of the cecum, usually accompanied by neutropenia.",
                            "codes": [
                                "ncit:C38043"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Multi Organ Failure": {
                            "description": "Complete impairment of two or more organs or organ systems.",
                            "codes": [
                                "ncit:C75568"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Hyperbilirubinemia": {
                            "description": "Abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.",
                            "codes": [
                                "ncit:C27088"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Hemorrhage": {
                            "description": "The flow of blood from a ruptured blood vessel.",
                            "codes": [
                                "ncit:C26791"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Neurotoxicity Syndrome": {
                            "description": "A group of neurologic disorders caused by damage to the nervous system following exposure to pharmacologic, biologic, and chemical agents. Examples of neurotoxins include chemotherapy agents, radiation treatment, heavy metals, pesticides, and food additives.",
                            "codes": [
                                "ncit:C27961"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Graft Versus Host Disease": {
                            "description": "A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.",
                            "codes": [
                                "ncit:C3063"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "AE_CODE": {
                    "type": "String",
                    "tier": "n/a",
                    "description": "The code of the adverse event.",
                    "codes": [
                        "ncit:C173313"
                    ],
                    "implementation_notes": [
                        "For AML, include when available if a 1:1 mapping to the ADVERSE_EVENT bucket"
                    ],
                    "mappings": []
                },
                "AE_CODE_SYSTEM": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The name of the system used to grade the adverse events.",
                    "codes": [
                        "ncit:C168872"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Adverse Events].[AE_SYSTEM] skos:exactMatch [aml_v2.0].[Adverse Events].[AE_CODE_SYSTEM]"
                    ],
                    "permissible_values": {
                        "SNOMED": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "ICD": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "European Society for Blood and Marrow Transplantation (EBMT)": {
                            "description": "A non-profit organization established in 1974 to allow scientists and physicians involved in clinical bone marrow transplantations to share experiences and develop co-operative studies.",
                            "codes": [
                                "ncit:C168842"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "CTCAE": {
                            "description": "A standard terminology developed to report adverse events occurring in cancer clinical trials. Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration. The CTCAE contain a grading scale for each adverse event term representing the severity of the event.",
                            "codes": [
                                "ncit:C49704"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "AE_SYSTEM_VERSION": {
                    "type": "String",
                    "tier": "n/a",
                    "description": "The version of the adverse event grading system.",
                    "codes": [
                        "ncit:C173314"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "GRADE": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "A numeric value corresponding to the degree of severity of an adverse event.",
                    "codes": [
                        "ncit:C166200"
                    ],
                    "implementation_notes": [
                        "Only applicable for CTCAE- or EBMT-coded AEs"
                    ],
                    "mappings": [
                        "[aml_v1.7].[Adverse Events].[AE_GRADE] skos:exactMatch [aml_v2.0].[Adverse Events].[GRADE]"
                    ],
                    "permissible_values": {
                        "Grade 1": {
                            "description": "An experience that is usually transient, and requires no special treatment or intervention. The event does not generally interfere with usual daily activities. Includes transient laboratory test alterations.",
                            "codes": [
                                "ncit:C41338"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Grade 2": {
                            "description": "An experience that is alleviated with simple therapeutic treatments. The event impacts usual daily activities. Includes laboratory test alterations indicating injury, but without long-term risk.",
                            "codes": [
                                "ncit:C41339"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Grade 3": {
                            "description": "An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.",
                            "codes": [
                                "ncit:C41340"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Grade 4": {
                            "description": "An adverse event that has life-threatening consequences; for which urgent intervention is indicated; that puts the patient at risk of death at the time of the event if immediate intervention is not undertaken.",
                            "codes": [
                                "ncit:C84266"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Grade 5": {
                            "description": "The termination of life associated with an adverse event.",
                            "codes": [
                                "ncit:C48275"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "ATTRIBUTION": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "A specific identifiable level (defined qualitatively or quantitatively) of probability of adverse event being caused or associated with the product or procedure administration to a patient.",
                    "codes": [
                        "ncit:C41358"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Adverse Events].[AE_ATTRIBUTION] skos:exactMatch [aml_v2.0].[Adverse Events].[ATTRIBUTION]"
                    ],
                    "permissible_values": {
                        "Definite": {
                            "description": "A characteristic used to qualify the adverse event as certainly related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, occurring in a plausible time relationship to medical intervention, and which cannot be explained by concurrent disease or other interventions. The response to withdrawal of the medical product (dechallenge) should be clinically plausible. The event must be definitive pharmacologically or phenomenologically, using a satisfactory rechallenge procedure if necessary.",
                            "codes": [
                                "ncit:C53260"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Probable": {
                            "description": "Probable adverse event relationship to study product or procedure is defined when there is a clear-cut temporal association between product or procedure administration and adverse event, and a potential alternative etiology of the event is not apparent.",
                            "codes": [
                                "ncit:C41357"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Possible": {
                            "description": "A characteristic indicating that an adverse event may be related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the drug, but which could also be explained by concurrent disease or other drugs or chemicals. Information on drug withdrawal may be lacking or unclear.",
                            "codes": [
                                "ncit:C53258"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unlikely": {
                            "description": "A characteristic used to qualify the adverse event as unlikely related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a temporal relationship to the medical intervention which makes a causal relationship improbable, and in which other interventions or underlying disease provide plausible explanations.",
                            "codes": [
                                "ncit:C53257"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unrelated": {
                            "description": "A characteristic used to qualify the adverse event as clearly not related to the medical intervention.",
                            "codes": [
                                "ncit:C53256"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "OUTCOME": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "A condition or event that is attributed to the adverse event and is the result or conclusion of the adverse event.",
                    "codes": [
                        "ncit:C49489"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Adverse Events].[AE_OUTCOME] skos:exactMatch [aml_v2.0].[Adverse Events].[OUTCOME]"
                    ],
                    "permissible_values": {
                        "Death, Contributory": {
                            "description": "Any adverse event contributing to the cause of death.",
                            "codes": [
                                "ncit:C168948"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Death, Noncontributory": {
                            "description": "The adverse event did not directly contribute to the death of the subject.",
                            "codes": [
                                "ncit:C173315"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Recovered": {
                            "description": "One of the possible results of an adverse event outcome that indicates that the event has not improved or recuperated.",
                            "codes": [
                                "ncit:C49494"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Recovered with Sequelae": {
                            "description": "One of the possible results of an adverse event outcome where the subject recuperated but retained pathological conditions resulting from the prior disease or injury.",
                            "codes": [
                                "ncit:C49495"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Recovered": {
                            "description": "One of the possible results of an adverse event outcome that indicates that the event has improved or recuperated.",
                            "codes": [
                                "ncit:C49498"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "ICU": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "An indication of whether the subject was admitted to the intensive care unit.",
                    "codes": [
                        "ncit:C173316"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Adverse Events].[AE_ICU] skos:exactMatch [aml_v2.0].[Adverse Events].[ICU]"
                    ],
                    "permissible_values": {
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "SUPPORTIVE_MEDICATION": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The medication related to the adverse event.",
                    "codes": [
                        "ncit:C173317"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Adverse Events].[AE_MEDICATION] skos:exactMatch [aml_v2.0].[Adverse Events].[SUPPORTIVE_MEDICATION]"
                    ],
                    "permissible_values": {
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "INTERVENTION_STATUS": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The intervention related to the adverse event.",
                    "codes": [
                        "ncit:C173318"
                    ],
                    "implementation_notes": [
                        "changed to general INTERVENTION variable (was previously SOS_INTERVENTION)"
                    ],
                    "mappings": [
                        "[aml_v1.7].[Adverse Events].[AE_INTERVENTION] skos:exactMatch [aml_v2.0].[Adverse Events].[INTERVENTION_STATUS]"
                    ],
                    "permissible_values": {
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "INTERVENTION": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The intervention or medication detail of the adverse event.",
                    "codes": [
                        "ncit:C173319"
                    ],
                    "implementation_notes": [
                        "If multiple medications or interventions performed, include one observation per medication or intervention ",
                        " Only fill in this variable if MEDICATION and/or INTERVENTION are marker as \"Yes\""
                    ],
                    "mappings": [
                        "[aml_v1.7].[Adverse Events].[AE_MED_INTERVENTION_DETAIL] skos:exactMatch [aml_v2.0].[Adverse Events].[INTERVENTION]"
                    ],
                    "permissible_values": {
                        "ACE-Inhibitor": {
                            "description": "Any substance that inhibits angiotensin-converting enzyme (ACE), an enzyme that catalyzes the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in a reduction in angiotensin II and angiotensin II-induced aldosterone secretion, causing vasodilation and natriuresis.",
                            "codes": [
                                "ncit:C247"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Inotropic Support": {
                            "description": "An agent used to modify the strength of the contraction of the heart muscle.",
                            "codes": [
                                "ncit:C168966"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Heart Transplant": {
                            "description": "A surgical procedure in which a damaged heart is removed and replaced by another heart from a suitable donor.",
                            "codes": [
                                "ncit:C15246"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "AE_PATHOGEN": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The pathogen identified as the agent causing the adverse event.",
                    "codes": [
                        "ncit:C185665"
                    ],
                    "implementation_notes": [
                        "If multiple pathogens involved, include one observation per pathogen. ",
                        " Only fill in this variable if ADVERSE_EVENT is \"Infection.\""
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Bacteria": {
                            "description": "Unicellular, prokaryotic organisms that reproduce by cell division and usually have cell walls; can be shaped like spheres, rods or spirals and can be found in virtually any environment.",
                            "codes": [
                                "ncit:C14187"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Virus": {
                            "description": "An infectious agent which consists of two parts, genetic material and a protein coat. These organisms lack independent metabolism, and they must infect the cells of other types of organisms to reproduce. Most viruses are capable of passing through fine filters that retain bacteria, and are not visible through a light microscope.",
                            "codes": [
                                "ncit:C14283"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Fungus": {
                            "description": "A kingdom of eukaryotic, heterotrophic organisms that live as saprobes or parasites, including mushrooms, yeasts, smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi refer to those that grow as multicellular colonies (mushrooms and molds).",
                            "codes": [
                                "ncit:C14209"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "AE_PATHOGEN_CONFIRMATION": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "An indication that the reported pathogen was confirmed or suspected as the cause of an infection.",
                    "codes": [
                        "ncit:C168955"
                    ],
                    "implementation_notes": [
                        "Only fill in this variable if ADVERSE_EVENT is \"Infection\" and there is a value filled in for PATHOGEN."
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Confirmed": {
                            "description": "Having been established or verified.",
                            "codes": [
                                "ncit:C25458"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Suspected": {
                            "description": "Believed likely.",
                            "codes": [
                                "ncit:C71458"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "GVHD_ACUITY": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The assessed level of seriousness assigned to the graft vs host disease.",
                    "codes": [
                        "ncit:C168861"
                    ],
                    "implementation_notes": [
                        "Only fill in this variable if ADVERSE_EVENT is \"GVHD.\""
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Acute": {
                            "description": "A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.",
                            "codes": [
                                "ncit:C4980"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Chronic": {
                            "description": "A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.",
                            "codes": [
                                "ncit:C4981"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "GVHD_ORGAN": {
                    "type": "Enum",
                    "tier": "n/a",
                    "description": "The organs involved in the graft vs host disease.",
                    "codes": [
                        "ncit:C168883"
                    ],
                    "implementation_notes": [
                        "If multiple organs involved in GVHD, include one observation per organ. ",
                        " Only fill in this variable if ADVERSE_EVENT is \"GVHD.\""
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "Skin": {
                            "description": "An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.",
                            "codes": [
                                "ncit:C12470"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Liver": {
                            "description": "A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.",
                            "codes": [
                                "ncit:C12392"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Lung": {
                            "description": "One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.",
                            "codes": [
                                "ncit:C12468"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Gastrointestinal Tract": {
                            "description": "The upper gastrointestinal (GI) tract is comprised of mouth, pharynx, esophagus and stomach while the lower GI tract consists of intestines and anus. The primary function of the GI tract is to ingest, digest, absorb and ultimately excrete food stuff.",
                            "codes": [
                                "ncit:C34082"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Other": {
                            "description": "Different than the one(s) previously specified or mentioned.",
                            "codes": [
                                "ncit:C17649"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "ncit:C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "ncit:C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "subsequent_malignant_neoplasm": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "1 - contributors must include, regardless of the resource cost",
                    "description": "The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "ncit:C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_SMN": {
                    "type": "Integer",
                    "tier": "2 - contributors should prioritize inclusion if resources are available",
                    "description": "The age (in days) of subject at the diagnosis of the subsequent malignant neoplasm.",
                    "codes": [
                        "ncit:C168860"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "MORPH_CODE": {
                    "type": "String",
                    "tier": "2 - contributors should prioritize inclusion if resources are available",
                    "description": "The morphology code describes the cell type of the tumor and its biologic activity.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Secondary Malignant Neoplasm].[SMN_ICD_O_MORPH] skos:exactMatch [aml_v2.0].[Subsequent Malignant Neoplasm].[MORPH_CODE]"
                    ]
                },
                "MORPH_CODE_SYSTEM": {
                    "type": "Enum",
                    "tier": "2 - contributors should prioritize inclusion if resources are available",
                    "description": "The coding system for the code used in MORPH_CODE.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "ICD-O": {
                            "description": "A code for the primary site of a tumor being reported using either ICD-O-2 or ICD-O-3.",
                            "codes": [
                                "ncit:C160903"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "MORPH_CODE_SYSTEM_VERSION": {
                    "type": "String",
                    "tier": "2 - contributors should prioritize inclusion if resources are available",
                    "description": "The version of the coding system indicated in MORPH_CODE_SYSTEM.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "TOP_CODE": {
                    "type": "String",
                    "tier": "2 - contributors should prioritize inclusion if resources are available",
                    "description": "The topography code describes the site of origin of the neoplasm.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "[aml_v1.7].[Secondary Malignant Neoplasm].[SMN_ICD_O_TOP] skos:exactMatch [aml_v2.0].[Subsequent Malignant Neoplasm].[TOP_CODE]"
                    ]
                },
                "TOP_CODE_SYSTEM": {
                    "type": "Enum",
                    "tier": "2 - contributors should prioritize inclusion if resources are available",
                    "description": "The coding system for the code used in TOP_CODE.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "ICD-O": {
                            "description": "A code for the primary site of a tumor being reported using either ICD-O-2 or ICD-O-3.",
                            "codes": [
                                "ncit:C160903"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "TOP_CODE_SYSTEM_VERSION": {
                    "type": "String",
                    "tier": "2 - contributors should prioritize inclusion if resources are available",
                    "description": "The version of the coding system indicated in TOP_CODE_SYSTEM.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                }
            }
        }
    }
}